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ABSTRACT
Previous studies have shown that cultured and circulating cells from women may differ
in immune responses, the differences relating to the phase of the menstrual cycle in which
they were harvested . In this investigation, specific enzyme-linked immunosorbent assays
for IL-2. IL--4, IFNY,IL-Ira and n.~lll were used to determine if there are differences in
levels of cytokine expression at different phases of the menstrual cycle .
A sample set of mononuclear cells and serum were isolated from nine healthy .
cycling females (19-29 years) at known points in their cycle and from four male controls .
The gonadal hormones 171J-estradiol, progesterone and luteinizing hormone. as well as
serum cytokine levels and cytokine production by unstimulated and stimulated cells in
culture were monitored Results indicated that the levels of all the cytckmes measured
varied in relation to the menstrual cycle. lL·2 . [L-4, and lFNy secretion by PHA
stimulated PBMC was low at time of ovulation and high in the luteal phas e of the
menstrual cycle . There appears to be a TK I to TR2 shift from the follicular to the luteal
phase . Secretion of IL-l p and Ils-I ra in LPS stimulated cultures changed during the
menstrual cycle . The IL·I ratio (ll.-I fl/ll..-l fa) was low at ovulation in unstimulated
cultures and low at the late follicular and the midluteal phases of the cycle in LPS
stimulated cultures . The IL-I ratio in serum was lowest at ovulation with higher levels
in the follicular and luteal phases. Variability in the levels of the cytokines detected in
successive samples . both in serum. and in culture supernatants. was greater for women than
men for IL-4, lFNy in culture supernatants, and for lL-lra and IL-II} in serum. In
addition. females had significantly higher mean values for IL-Ira in nonstimulated cultures
and lower mean [L.I ratios in serum as compared to males. Finally, multiple regression
analysis of the cytokine data with the hormones estrogen, progesterone. and luteinizing
hormone as well as with age of the volunteer, day in the cycle the sample was obtained,
length of cycle. and day of ovulation demonstrated that 1L-4 and possibly IFNy
production by stimulated PBMC and IL-Ira production by unstimulated PBMe are
positively correlated with age. In contrast, 1L-2, production by stimulated PBMC and
serum levels of IL-Ira and IL-IJJ are negatively correlated with age. D..-Ira secreted by
both stimulated and nonstimulated cells is positively correlated with day in the cycle the
sample is taken whereas IL-I Pcorrelates with day of ovulation and length of cycle. All
of the correlations that were found to be significant in this study suggest thar the
menstrual cycle has a marked effect on the levels of eytokine production as detected in
vivo in serum samples and in vitro in the supernatants of cells in culture.
In summary , these data demonstrate that a) there is greater variation over time in
amounts of cytckine produced by women than by men b) there are changes in cytokine
production in women related 10 the menstrual cycle c) the lowest eytokine production
occurs at time of ovulation (the exception being IL-I in stimulated cultures) and d) age
influences the amounts of cytokines produced by women.
The data presented here support the hypothesis that (i) there are cyclical changes
in immune responses in women (ii) the immune response is influenced by changes in
ii
hormo ne status and (iii) reg ulation of cytokine produ ction is fundamentally different in
women than men.
iii
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CHAPTER I
INTRODUcnON
It is generally recognized that women have more vigourous immune responses than
men . lt would appear that gender influences both humoral and cell mediated immune
responses since a number of autoimmune diseases occur with higher frequency in women
than in men .
It is suggested that a woman 's imm une responses are influenced by hormones, and,
since hormone levels change throughout the menstrual cycle one would expect her
immune responses to also change.
I have followed nine women through a full menstrual cyc le . Hormone levels and
cytckines were measured in blood samples taken in different phase s of the cycle . The aim
of the study was to see if changes in cytokine production correlated with the phases of the
menstrual cycle .
1.1 The Menstrual Cycle
Females undergo complex cycl ing of reproductive hormones; this cycling is
referred to as the menstrual cycle (or perhaps more correctly, the ovarian cycle ).
The menstrual cycle alternates between two major phases, the follicular phase ,
which typically persist for 12 to 16 days and is characterized by the presence of maturing
follicles, and the luteal phase, which most commonly persists for 10 to 16 days and is
chars cterised by the prese- e of tit,. corpus luteum in the ovary (Marshall, 1995).
The cycling that is exhibited in females is due to the ovarian and pituitary
hormones that are produced. The levels of these hormon es that are seen in a typical
female cycle are illustrated in Figure 1.1 (modifi ed from Assc, 1983) and the plasma
concentration of various ovarian steroids as well as their production and secretion rates
arc shown in Table 1.1 (modified from Hsuch et a/ .,1995).
1.1.1 The Feedback Relationship between Ovariu and Pituitary Hormones
The feedback relationship that exis ts between the ovarian hormon e estrogen and
the pituitary hormones. folli cle stimulating horm one (FSH) and luteinizing hormon e (LH ),
determines the even ts of the menstrual cycle (Asso, 1983). The main estrogenic product
of the ovary is 17~estradiol (E2) and it also produces progesterone (P). FSH and LH are
controlled by the hypothalamus through gonadotropin releasing hormone (GnRH).
The control mechan isms are a comb ination of negative and positive feedback
systems (Clarke, 199 5). Estrogen exerts negative feedback control on FSH and LH
through GnRH. If estrogen is increased, the tenden cy is to suppress GnRH. release in the
hypothalamus . thus in tum suppressing FSH and LH productio n and release. In addition,
the ovarian hormon es also act at the pituitary level to decrease the sensitivi ty of FSH and
LH producing cells to GnRH (Asso , 1983). How ever , there seems to be a unique switch
in the effect of estrogen at the time of the preovulatory GnRHILH surge. At this time the
situation is reversed and estrogen exerts a pos itive feedback:effect on the syst em (Clarke,
1995).
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Figure 1.1. Relative levels of estradiol, progesterone. FSH and LH throu ghout the
menstrual cycle.
Table 1.1. Plasmaconcentrations, production rates,and ovarian secretion rates of ovarian
steroid hormones.
Steroid Pbase of Plasma cone. Production Secretion rate
Menstrual <ng/IOOmI) rare (mglday) (mglday)
Cycle
Estradinl Early follicular 008 0.07
Late follicular 33-70 0.5-1.0 0.4-0 .8
Midluteal 20 0.27 0.25
Estrone Early follicular 0.11 0.08
Late follicular 15-30 0.3-0.7 0.25-0 .50
Midluteal II 0.24 0.16
Progesterone Follicular 50-100 2.1 1.5
Luteal 1000-1500 25.0 24.0
17a- Early follicular 30 0.6 0.2
hydroxyproges
terone
Late follicular 200 4.0 3-4
MidluteaJ 200 4.0 3-4
Androsten- 130-160 3.2 0.8-1.6
edione
Testosterone 38 0.3
1.1.2 BqiDOiDZ: or the Cycle
The beginning of the cycle is referred to as Day I and is the first day of
men.struation . The levels of hormones at the end of one cycle are preparing the body for
the next cycle . This can be seen in the honnone FSH. As estrogen levels declin e toward
the late luteal pbase, FSH is beginning to rise commencing the growth of follicles that
will be invo lved in the next cycle (Asso. 1983) .
1.1.3 Follic ular Phase
The follicular phase begins with Day I of the cycle and ends with ovulatio n.
Throughout this phase the foll icles that can eventual ly give rise to a mature ovum
influence the changes seen in this phase and the hormonal changes that occur in this phase
provide the correct environment for maturation of the follicl e.
FSH stimulat es the growth of these follicles which in tum become the source of
estrogen in the cycle (Asso , 1983) . Thus the early follicular phase is characterized by
relatively high plasma leve ls of FSH and 10w levels of LH.. estrogen, progesterone, and
inhibin. FSH and LH exert a combi ned effect on the follicles to stimulate secretion of
estradiol which by the middle to the late follicular phase is secreted by the dominant
follicle (Marshall, 1995).
In the midfollicular phase estradiol concentrations in plasma are rising and
suppressing secretion of FSH by action OD the pituitary . As well . lohibin levels are rising
possibly contribu ting to the suppr ession of FSH (Marshall. l99S ).
Esuadiol is increased in the late follicular phase and exerts a positive feedb ack
effect on LH by enhancing LH respoesrveness eo GnRH and by in creasing Gn.RH
secretion (Marshall. 1995).
Progesterone. at this time in the cycle . is also beginning to rise and exerts a
positive feedback effect on LH. lt is the "ovarian estradiol-progest erone signal system "
that induces the "GnRH -LH·FSH" ovulatory surge (Marshall. 1995).
Several follicles develop in the ovary at the same time but only one will go on to
become the ovum that is released at ovulation. The other follicles will undergo atresia,
The developing or atretic stage of a follicle is characterized by the follicular fluid content
of estrogen s and androgens (Hsueh er al., 199 5). As they undergo atresia the follicles will
begin co switch from secreting principally estrogen to the secretion of' androgens. One of
the androgens that is secreted in this stage is testosterone and it is seen to peak just prior
to ovulation (Asso . 1983)
The menstrual cycle of' a woman is generall y stated to be 28 days in length .
However , the length varies greatly between women . On average the cycl e is 29.5 days
with a range of 26·34 days in normal females (Asso , 1983).
1.1.4 Ovu •• rioa
As estrogen declines in the late follicular phase a surge in LH is seen and
maintained for approximately 24 hours . This UI surge causes the largest follicle of the
ovum to be released from the ovary thereby allowing for possibl e fertiliza tion and
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implantation (Asso, 1983).
The rupture of the follicle at ovulation signals the end of the follicular phase and
the beginning of the luteal pbase (Marshall. 1995).
1.15 The Luteal Ph ...
The ruptured follicle that is left bebind in the ovary following release of the oocyte
undergoes a process called luteinization resulting in the formation of the corpus luteum
(Marshall, 1995).
This corpus luteum is responsible for the production and secretion of progesterone
and estrogen that are seen in the luteal phase of the menstrual cycle.
This increased secretion of progesterone and estrogen lasts for a number of days
after ovulation during which time FSH secretion is inhibited and remains low (Marshall.
1995).
This increase in progesterone stimulates the growth of the endometrium that will
allow for development and growth of the fertilized ovum (Asso, 1983). If fertilization
does Dot take place. plasma levels of estradiol and progesterone decline leading to
shedding of the endometrium and is seen as menstrual flow (Asso, 1983).
At this time FSH levels begin to rise initiating the development of a new set of
follicles , beginning the cycle allover again (Asso, 1983) .
1.2 SeE. bormoDes and Immune Response
It has long been known that the sex hormones infl uence or are interrelated with
the immune response. Research in the field of immune-endocrine interactions has been
ongoin g for some time. Four main areas of research today have provided significant
evidence for the role of sex hormone s in the immune response, including : I) the
differences in immune responses between males and females; 2) the knowledge that
gonadectomy and hormone replacement alter the immune response; 3) the observation that
the immune response is altered during pregnancy; and 4) the presence of receptors for sex
hormones on celts of various arms of the immune system (Grossman, 1984) .
1.2.1 Sex Related Differences in Immune Response
Sex related differences in immune response have been observed in several strains
of mice and in humans (Huber et aJ., 1981; Shuurs and Verheul, 1990) . It has been
observed that males are less likely to develop autoimmune diseases than females (Lillehoj
et al ., 1981; Ahmed and Penhale, 1982), that autoimmunity in males can be induced by
injection of estradiol (Gershwin et al ., 1980) and that females have higher titres of
autoantibodies in serum (Inman, 1978; Ahmed et at., 1985) . The immune response of
females is greater than that of males (Grossman, 1985) . Females have higher serum
immunoglobulin levels than males, mount higher antibody (Ab) responses to various
antigens (Schuurs and Verheul, 1990) and reject allogeneic skin grafts faster than males
(Butterworth et al., 1967 ; Graff et aJ., 1969). In addition, it has been noted that
prevalen ce of predisposition to allergy changes at about age IS from males to females
(Scbuurs and verheul. I990) .
The evidence thar there is a difference between the immune system of males and
females suggests that the influence of gonadal steroids is very importan t. Much of the
work done has been on determining the infl uence of these hormo nes on various arms of
the immune response.
It is important to note here that the outcome of in vivo studies done in various
laboratories is influenced by the dose and type of administr ation of the hormone as well
as by age of the animals used (Ahmed er 01., 1985).
1.%.% Humoral Immuni ty
1.%..%.1 DirKt Acti on or Gonadal Horm ones
Estrogen has been shown to enhan ce the immune response to various antigens in
several species (Stem and Davidson, 1 95 5 ~ Kenny and Gray, 197 1 ~ Myers and Petersen,
1985; Erbach and Babr., 1988). Nikolaevich et at., 1991 demonstrated that injection of
estradio l into ovariectomized mice stimulated the immune response as indicated by
increased Ab response to sheep erythrocytes, while injection of progeste rone did not have
such an effect. In vitro studies indicate that estrogen has a direct effect on the immune
system by influencing lym phocyt e functio n (Erbach and Bah r, 1991) . Kenn y et al ., 1976.
incubated" in vitro, E. coli primed murine spleen cells with various concentrations of
estrogen . They foun d that physiological levels of E2 caused an increase in the number
of A" secreting cells in male mice compared to untreated cells as demonstrated in a
haemolytic plaque assay (PFC), by examining the ratio of rota! plaques from E2 treated
cells with control cells. The authors suggest that the pheno menon obse rved is independent
of phagocytic function and that E2 directly affects lym pho id cells in the spleen.
Myers and Petersen. , 1985 , found that intraperitoneal (i.p.) injectio n ofE2 in male
rats resulted in a dose-related increase in anti- sheep red bloo d cell (SRBC ) antibody titres
during the primary immune response (characterized by lbe prod uction ofanri-SRBC IgM ).
Unlike Kenny, these investigators found no increase in the number of Ab produ cing cells
between contro l and estradiol treated animals as measured by a plaque forming assay .
Similarly, in humans, incubation of peripheral bloo d cells (PBL) with E2 cause d
an increase in the number of cells secreting [gM (paavonen et al., 1981) and IgG
(Weetman et al ., 198 1).
Ainbender et al ., 1968 , examin ed differences In specific Ab to poliovirus in the
serum of males and female and found a differen ce between men and women in the
proportion of [gA and [gG polio antibody . Specifically, it was found that in women the
IgA polio antibody titre was equal to or greater than the IgG titre and that in men it was
less . There was no difference in the serum concentrations of IgA or IgG betw een the two
groups .
KonstadouJak is et al., 1995, compared in vitro and in vivo immune parameters
between female and male rats using a compli cated experim ental des ign involving honnone
injecti ons and gonadectomy. The results of the study considering only the in vivo [gG
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levels in serum were as follows: [10 levels in serum of male pups treated with
testosterone propionate (TP) were increased as compared 10 contro ls and [gG levels in
serum of female pups treated with TP decreased; gonadectomy in both sexes produced
effects similar to those as animals treated with TP . Thus in male rats the increase ofIgG
production in vivo after castration indicates that testosterone suppresses T and B cell
functions.
Another study examined the in vuro effect of physiolo gical concentrati ons of E2
and testoste rone (Te) 00 Ag non-specific differentiation of human peripheral blood
mononuclear cells (pBMC) stimulated with pokeweed mitogen (PWM) . Assessment of
B cell differentiation was indicated by the number of Ab secreting ceJls assayed by
reverse hemolytic PFC assay using SRBC as indicato r cells . II was found that in vitro
differentiation of B cel ls. from both men and women. stimulated with pokeweed mitogen
and cultured with physiological levels of E2 was significantly augmen ted as compared to
controls and that physiological concentrations of Te inhi bited PWM ·induc:ed B cell
differen tiation (Sthoeger er aJ.• 1988).
The variable effects of estrogen on the humeral immune response is illustrated in
the observation that production of Ab to Candida albtcans in mice is enhanced by E2 at
low levels but depr essed at high levels of the hormone (Mathur et al ., 1979).
Similarly , it bas been found that women have better Ab respons e 10 the Hepatitis
B vaccine th.an men do as indicated by the great er geometric mean titers for anti·HBs
(Struve <I aJ.• 1992) .
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Evidence for the direct effect of sex honnones on the immune response is also
supported by the fact that receptors for estrogen have been found in mouse spleen
(Detlefsen et aJ.• 1977). human. spleen (Dan el et al .; 1983; Stimson. 1988) and on human
PBL's (Danel et al .• 1983; Weusten et al.• 1986).
1.2.1.1 lDdirect Actio. of Go.adaJ Hormones
Several papers. illustratin g both in ""'" and in VItro experiments, have indicated
that the influence of hormones on humoral immunity is indirect (paavovnen et al.• 1981;
Barnes et 01.• 1974; Stimson and Hunter, 1976; Holdstock et al.; 1982).
Erbach and Bahr, 1991. investigated the requirement of the thymus in the
enhancement of humoral immune responses by estrogen . Adult female rats were
ovariectomized and thymectomized or sham. thymectomized and s.c. given E2 or left
untreated. Results showed that E2 enhancement of in vivo hum oral immuni ty requires the
thymus. Both male and female rats need an intact thymus to achieve E2 enhancement of
Ab titres.
1.2.3 Cellul ar Immun ity
Estrogens and progestins inhib it proliferative responses of T cells to certain
mitogens and antigens [phytohaemagluttin (PRA) , Con A or purified protein derivatives
(Mendelsohn et al ., 19n; Wyle and Kent. 1977)]. Athreya et aJ.• 1993, evaluated the
effect of the presen ce or absence (controls) of vario us sex stero ids 00 the proliferative
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responses to PHA. n.~2 or anti·CD3 o f PBMe s taken from normal human adul t males
and found that E2 and Te bad no consistent effect on the proliferative response to any of
the stimuli tested E2 + PHA caused a decrease In the percentage of CD4· T cells and
E2 + IL-2 an increase in the number of cos· T cells. Te + 1L·2 increased the percentage
of CD4· cells indicating a potential role of hormones in T cell activation. In contrast to
this, Gilbody et al., 1992, studied dose related effects of estradiol 00 rat thymic and
splenic T lymphocyte responsiveness to mitogeos and found that estradiol stim ulated
responsiveness of lymphocytes.
Konstadoulakis et al ., 1995. did in vitro studies en rats and the cellular response
during self MLR (p.IO). They found that in W\lO administration of Te had a negative
effect on self~ and E2 injection had a positive effect as shown by an increase in
~ after castration and a decrease in~ after oophorectomization.
Bara! et al .; 1996, found that pretreatment of PSIS target cells (8 murine
mastocytoma cell line) with esttadi ol or tamoxifen (estrogen antagonist and potent
immunomoduIatory agent) makes them significantly more susceptible to Iymphokine
activated (LAK) cell mediated cytotoxicity.
1.2.4 The Cycl e and Immune Response
1.2.4.1 Humo ral aod M ucosal Immunity
Studies done in mice and rats indicate that the levels of Ab's fluctua te during the
estrous cycle. Total [gA levels in rat uterine secretions obtained by uterin e flushing are
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higher during the estrus and proestrus when compared to the diestrus; total IgG levels In
uterine secretions are higher in the proestrus phase of the cycle as compared to the other
phases (Win and Sandoe , 1971, 1980). In addition. migration of lymphocytes to the
genital tract.specifically the uterus. vagina and cervix, in female mice is influenced by
the estrous cycle; it has been found that the re is an increased number of IgA producing
plasma cells at these sites during proestrus and estrus (McDermott et al ., 1980; Rachman
et a/ ., 1983).
Several groups have shown that progesterone and estrogen directly influence the
fluctuating levels of secretory component (SC) and antibodies, as well as the number of
B cells in the genital tract of female rats and mice (Wang et al., 1996; w rre and Sandoe,
1977; Sullivan et al .• 19&3). Similarly, cyc lical changes in SC, measured in uterine
secretions, and total Ab levels have been demo nstrated in humans (S ullivan el al., 1984;
Usala et aI., 1989). SpecificalJ y, Usala et al ., 1989, investigated imm unoglobulin levels
In cervicovaginaJ secretions during the menstrual cycle using the microradial
immunodiffusion method . Results indicated that IgG levels in vaginal fluid samples were
high in the follicular phase with a steady decline to low levels throughout the luteal phase.
IgA was present at levels In-fold less than IgG and near the assays limit of detection
though it was seen that the lowest vaginal concentration was around the midluteal phase.
Several different systemi c routes of admi nistration (s.e., i.m. and i.p.) of antigen
have been shown to induce specific Ab's in the female genital tract of several species
including humans (Gallichan and Rosenthal , 1996 ; Miller et a/.• 1992 ; Ogra and Ogra.
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1973; Parr and Parr. 1990).
Intravaginal and intraut erine imm unization are mucosal ro utes of immunization and
have been able to induce both spec ific (gG and 19A in the genital tract, vaginal secretions,
and in serum (Milleigan and Bernstein. 1995; Ogra and Ogr a., 1973 ). Other mucosal sites ,
for example. intranasal (i .n..)generates both IgG and IgA in the vaginal secretions of the
geni tal tract (Gall ichan and Rosenthal, 1996; Muster et al., 1995 ).
Few of th ese studies take into account the stage of the c;;ycle. Gallichan and
Rosenthal, 1996. examined the influence of the estrous cycle in mice on the levels of
Herpes Simplex Virus Type 2 glycoprotein (HSV- gb) speci fic IgA and IgG Ab', in the
female geni tal tract. speci fically vaginal fluid. The mice were immunized i.n. with
AdgBl. a recomb inant adenovirus type S vector. Resul ts indicated that there was a
cyclical fluctuation in the Ab production, JgG was highest in diestrus and lowest at estrus,
IgA was high est in estrus and lowest in diestrus. Susceptibility of ua immunized mice to
intravaginal HSV -2 infection was studied during various estrous cycle stages and it was
found that mice infected during estrus were prot ected from infection since no viral
replication or genital pathology was observed, In addition . results showed that i.n.
immunization during a progesterone-induced diestrus-like state protects against subsequent
intravaginal challenge as significantly less virus replication and genital pathology was
observed. The discovery that levels of IgG and IgA antibodies in the genital tract of i.n.
immunized mice vary inversely with each other and are dependent on the stage of the
cstro us cycle reflects the chang es that occur in the reproductive tract during the course of
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the cycle . Estrus is the time of mating and it follows that high levels of IgA should be
present to take care of the pathogens associated with mating (Gallichan and Rosenthal,
1996). These increased levels of IgA seen at estrus are supported by the findin g that there
is an increase in the number of IgA prod uciog plasma cells in the uterus. vagina and
cervix during proestrus and estrus (McDermott et 01., 1980; Rachman er aJ., 1983) and an
increase in SC in the uterus during estrus (Sul livan er al., 1983).
Simi larly , Parr et al., 1994 investigated the effect of the estro us cycle and sex
hormones on vaginal infection of adult mice by HSV-2 . Results indicated that inoculation
dwin g estrus res ulted in no infecti on whereas inoc ulatio n in the progesterone domi nate d
phase resulted in mice becoming infected with the virus (pan et al .; 1994)
1..1.4..1 Prosta llaodial
Prostaglandins (pG) are also inv olved in the immune response. They are mediators
at several levels (Kunkel, 1988). Les lie et al.• 1987 noted that female mice synthesized
8 grea ter amount of PG than male mice and with greate r variation between females in the
group, therefore leadin g to the hypothesis that PG synthesis was modified by hormo nes
during the estrous cycle . A later study fo und that hormonal status of human fem ales is
associated with changes in PG metabolism. Leslie and Dubey , 1994, found that both
~ and PGI: were increased in the medi um of cultured monocytes isolated during the
luteal phase compared to medium from follicular phase cultures and to monocytes cultured
from males don ors.
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1.2.4.3 CeUular Immunity
Herrera et al .; 1992. examined the response of human lymphocytes to mitogenic
stimulation over the course of the menstrual cycle and in response to in vitro addition of
phys iological concentrations of E2 and P. The study showed that there was large intra-
individual variation over the course of the menstrual cycle and that in vitro administration
of estradiol and progesterone at physiological concentrations inhibited prohferation of
male aod female PHA stimulated human lymphocytes.
Similarly, Bjune, 1976. investigated in vitro lymphocyte responses to PHA during
the menstrual cycle and pregnancy . In this study , 2 healthy women were bled twice
weekly for 2 months . Response of PBMe to PHA were recorded IS incorporation of ~.
thymidine in the presence of 10% autologous plasma and 10% pooled human serum. One
pregnant woman and two males served as controls . The results indicated that in the two
cycling women , PHA responses varied greatly throughout the cycle . They found that at
the time of ovulation the responses were low and that during menses they were high .
They also found that addition of autologous serum resulted in strong suppression in the
pregnant woman and in cycling women in the luteal phase of the cycle. whereas it had
an augmenting effect in the follicular phase . The PHA responses to autologous plasma
were constant in the males and the pregnant woman .
In contrast, another study investigated nine women over the course of one
menstrual cycle measuring reactivity of blood lymphocytes to PHA during the menstrual
(low levels of E2 and P), midfollicuJar (peak levels of estradiol), and midluteal phases
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(peak. levels of progesterone). Data indicated that there were no differences in reactivity
to PHA over the three menstrual cycle phases and no relationship with any of the
hormones measured (Caggiula et aI., 1990).
In addition to studies done on the PHA response during the menstrual cycle, a
recent study has been done on cytotoxic lymphocyte (Cl'L) activity during the menstrual
cycle . In this study en. activity was monitored in the reproductive tract in relation to
the menstrual cycle . Human female reproductive tract cells were isolated from
hysterectomy patients from the fallopian tube, uterine endometrium, endocervix, ectocervix
and vaginal mucosa. The cells were cultured overnight in the presence of fi..-2 to yield
effector cells and then these effector cells were incubated with or without OKD (anti-
CD3 mAb) in a chromium release assay. This assay measured total CDr T cell mediated
lytic activity by use of FcRIIllll bearing, 51 Cr-Iabelled PSIS target cells . Results
indicated that cor CDS " cytolytic T cells are found throughout the reproductive tract
and, when the proliferative phase (follicular) and the secretory phase (luteal) were
compared, that the capacity for CD3" T cell cytolytic activity in the uterine endometrium
is present during the proliferative phase but absent during the secretory phase . This
indicated that COl' CDS" cytolytic T cells are hormonally regulated. It was also found
that in postmenopausal women, the entire reproductive tract retains the capacity for strong
cor T cell cytolytic activity . The authors suggest that the data support the idea that high
levels of E2 and P present in the luteal phase of the menstrual cycle downregulate CTL
activity in the uterus thus allowing for implantation of the semiallogeneic embryo. They
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also conclude dlat CTL activity is regulat ed differentl y in different regions of the
reproductive tract (Whit e et aI .• 1991)
Fluctuations in the WBC counts heve been observed during the menstrual cycle
ofbumans. Mathur eraJ., 1979 investi gated cyclic variations in whit e cell subpopulations
in serial blood sampl es from males and females. Monocytes and granulocytes were
increased in the luteal pbase as compared to the follicular phase ; WBC. total T cells and
lympbocyte coun ts were decreased at the pre-ovul atory E2 peale in the follicular phase .
The conclusion of Mathur et al ., 1979 was that lympbocyte coun ts were negatively
correlated with E2 and monocyte and granulocyte counts were positively correlated with
proge sterone . Results also showed that there were no cyclical varia tions in wac
populations in men and in women with nonovulatory cycles.
There has also beensome interest in whether the immune response diff erences that
are seen between males and femal es exis t at the level of extrathymic T cells , defined as
T cells expressing T cell receptor . (CD3) of intermediate intens ity {i.e.intermediate Teells )
and a bigh level of 1L-2 receptor fJ-<;bain. in various organs of mice . It was fowles that
the C04·'C08" T cells ratio is higher in females as compared to males and that
intermediate T cells of possibly extrathymic ongin were more predominant in the liver and
other organs of femal e mice than in males (Kimura et aJ., 1994).
Sex hormones play a role in regulating antigen presentation by uterine cells
(obtained by uteri enzy mati c digestio n) in female rats as demo nstrat ed by Wira and
Rossoll . Antigen presentation was measured by ovalbumin-sensitized T cells cultured in
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the presence of irradiated epithelial or stromal cells and ovalbumin with proliferation
measured by )H thymidin e uptake. Results indicated that antigen presentation by uterine
epithelial cells is high at diestrus . low at estrus. Antigen presentation by uterine stromal
cells was high at estruS, low at diestrus . In addition . if estradio l is given to ovariecromized
rats this causes an increase in antigen presentation by the epithelial cells and a decrease
in antigen presentation by stromal cells as compared with controls (Wira and Rosse ll,
1995).
1.25 Conclusioas
It is apparent from the volume of work thai has been done on the influence of
gonadal hormones on the immune system that there is much interest in the area but the
picture is still unclear . Contributing 10 this phenomenon is the knowledge that many
investigations yield different results depending on the route of administration and dose of
the hormones used for studies . As well, different results are obtained from differen t sites
including uterine. vaginal, mucosal, and systemic areas of the system. Altho ugh the
results differ in these circumstances it has been shown conclusively that gonadal steroids
do indeed influence the immune response in humans and animals .
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1.3 Cytokines
Cytokines are peptides or glycoproteins that act as soluble mediators of immune
response . They regulate local and systemic immune and inflammatory responses as well
as many other biological processes (Oppenheim et al. ,1994) .
They are highly potent molecules that act at concentrations of 10.10 to 1O'1SM
influencing the immune system as autocrine, paracrine and endocrine hormones
(Oppenheim et al ., 1994).
All the information in the following sections on cytokines has been obtained from
two primary sources j.g, Abbas et al., 1994, and Oppenheim et al., 1994. Due to this fact
the publications will not be sited throughout the text.
1.3.1 Interleukin 1
Interleukin 1 is a cytokine that is principally produced by activated mononuclear
phagocyctes but can be produced by other cell types . These include : B lymphocytes,
natural killer cells (NK) , T cell clones grown in culture , keratinocytes, dendritic cells ,
astrocytes, fibroblasts, neutrophils, endothelial cells and smooth muscle cells . Significant
amounts of IL~ I have been found in skin , amniotic fluid , sweat and urine .
Lipopolysaccharide (LPS) , a bacterial cell wall product , tumour necrosis factor and
interleukin 6, other cytokines, and CD4 +T cells interacting with antigen presenting cells ,
can all initiate production of IL-I by mononuclear phagocytes.
The principle function of IL-l is as a mediator of the host inflammatory response .
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The actions of IL· l depend on the concentration of IL-I present in the system.
At low concentrations of IL-I, [1.. 1 acts on mononu clear phagocytes in an
autacrin e fash..ioa to furth er stimulate synthesis of IL·l and to induce synthesis of IL--6
It also acts on mononuclear phagocyctes to synth esize chemc kines, molecul es that
stimulate and direct leucocyte movement
When lL-1 is present at higher concentrations it can exert endocrine effects by
causing fever, synthesis of acute phase proteins and cachexia.
fL· I exerts its actions through two distinct forms, those of IL·la and IL·lJl
These two types of a-I are peptides that are encoded by separate genes and share 26%
amino acid sequence homo logy. Although thes e are distinct forms of 0..-1 they are
virtually identical in pot ency and activi ty.
In addition to havin g two distinct forms of IL· I present in the system there is also
a natural ly occurring inhibitor of ll..-l . This inhibitor is called n. ·l receptor antagonist
(IL. Ira) and acts to inhibit IL· l by binding to IL-I recepto rs preventing the functional [L.
I from binding and exerting it's influence. Ils-I ra is a competiti ve inhibitor that acts to
endogenously regulate IL-I in the system.
lL-l a and IL· l fJ bind to high affinity receptors (K.._l0-10 M) that are found on all
IL-I target cells. Two distinct types of receptors, IL·IRI and n.·IRll. have been found
to bind to a-Ia and IL-lfJ equal ly. These receptors are 28% homologous in sequence
similarity and have three extracelluar domains.
[1..1RI is the type I receptor and it has a 217 a.a. cytoplasmic tail that can trans mit
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signals to the cytoplasm of the cell when lL-I is bound.
lL-IRII is the second distinct type of receptor found that will bind lL-I and. unlike
[l-IRl. it does not have a cytoplasmic tail. Thus it cannot transduce signals to the
interior of the target cell.
It is also important to note that one of the major functions of IL-I Rll is thought
to be as an endogenous inhibitor of lL-11J at inflammatory sites due to the release of the
extracelluar domain of the receptor into solution at times of inflammation. This soluble
lL-IRll can bind lL-IP more strongly than lL-la.
1.3.2 Tumour Necrosis Factor a.
Tumour necrosis factor a is a cytokine that is primarily produced by activated
mononuclear phagocytes but can also be produced by antigen stimulated T lymphocytes,
activated NK cells and activated mast cells . TNFa is the mediator of response to gram
negative bacteria with the response due directly to the presence of LPS in the bacterial
cell wall. The effects of TNFa on the systems of the body depend largely on the
concentration of TNFa present. TNFa. can act in an autocrine , paracrine and endocrine
manner and has effects in much the same way lL-I does.
At low concentrations TNFa acts locally as a paracrine and autocrine regulator of
leukocytes and endothelial cells. TNFa.., at these low concentrations. causes activation of
neutrophils ; increase in expression of adhesion molecules contributing to accumulation of
leukocytes at the area of inflammation; production of other cytokines like [l-I , IL-6 and
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TNFa itself as well as chemckines; and augmentation of expression of Class I MHC
molecules thereby assisting in cytotoxic lymphocyte (CTL) mediated killing of infected
cells.
At high concentrations . TNFa acts in an endocrine manner and enters the blood
stream . When TNFa is acting in this manner it produces different effects on biological
systems. These effects include the induction of fever by acting on the hypothalamus.
induction of mononuclear phagocytes to secrete ll.-I and fi...6 into circulation . increased
secretion of serum proteins like serum amyloid A protein thus contributing to the acute
phase response, activation of the coagulation system, and suppression of bone marrow
stem cell division.
As with IL· l , two types of high affinity receptors have been identified to bind
TNFa . The type Il receptor has a higher affinity for TNFa than Type I. Each receptor
is composed of a large extracelluar domain . a hydrophobic transmembrane region and an
intracellular transducing piece. It is thought that the two types of receptors induce
different effector functions. Binding of TNFa to Type I receptor promotes cytotoxic
activity and Type Il promotes T cell proliferation.
1.3.3 Interleum 6
lnterleukin 6 is a cytokine that has a wide variety of biological effects . It is
mainly produced by mononuclear phagocytes , vascular endothelial cells and fibroblasts.
The secretion of IL·6 is often in response to ll.-I and TNFa secretion .
24
IT.-6 synergiz.es n..( and TNFa to induce the acute phase response. ll.-6
participates in this response by inducing hepatoeyetes to produce serum proteins like
fibrinogen . It is also known to serve as a growth factor for activated B cells . It enhances
B cell replication, differentiation., and imm unoglobulin production.
IT.-6 has the abillty to synergizc with ll.·1 and TNFa augmenting the mitogenic
effects of these cytokines on T helper cells. This effect is in part due to the ability of [1..-
6 to increase expression of 1L-2 receptors.
The high affinity receptors for IL-6 , (K.t-IO·IO- 10.1: M), are expressed on a variety
of cell types . These include macrophages, myelomonocytic cell lines, hepatocytes, resting
T cells, activated or EBV infected B cells , and plasma cells . The receptor is composed
of an a and a JJ chain . The ll.-6Ra chain does not have a cytoplasmic domain. This
chain binds [1..-6 with low affinity producing the IL-6Ra-IL-6 complex which then binds
with high affinity to IL-6Rll chain . This chain does contain a cytoplasmic tad and thus
the signal can be transduced.
1.3.4 lDterieukio 2
ll..-2 is the principle cytokine responsible for the growth of T cells , specifically the
induction of T cells to move from the G) phase to the 5 phase of the cell cycle. This
cytokine is produced by T cells, specifically CD4- T cells but also by CDS- T cells when
antigen and costimulatory factors are present.
[1..-2 has the ability to act in an autocrine and paracrine mann er. It functions in an
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autocrine manner by acting as a growth factor for the T cells that produce it but can also
act on nearby T cells to induce n..· 2 thus acting in a paracrine manner. It does not
circulate in the blood during an immune response thus does not act as an endocrine
growth factor .
Because of its effects on T cells, a major component of the immune system. it is
thought to be a critical immunoregulatory cytokine. It influences hwnan lymphocytes to
promote not only proliferation but also production of other lymphokines like IFNy, TNFl\,
IL-6, 1L-4. lL-l. IL-S, and GM-CSF. IL-2 will also stlmulate NK cells to produce other
cytokines that in tum activate macropbages and enhanc e the cytolytic activity ofNK cells.
The effect of fi.-2 on NK cells produ ce a superior killing cell called the Iymphokine
activated killer cell (LAK). IL-2 influences B cells as well by enhancing proliferation and
antibody productio n, preferen tially promoting produ ction of IgG2 antibodi es.
The IL-2 receptor is composed of three polypep tides, a, P and y. Each
polypeptide on its own can bind IT.-2 but with low affmity. Together they bind with a
high affini ty <K..-IO·" M).
The a chain has only a small cytoplasm ic domain and thus canno t transduce
signals to the interior of the cell. The Pand y chains have larger cytoplasmic domains
and can transduce signals to the interior of the cell .
1.3.5 laterieukin 4
Interleukin 4 is a cytokine that is principal ly produced by CD4+T lymphocytes,
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specifically those of the T82 subset. It is also produced by mast cells. lL-4 was initiall y
described as a B cell growth factor as it helps in B cell proli feration and as a B cell
stimulatory factor because of its abili ty to induce Class n MHC expression on resting B
cells . 1L-4 is a major regulator of heavy chain class switching as it is required for the
production of IgE antibodies. In addition, 1L-4 influenc es expression of low affinity Fe e
recep tors on B cells.
IL-4 acts on macroph ages to inhibit activation and block the effects of another
cytokia e, lFNy, produced by the TH I subset JL.4 acts as a growth and differentiation
factor for T82 cells and suppresses the induction and fimction of THI cells .
IL-4 also influences expression of some of the adhesion molecules like VCAM ·l
on endothelial cells and causes endothelial cells to secrete MCP·I , a chemota ctic protein.
Th ese functions allow for inflamm atory reactions thal are rich in monocytes and
eosinophi ls. Mast cells are influenced by il. -4 as it promotes growth of this type of cell .
il.-4, through aU these functions, seems to be a princ iple mediato r of aller gic
reactions and, as it is chara cteristically produ ced by the TH2 subset. is responsible for the
prevention of many cell-mediated immune responses by preventin g the TH I subset
functions.
1.3.6 laterferoo y
lFNy is produced by both nai ve (T. O) and T.l CD4- helper T cells. by CDS" T
cells and NK.cells when activat ed It upregulares express ion of Class I and Class II MHC
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thus aiding in cytoto xic killing and promotin g antigen presentation to CD4- T
lymph ocytes. It acts as a poten t activator of mononuclear phagocty es inducin g the
microbi cidal and cytotoxic activity of macrophages and production of other cytokines such
as lL·t, IL-6, IL-S, and TNFa. NK cells , neuuophils, and vascular endothelial cells are
also activated by this cytokine.
IFNy acts on T and B lymphocyt es to promote differentiation. specificall y lFNy
prom otes differentiation of naiv e T cells to the Ta l subset and inhib its proliferation of the
TR2 subset. CDS· cells are aided in maturation by lFNy and B cells expose d to IFNy
produce IgG2a and IgG) subclasses of antibodies preventing production of IgG I and liE.
The effects of IFNy described above all contribute to cell mediated immune
responses and the suppression of humoral mediated immune response .
1'" Su Hormonu a.ad Cytokincs
There are sever al stu dies that indicate the infl uence of sex hormones on cyto kine
producti on. This influence has not been explained althoug h a great deal of evidence exists
for the relationsh ip. Much of the work has been done on the inflammatory cyto kine It·1
and some information is available on several other cytok ines. The focus of this section
will be on the cyto kines measured in this study.
1....1 Ses Hormones aad n-i
One of the earliest stu dies don e to show the influen ce of gonadal steroid on
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cytokine production was by Cannon and Dinarello in 1985. They examined lL~1 activity
as measured by the effect on proliferati on of 0 I0 cells, a murine T ce ll line. stimulated
with PHA. When JL. I activity was assayed using plasma from health y human females.
there was signi ficant Ila-l activity in the plasma isolated durin g the luteal phase as
compared to the fo llicular phase of the menstrual cycle. Subsequently. an experiment
done with plasma from five healthy women who were bled once durin g the follicular and
luteal phase of their cycl e (as determined by progesteron e concentrations) showed that the
luteal phase plasma had greater lL~1 activity than the foll icular phas e plasma. They
postuJated that this increas e in Il>t activity during the luteal phase of the menstrual cycl e
was consistent with the 0.2 to 0.6 °c rise in body temperature that is seen in the luteal
phase and the infl amm atory focus present after follicular ruptur e (Cannon and Dinarello,
1985 ).
Since then . there have been seve ral studies done on the influence of gonadal
steroids on the production of cytokines both by bumans and animals in both in vitro and
in vivo systems.
Hu et al .• 1988 examined the effect of estradiol on Ils-l synthesis/secretion by rat
peritoneal macrophages as measured by a thymo cyte proliferation assay. Using peritoneal
adherent cells (PAC ) isolated from five female and male rats they analyzed the amount
of n..t spontaneously secreted in culture and found that cells from adult femal es secret ed
more lL~l than cells from males or prepubescent females. In addition. ovariectomy led
to reduced synthesis of lL·I by PAC and in vivo estradiol administered subcutaneo usly
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effectively increased IL~I synthesis . To further show the influence of estradiol on IL~l
secretion, it wasdemonstrated that n.~1 secretion could be increased in PAC isolated from
male rats when the PAC were incubated in vitro with physiological concentrations of
estradiol. When PAC were incubated with E2 and LPS the enhanced IL~ I secretion was
greater than with E2 alone .
The effect of steroids on mcnocytes has also been demonstrated. Human monocyte
[L~ I activity as a function of increasing E2 and P levels have been examined. Human
peripheral monocytes isolated from males were incubated with increasing concentrations
of both steroids in separate cultures . IL-I was measured by the 010 thymocyte
stimulation bioassay and dose response curves as a function of E2 and P were established.
It was found that low concentrations of E2 (l0'!1 ~ 10·1~ and P (10.1 ~ IO-~) resulted
in maximal ITA production. At higher concentrations of E2 (lO"M) and P (2:IO·'M, this
being the physiological range of P seen in the luteal phase and early pregnancy) there was
a significant reduction in IL~I activity (polan et at.,198ga).
Similarly. Flynn, 1984, demonstrated that monocytes isolated from placental tissue,
both cultured and not cultured (lyzed by sonication to determine cellular n.~l content) ,
produce lL~1. In addition. Flynn also found that with estrogen and progesterone
stimulation of the monocytic tumor line P338D, production of lL~l was stimulated at
physiological concentrations but suppressed at high levels of these steroids.
The ability of peripheral monocytes isolated from varying endocrine milieux to
secrete lL~1 has been investigated. Polan et al.; 1990, examined the levels of IL-l
30
secreted by cultured peripheral mcnocytes isolated from eight women before ovulation
(follicular phase) and during the late luteal phase (Day 12 of luteal phase) in human
menopausal gonadotropin and human chorionic gonadotropin stimulated cycles a well as
durin g pregnancy, 0=6 . [L·l activity was measured by the 010 thymocyte prol iferation
assay . Significandy mo re Ils-I was secreted by monocyte! isolated during the luteal phase
of the cycle than by cells isolated during the follicular phase or the third trimester of
pregnancy . This observation is consistent with previous work (polan et al., 1988a; Polan
et al.; 1988b). These experiments were designed to determin e the effect of physiological
levels of E2 and P on [L. I secretion by iso lating the monocytes at vano us time points
representin g the concentration of circulating stero ids. The results of the in vitro culture
studi es suggest that IL·I production by circulating monocyte! may be contro lled in part
by circulating steroid levels . Specifically, that progesterone is the critical factor in the
control of n..1 production.
Trying to tie the two studies together it is important to realize that monccytes
isolated during the second and third trimester of pregnancy in the study done by Polan and
associat es in 1990 were isolated at a time point where the concentration of P in serum,
is approximate ly I.S x 10-7 and 2.9 x 10-7 M, respectively . This approaches the
concentration where in vitro bioactivity is decreased (Polan el al., I 988a) and where ItAJ}
mRNA content is dec reased (Polan et at., 1988b).
The relationship between E2 and P concentration and the level of lL·lfJ mRNA
in cultured human peripheral monocytes and pelvic macrophages has also been addressed.
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Human peripheral monocytes and peritoneal macrophages isolated during the luteal phase
of the cycle and stimulated with LPS and increasing amounts of P or E2 show an inverse
relationship between lL~l13 mRNA levels and steroid concentration. lL-IP mRNA levels
decrease as P or E2 increase to tO-~ indicating that regulation by gonadal steroids Occur
at the level of transcription (Polan et al ., 1989).
In females undergoing in vitro fertilization , Polan et al ., 1994, showed that
luteinized granulosa and cumulus cells isolated from the follicular fluid of five women in
the luteal phase stained for the presen ce of D..-I mRNA but that cells isolated during the
follicular phase did not and that Ils-I mRNA protein appeared in the follicle coincident
with imminent ovulation. In addition, this study found that IL-I mRNA levels in
peripheral macrophages isolated during the follicular phase were equivalent to those seen
in male controls, but that a three-fold increase in IL-Ill mRNA was seen in monocytes
isolated during the luteal phase.
The effects of menopause and ovarian steroid treatment on IL·I release by
monocytes has also been studied. Monocytes were obtained from venous blood, cultured,
and a-I activity measured by the D10 bioassay. ll.·l activity from cells isolated from
postmenopausal, n=14, (low estrogen) women was higher than in either premenopausal
women, n=7, or estrogen/progesterone treated postmenopausal women, n=8, and treatment
with estrogen/progesterone for I month caused a substantial decrease In IL-I activity in
the postmenopausal women (Pacifici et al ., 1989) further establishing a relationship
between gonadal steroids and IL·l production.
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Pacifici et aJ.• 1991. evaluated the effects of oophorectomy and subsequent
estrogen.replacement on spontaneous secretion of IL~ l and TNFa from peripheral blood
mononuclear cells. They demonstrated that women who underwent oophorectomy. n=IS.
had increased production of Il>I and TNFa and that those who staned estrogen
replacement therapy showed a decrease in both cytckines. It was also demonstrated that
io women who had hysterectomy without ocphcrectcmy , 0=9 , no chan ge in cytokine
production was seen. This study indicates that changes in estrogen status in vivo are
associated with changes in secretion of mononuclear cell cytokines in vitro .
Another study. (Lynch et aJ.. 1994) looked at gender and menstrual cycle
dependent variation on IT.~1 production . Secretion of IT.-Ia.. a ·l p, and IL- l ra by cultured
PBMC and urine eytokine concentrations were examined to determine if in vitro secretion
corresponds to in vivo status. Mononuclear cells were isolated from five women. once in
the follicular phase and once in the luteal phase of the menstrual cycle. and from six men.
In unstimulated cell cultures it was found that there were significantly higher levels of
each of the three isoforms in females as compared to males and that in females cytokine
production was higher in the cells isolated during the follicular phase of the cycle. The
agonist/antagonist ratio (IL-Ia + lL-ll3m..~lra) was higher in the luteal sampl es consistent
with Polan et al., 1990 and Cannon and Dinarello, 1985. In the LPS stimulated cultures
there was no significant gender or menstrual cycle related difference seen among any of
the isoforms. The agonist/antagonist ratio (JL..la + n.~IJYU.-lra) was thre e-fold higher
in the follicular phase as compared to the other groups indicating that although women
33
have elevated [L·l activity in the luteal phase they have a more vigourous response to
cbaIlenge in Ibe follicular phase (Lynch et al., (994) .
1.4.2 Sex R ormoDes aDd TNFa
The effects of E2 on TNF a release. measured by bioassay . from hwnan PBMe in
vitro has been demonstrated by Ralston et al.• 1990 . Ralston examined TNF a release
from eight healthy premenopausal and postmeno pausal women and from men. It was
found that in nonstimulated cultures of cells isolated from postmeno pausal fem ales with
E2 added at concentrations between 10-1: • 1(r6 M. TNFa release was significantly
inhibited but the male ho rmone DHT had DO effect. In cells isolated from males and
premenopausal women E2 and OHT had no effect on TNF a release . In cultures stimulated
with LPS in the presence of either E2 or OKf DO effect was seen in either of the groups
Ralston also established that cytOtoxcicity mediated by the PBMe supernatants was due
to the TNFa as it was abo lished by a specifi c monoc lonal Ab to TNFa.
The effect of femal e sex hormon es on perito neal macrophage TNFa release was
sho wn in a study on five male rats. In this study resident periton eal macrophages
obtained by peritoneal lava ge or oil -elicit ed macropbages were used to determi ne TNFa
release after treatm ent with E2. P or LPS. The results indicated that resident peritoneal
macro pbages treate d with concentrations of E2 o r P greater than 10.1 ngl ml had
signific:andy reduced TNFa release compared to untreated con trols. Using oil-elicited
macropbages it was found that TNFa. release was dose dependent Maximal TNFa release
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was induced by E2 concentrations of 10.2 nglmJ and this release was greater than that of
the contro ls. Concentrations less than 10--4 or greater than 10-1 reduced TNFa release by
the macrophage s. Progesterone results were similar to the E2 results. They also showed
that Te depressed TNFa release from male rat peritoneal cells (Chao et at a l., 1995).
In addition to studies showing the effects of hormones on TNFa production other
studies have shown alterations in TNFa. mRN A levels. Loy et at., 1992, tested whether
TNFa mRNA levels in human peripheral monocy1es were regulated by gonadal steroids.
In this study , monocyt es isolated from peripheral blood of 2 healthy females during their
respecti ve luteal phases were cultured with LPS and P or E2 in dose response
experiments. The results showed that an inverse relationship existed between TNFa
mRNA production and concentrations of E2 or P, that is, the higher the dose of bonnone
in the culture medium the lower the TNFa. mRNA levels.
1.4.3 Se:l Hormones and Otber Cytokioes
Tamoxifen and tormifene are anti-estrogenic chemicals tha t bind to estrogen
receptors. Jarvinen et ai, 1996 studied whether these compounds had any effect on
phorbaJ 12-myristate 13-acetate (PMA) induced cytckin e production of B, T or myeloid
cell lines. When tamcxifen or tormifene were added to B cell line cultur es it was found
that both stimulated overall production ofTNF.lFN·y.IL-4.IL·lO. and lL-lP by the B
cell line. Results using a T cell line indicated that only tamoxifen stimulated cytokine
production, specifically IL-IP. n..-6 and IFN-y, whereas tormifene inhibited cytokine
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production. Cultur es with a myeloid cell line showed no effect of the compounds on
cytokine production.
A study of fourteen normal women showed that there is no significant vari ation
in serum levels of n..-IO, measured by EUSA, during the mensuual cycle in humans. It
is impo rtant to note that this study made use of multiple samples during the menstrual
cycle , specifically , 61 successive samp les were taken in total from the 14 women
(Blake more et al ., 1996 ).
Matsuzaki et al., 199 5 investi gated the changes in soluble ll.-6R and lL-6 levels
in serum of eighty pregnant and ferry- five nonpregnant wom en by EUSA (n=18 in the
follicular and luteal phase , n=9 at ovul ation ). The group found that sIL -6R in
nonpregnant women remained uacbaaged during the menstrual cycle; that the level in
pregnant women , although higher than in nonpregnant wo men did Dot show changes with
respect to stage of pregnancy and that serum ll..o concentration did Dotdiffer between the
groups or during the cycle .
Another study quanti tated the amounts of IL-6 present in the cervical mucus of
women with regular menstrual cycles both befor e and after ovulation . Cervical mucus
was obtained from 15 ovulating women during the 5 days before ovul ation (foll icular) and
durin g the 5 days after ovulation (luteal) . Analys is of lL-6 showed a wide range of
individual varia tion in the levels of IT.-6 and trend anal ysis demonstrated an increase in
ll.·6 levels in sampl es obtained from the follicular phase with a decrease at ovulation
(Kuneb et aJ., 1996) .
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Although much work has beendone on the influence of female sex hormone less
has been done on the influence of male hormones on cytokine production. In vivo i.p.
injection of mice with DHEA or DHEAS (sulfonated form of DHEA) resulted in greater
levels of 1L-2 produ ced by T cells in subsequent in vitro cultures stimulated with anti-
CD3 than in untreated controls. This study also showed that direct in vi tro culture with
DHEA at low doses enhanced the capacity to secrete IL-2 following stimula tion (Daynes
et aI., 1990).
1.4.4 Pilot Study
Our unpubl ished pilot study. similar to this project, suggested that there were
cyclical changes in cytokine production in females in relation to the menstrual cycle. In
the pilot project we measured the cytokines 1L-2. ll. -4 and lFNr. in cultures of
mononuclear cells stimulated with anti-C03 . We isolated PBMe from S women four
times during their cycle. twice in the follicular phase and twice in the luteal phase. Our
results indicated that production of ll. -2 fluctuat ed during the menstrual cycle with a peak
in the follicular phase and possibly a second peak in the luteal phase. The pilot study
failed to take into account length of cycle. health of the volunteers. and whether or not
the volunteers ovula ted.
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1.4.5 ConclusioDs
A summary of the relevant human eytokine information in rela tion to gonadal
hormones is presented in Table 1.2. Thi s table includes the cytokine examined. the
number of participants in the study, the source of the material tested,. the results that are
applicable to this project and the reference. The table is organized by cytck ine.
It would thus appear that i) estrogen and progesterone do influence Ils-I and TNFa
produe:tion in in vitro cultures. the effect depending on the concentration of the hormones.
ii) n.~1 production by unstimulated cell s is higher when cells are isolated from women
in the luteal phase than in the follicular phase , the reverse is true when the cells are
stimulated with LPS (what happens in between the two points is unknown). iii) Plasma
[L..l is higher in women in the luteal phase than in the follicular phase . but again. what
happens between the two time points is unknown. IV) There is DOsignificant change in
serum ll.·IO concentration during the mensuual cycle .
It is apparent thu many of the studies on hormonal influence of cytokines
employed onl y few subjects and only one time point. In about half of the studies 2 points
were obtained in the cycle. one in the follicular phase and one in the luteal phase . We
wanted to investigate the influence of hormones on cytokine expression at different phases
of the menstrual cycle using a larger sample size and many more sampling days .
Differences are observed between the follicular and luteal phases in several studies but
whether changes occurred that were not being picked up as a result of taking only two
time points is unknown . In addition. in several studies the women who provided the
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follicular phase samples were not the same as those who provided the luteal phase
samples . It was our intent to control for the extra variable by using the same volunteers
and sampling them throughout their menstrual cycle so we could see the differences that
occur in individual women.
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Table 1.2. Summ ary of buman e:ytolrine data in relation to the femaJe gonadal honnones.
The cy10kine examined. the Dumber of participants in the study . the 5OW'Ce of the materi al
tested, the resuJts and the references are given.
CylOlcine nO Source Results Reference
IL-I
5 s- plasma IL ·I activity r Cannoll and
ill L· Dinarello ,
1985
d" peripheral E2 10".10.10 M
mo eccytes t IL - I
P 10·-llr ' M t Polan et at,
IL-I 1988b
E2 or P 10·' M
~· IL· I
placental produce IL·I
monoc:ytes
Rynn, 1984
P338 D cell t IL - I . ,
line physioL CODC. or
E2 and P
~ IL-I al>
cone.
8 ~ F' peripher al r IL·I in L Polan el at,
8 ~ L mono cyt es 1990
6 ~ pregnant
~L peripheral t in IL·I~
monocyt es mRNA as E2 or Polan et al .,
P ~ 1989
peri ton eal
macrophages
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S ~ granulosa and IL·I rnRNA in L
cumulus cells phase not in F
from F fluid pbase Polan a at,
1994
peripheral u-i mRNA in F
macrophages
- men
j -fold > in L
n-r 14 pm- ~ peripheral IL -I activity in Pacifici et al .,
7 prm· i: monocytes pm > pnn or 1989
8 ElIP pm ~ E2IP pm
IS i PBMC t n- i and
oophorectomy TNFa Pacific et aI. ,
E2 treatment J,. 1991
u-i and TNFa
S ~ PBMC I WlStimuIated
6<1' sample in F a-Ia t F vs L
andL a-I~ t F vs L
a-I ra t F vs L
a - Ia + a-I~ Lynch et al .;
IlL-Ira t L 1994
stimulated
all iso forms of
n..-l-t>'
lL-la + a-I~
IlL- Ira t r
TNFa
8 prm ~ PBMC unstimulated
8 pm ~ pm + E2
8 <I' .J.TNFa
eecr prm + E2
TNFa -+ Ralston et al.,
1990
stimulated
no effect
2 i PBMc in L .J. TNFa as t in Loy et aJ.•
E2 or P 1992
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IL-IO 14 i serum
multiple
samples
IL·6 15 i cervical mucus
80 pm i
45 prm i (18
FandL.9at
0)
serum
IL·lO -->
IL·6 t F
IL·6 ~ at Ovul
sIL·6R and IL·6
--+ in prm
or in stages of
pregnancy
Blakemore et
al..1996
Kuneh et aI.,
1996
Matsuzaki et
al.., 1995
• number of participants in the studyif known
• female
It male
, increases or greater
<I Lutealphase
, Follicularphase
rdecreases or lower
• postmenopausal
h premenopausal
• no difference
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1.5 Aims and Objectivn
Based on the literature available and our pilot study data (section 1.4.4) our
hypothesis was that cytokine expression/secr etion is regulated in females by ovarian
hormones and therefore affected by hormonal changes of the menstrual cycle
Specifically. that the capacity of cells to produc e cytokines, as demonstrated either by
circulating cytok ine levels or secretion by cells in culture. is affected by the changing
levels of stero id hormones In vivo .
We chose to examine production of 1L-2. n.-4. lL- I ra, lL-la. lL-6. TNFa and
IFNy with a view to determining whether one or more of these displayed identical
patterns of change in all the women studied. The one or ones with the most predictable
pattern could then be used for futwe studies.
The objecti ves of this project were :
I ) to establish culture and stimulation conditions allowing detection in supernatants
of PBMC of various cytokines by commercial ELISA's
2) to creat e a sample set of serum and cells from normal healthy females at known
points in their menstrual cycle (ovarian cycle)
3) to create a similar sample set of contro ls using normal healthy males
4) to meas ure levels of estrogen, progeste rone, and lut einizing hormone in the
females and testosterone in the mal es
S) to com pare variability of eytokine production in circul ation and in supernatants
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of stimulated and unstimulated cells in culture, in males and females
6) to monitor serum cytokine levels and cytokine production by unstimulated and
stimulated cells in culture over the course of the menstrual cycle
7) to determine if there is cyclical variation, in females, of cytokine levels in
serum or cytokines produced by cells in culture
8) to determine if variation in cytokine expression is linked to cyclical changes in
the bormones estrogen, progesterone and luteinizing honnone
9) to select and use appropriate statistical methods for analysis of multiple data
points from a small number of individuals.
The parameters that were measured in serum were: n..·113. n.·l ra, n. ·6. TNFa.
The parameters that were measured in culture were: lL-lP, lL-lra. lFNy , 1L·2 . and lL4.
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CHAPTER n
MATERIALS AND MEmODS
2.1 Voluoteen
2.1.1 Cycling Women Selection Prot",:
The cycling volunteers were recruited from the university population through the
use of posters and presentations to various classes. They were screened using an Human
Investigation Committee approved questionnaire designed by us (Appendix A). Volunteer
criteria were as follows :
Healthy ( SUbjective, bued on the report
of the individual)
Caucasoid (subjective. based on appearance)
Women between tbe ages or 19-29 years
Not known to be pregnant
Not takiog any medication
Not taking oral cootraceptivea
Stable menstrual cycles, appro %8days
No bistory of major medical problems
Normal beipt and weiebt (Body Mus
Iudex. BMI)
Based on the above criteria 19 cycling volunteers were chosen to enter the study and
proceed to Phase [ out of 24 who volunteered to be screened.
2.1.2 Control Selection Process
Four males between the ages of 20·25 and 2 post-menopausal women, 57 and 59
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years old, respectively, were chosen through the use of a similar questionnaire. It was
intended to recruit 4 postmenopausal women but that could not be accomplished. In the
end we had only 2 and one women was not proved conclusively to be post-menopausal,
thus we did not include this data in the results though the raw data can be found in
Appendix B. The criteria for the controls were as follows :
Healthy (subjective, based on the self
report)
Caucasoid (subjective, bued on appearance)
No history of major medical problems
Normal height aad "eigbt (BMI)
Not takint any medicltion
2.1 Ph..., I
Phase I of the study was designed to determine which volunteers were acceptable
to proceed to the quantification stage (phase II) of the study . Volunteers were required to
monitor the symptoms they experienced during the course of three menstrual cycles using
a Menstrual Cycle Diary (2.2.1 and Appendix A). In addition, the volunteers monitored
their ovulation time with the aid of a commercial OvuQuick self-test kit (pharmasience
Inc ., Montreal) that detects the presence or absence of luteinizing hormone in urine. This
is useful because it is known that when LH peaks then ovulation proceeds 24 to 36 hours
later.
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2.2.1 Menstrual Cycle Diary
All the cycling volunteers. 21 in total. were required to complete the Diary in the
evening for each day during the cycle . This was done for 3 full cycles . The diary
demonstrated the symptoms that each volunteer had. heal th status, and medi cation
consumed. The diary is a single page. self repo rt questionnaire that measures the
magn itude of symptom seve rity on a scale from 1-3. There are 21 symptoms assessed in
the diary . The instruction s for completing the Diary as well as the Diary itself can be
seen in Appendix A. Briefl y. if the volunteer did not experience any symptoms the space
corresponding to that symptoms was left blank, if the sympt om wasmild (noticeab le but
not troubl esome). the number I was recor ded, if the symptom was moderate (interferes
""';th nonnal activi ty) a 2 was recorded. and if the symptom was severe (temporarily
incapacitatin g) a 3 was reco rded.
1.2.2 OvuQaick Kit
Mate rials :
Uriae Dropper- To add the uriae to the lest pad
Urine Cup- For collection of urine.
Test Pads- Pads that telt the urine.
BotUe A-D -Cbem icals that allow detection of
LB.
Buffer, Enzyme coajugate, Substrate . Stop
lolutiOD.
Method "
Urine was collected between 10:00 and 20:00 and was not the first urine of the
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day. Date. cycle day and time were recorded when the sample was obtai ned. The enzyme
conjugate was then prepared and left to stand for 10 minutes . The test pad was removed
from the pouch and 6 drops of urine placed in the centre . Three drops of buffer were
added to the test pad and allowed to soak in. Six drops of the enzyme conjugate
followed. timed for 1 minute exactl y. Six drops of substrate were added and the reaction
allowed to proceed for exactly 3 minutes with the reaction termi nated by adding stop
solution(6 drops) . A color change to blue at the site of urine application was considered
a positive reaction, u.. luteinizing hormone was present in the urine .
%.3 Pb... D
Nine cycl ing females were chosen to enter into Phase Il of the study based on the
datagathered from Phase I. During this phase the subjects were also asked to continue
to monitor their ovulati on times and continue to complete the Menstrual Cycle Diary . In
addition, both the female volunteers and the male controls were asked to complete a
questionnai re every time they were bled (Appendix A). This ensured information on the
health, sexual activity and general well-being of the individual.
2.3.1 Collec tion of Blood Samples
The 9 cycl ing female volunteers were bled three times a week for five weeks.
Blood was obtain ed by venepuncture in vacutainer tubes between the hours of 8:30-20:00 .
A toral of S x 10 mI Vacutaine r (Becton ·DickensonflJ) tubes of blood was collected from
48
the subject; 3 tubes contained ACD (acetate-citrate-dextrose) as an anticoagulant and 2
Vacutainer tubes contained no additive (serum separating tubes) .
The control volunteers were bled 3 times a week for 3-4 weeks, in the same
manner as the cycling females .
Before they could consent to the above all subjects were required to have their
hemoglobin levels measured (Hematology Laboratory , Health Sciences Centre, St. John's,
NF) . A minimum value of 90gll was required for entry into the study. As well
hemaglobin levels were measured at the end of the five weeks. This data can be seen in
Appendix A. Table A.!. This table also includes information on cell populations at the
beginning and the end of the study .
2.3.1.1 Preparation of CeDI
Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood using
density gradient centrifugation in Lymphoprep tM (Cederlane.Ontario]. The ACD
Vacutainer tubes were spun at 2000 rpm (1000 x g) for 10 minutes and the buffy coat
removed. The resulting 9 ml from the 3 tubes were combined and diluted 1:2 in sterile
PBS (Phosphate Buffeted Saline) then layered onto 4.5 ml of Lymphoprepl'" in each of
three I5-ml centrifuge tubes at room temperature . The tubes were then centrifuged for 20
minutes at 2000 rpm. The PBMC layer was removed with the aid of a Pasteur pipette and
washed twice in Hanks Balanced Salt Solution (IBN Biomedicals, Califomia),and once
in culture medium, counted and resuspended at a concentration of 5 x I06/ml or 2.5 x
I06/ml in culture medium.
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2.3.1.2 Culture Medium
The culture medium used for the cytokine stimulations was prepared sterile and
consisted of:
500 ml RPMI 1640 (Gibc.lBRL,Burlingt••)
5 ml FCS (F.e'aI Calf serum) (Gibc.IBRL)
5 ml L-Glutamine 200mM (Gibc.IBRL)
5 ml S.dium Pyruvat. lOOmM (ICN Bi.m.die.... CAl
5 ml PeDidllio Streptomycin SOOOLUJml(lCN Biomedicals)
2.3..2 StimulatioD Protocol
The stimulation protocols varied depending on which type of cytokine we wished
to measure. The systems were worked out prior to the beginning of Phase I and Il (see
section 3.5)
2.3.2.1 Induction of IL-2 and IL-4 Secretion
IL-2 and IL-4 secretion was induced with 50 lJ.g/ml PHA (phytohemagglutinin,
Boehringer Mannheim, Montreal) for 24 hows. Aliquots of lml offreshJy isolated PBMC
at a concentration of 5 x 106 cellslml were deposited in 2 sterile Falcon tubes (Becton!
Dickinson, Montreal) . The cells in one tube were stimulated with l0l-l[ PHA (5mg/ml)
dissolved in sterile water , while the other cells served as a control, having no known
stimulant, to see if the cells were naturally secreting IL·2 and IT.-4. The cells were
incubated at 3,oC in a 5% humidified CO 2·incubator for 24 hours .
so
2.3.z.z Induction of IL-lt! and fL..lra Secretion
2.5 x 10' c:ellslmJ were stim ulated with Lipopolysacc:baride (Sigma. NJ. stoc k
solution at ImglmJ in RPMI ) in ro und -bo ttom sterile polystyrene plates (Life
Technologies, Burlington) at 200Jl.I of cell suspension per well with 8J1.g1mJLPg per well
fo r 24 bows at 3'PC in a bumidi fied 5% CO:. inc:ubator. There were 16 wells in total , 8
stimulated and 8 unstimulated .
2.3.2.3 Induction or lNF~y Secretion
5 x 10' cellslml were incubated in 0.5 mJ aliquots. in 2 steri le Falcon tubes. for
48 hours at 3"fC in a 5% humidified C01· incubator. To ODetube, PHA bad been added
(50 jJ.glmJ). the other tube served as an unstimulated control.
2.3.2.4 Harvest or Culture Superuatants
At the end of the stimulation time the tubes were centrifuged at 1500 rpm for 10
minut es. The supernatants were removed with a steril e pipett e. und er sterile conditions
and frozen at -70'C in 250~1 (ll.- 2) and 500~1 (1L-4.lNF-y.lL-lra, IL-I~) aliquots to be
tested later in ELlS As.
2.3.3 Serum samples
The serum -separati ng tubes wer e left at room tempe rature to clot for at least 1 how
before spinning the tubes at 2000 rpm for 20 minutes. The serum was then removed from
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the tubes and divided into several aliquots which were frozen at _70°C. There were
approximately 12 aliquots per person and these were later used to determine the leve ls of
UI. estrogen . progesterone. testosterone. n..- IP. n..·lra. n..-6 and TNFa (also total
hemolytic complement and C3, see discussion).
1.4 ELISA A.say.
The cytckmes in this study were all measured by comme rcial EUSA assay . Table
2.1 summarizes the manufacturer of each ELISA kit, the sample assayed, the sample
volume used, and the sensitivity of the assay . All samples were run in parallel and all the
samples collected for one volunteer during the menstrual cycle were run on the same
plate. Specifi c details about the procedure can be found in the following sections.
2.4.1 Gen eral Princ ip le of the [L. 2 Immunoassay
The plates were purchased from R&D Systems Minneapo lis, MN. This assay
employs the quantitative "sandwich" enzyme immunoassay techniqu e. A monoclonal
antibody specific for n..·2 has been coated onto the micretire r plate provide d. Standards
and samples are pipene d into the wells and any n..·2 present is bound to the immobilized
antibody . After washing away any unbound proteins, an enzym e-linked polyclonal
antibody specifi c for «'-2 is added to the well s to "sandwich" the n..·2 immobilized during
the first incubation. Following a wash to remove any unbound antibody -enzyme reagent .
a substrate solution is added to the wells and color develops in
52
Table 2.1 Summary of the cytokines examined for each of the volunteers with reference
to the commercial source of the ELISA kit. sample and sample size, and sensitivity of the
assay as determined by the manufacturer.
Cytokine Commercial Sample Sample Sensiti vity
Source Volume
lL-2 R&D Systems Supernatant 100~1 6.0 pglml
lL-4 R&D Systems Supernatant 200~1 3.0 pglmJ
lL-4 Biosource Supernatant 50~1 2.0 pglmJ
(L·lra R&D Systems Supernatant 200~1 22.0 pglmJ
Serum 200~1 22.0 pglml
lL-IP Biosource Serum lOOIl! 0.083 pglmJ
lL-IP Biosource Supernatant 50~1 1.0 pglmJ
IFNr R&D Systems Supernatant 200~1 3.0 pglmJ
lL-6 Biosource Serum I OO~1 0.104 fglmJ
TNFa Biosource Serum 100~1 0.112 fglml
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proportion to the amount of n..·2 bound in the initial step. The color development is
stopped and the intensity of the color is measured.
%.4.1.1 Procedure:
The materials were provided by R&D Systems and accompanied the kit. The [L·2
standard curve was generated by preparing doubling dilutions from 2000pglml to
31.3pglml in the 'calibrator diluent RDs' provided. The first dilution was prepared by
reconstituting the lOng of recombinant human ll.-2 with 5 ml of 'calibrator diluent RDS'
to give a concentration of 2000pglmJ. This stock solution was left to stand for IS minutes
before the dilutions were made.
After the samples needed to generate the standard curve were made. I00J.11 of
Assay Diluent RDtA was added to the wells prior to adding the samples (the supernatants
resulting from the PHA stimulation) and standards. t00J.11 of standard or sample were
added to the wells in duplicate . mixed. covered and incubated at room temperature for 2
hours.
Each well was then washed with the wash buffer provided by alternately filling
and aspirating the wells 3 times. After the final wash the plate was inverted and blotted
on paper towel to remove any remaining liquid.
200J.11 of IL-2 'conjugate'. Horse Radish Peroxidase(HRP) labelled anti·lL·2 , were
then added to all the wells with a multi-pipette. The plate was covered and incubated at
room temperature for 2 hours.
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After washing the plate 3 times . 200lli of 'substrate' (chro mogen and hydrogen
peroxide) were added per well and incubated for 20 minutes .The reaction was stopped by
adding SOIlI of the 'stop solution ' provided. The optical densiti es (OD) were read at
4SOnm 00 a Bic-Rad Microplate Reader.
Standard curves were generated with Log OD's plotted against Log standard 1L·2
concentrations . ll..-2 concentrations in the culture samples were determine d with the
Microplat e Manager softwar e (Bio-Rad, Mississauga. ON). The minimum detectab le dose
of the assay was 6.Opglrnl .
2.4.2 GeDerai Principle of the JL.4 Immoaousay(1)
The plates were purchased from R&D Systems. Minneapolis, MN. This assay
employs the quantitative sandwich enzyme immunoassay technique and is identical to that
of ll. -2 with the exception that the cytckine assayed for is ll..-4 .
2.4..2.1 Pro cedure:
The materials were provided hy R&D Systems and were included in the kit. The
ll..-4 standard curve was generate d by preparing doubting diluti ons from 2000pglml to
31.3pglml in the 'calibrator diluent RDS' (culture media diluent) provided The first
dilution was prepared by reconstituting the lOng of recombinant human 0..-4 with S ml
of 'calibrato r diluent RD S' 10give a concentration of 200Opglml. This stock solution was
left to stand for 1S minut es before the dilutions were made .
ss
After the dilu tions were made, 200~1 of standard or sampl e (the supernatants
resulting from the PHA stimulation) were added to the wells in duplicate. covered and
incubated at room temperatur e for 2 hours.
Each well was thea washed with the wash buffer provided by alternately fillin g
and aspirating the wells 3 times. After the final wash the plate was inverted and blotted
on paper towel to remove any remainin g liquid.
200~1 of ll..-4 'conj ugate' (HRP labelled anti-lL-4) were then added to all the wells
with a multi-pipette . The plate was covered and incubated at room temperature for 2
bours .
After washin g the plate 3 times, 200~1 of 'substrate' were added per well and
incubated for 20 minutes . The reaction was stopped by adding SO~J of the 'stop solution '
provided. The opticaJ densities (0 0 ) were read at 4SOnm on a Bic- Rad Microp late
Reade r.
Standard curves were generated with Log OD's plotted against Log stan dard IL-4
concentrations. lL-4 concentrations in the culture samples were determined with the
Micro plate Manager software {Bic-Rad, Mississauga, ON) . The minimum detectable dose
of the assay was 3.0 pglm l.
2.4.3 General Pm aple or the D..-4 lmm ua ousay (IT)
The plates were purchased from Biosource International, Cam arillo, CA . Thi s lL-4
assay is slightly different from the R&D Systems one. The use of a different assay was
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due to monetary constraints as the Biosource plates are less expensive. As in the previous
assay the wells of the plate are coated with anti·lL-4 . The difference lies in the fact that
once the samples are added to the wells a biotinylated second antibody is added and
incubated. During the first incubation the IL-4 antigen binds simultaneously to the
immobilized antibody on one site and to the solution-phase biotinylated antibody on a
second site .
After removal of the excess second antibody, Streptavidin-Peroxidase (enzyme) is
added. This binds to the biotinylated antibody to complete the four-member sandwich.
The remainder of the assay is the same as for the R&D plates.
2.4.3.1 Proudure:
The materials were provided by Biosource International and were included in the
kit The fi....4standard curve wasgenerated by preparing doubling dilutions of lL-4 from
500pglm l to 3.9pglmJ io the 'standar d diluent buffer' provided. The first dilutioo was
prepared by reconstituting the recombinant human ll..-4 with 'standard diluent buffer to
give a concentration of 2.Sng/ml. This stocIe. solution was left to stand for IS minutes
before the dilutions were made . Then 100~1 of this stock solution was diluted in 4001-11
to give a concentration of SOOpglmI n.-4 .
100}!1 of the 'standard diluent' were added to each well and an additional SOJ.l1 of
the 'standard diluent' were added to the zero wells (no ll.-4) prior to adding the standards
and samples. SOIlIof the standards and sampl es were added in dupl icate followed by 50,,11
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of 'biotinylated anti-IL-4' (biotin conjugate) solution into each well except the blank wells
(no anti-IT.-4). The contents of each well was mixed by tapping the plate gently . The
plate was covered and incubated for 2 hours at 3'1'C.
The plate was washed with the buffer provided by alternately filling and aspirating
the wells. After the final wash the plate was inverted and blotted on paper towel to
remove any excess liquid. 100,..1 of 'streptavidin-HRP working conjugate' were added to
all the wells except the blank . the plate was covered and incubated at 3'1'C for 2 hours .
After the plate was washed 4 times, 100,..1 of 'stabilized chromogen' were added
to each well and the plate incubated in the dark for 2S minutes . The reaction was
terminated with 100,..1 of the 'stop solution' provided. The optical densities (00) were
read at 4SOnm on a Bio-Rad Microplate Reader.
Standard curves were generated with OD's plotted against standard 1L-4
concentrations. IL-4 concentrations in the culture samples were determ ined with the
Microplate Manager software (Bio-Rad, Mississauga, ON) . The minimum detectable dose
of the assay was 2.0 pglmJ.
2.4.4 General Principle or the IL-lra lmmunoas.say
The plates were purchased from R&D System s. Minneapolis.,MN. This assay
employs the quantitative sandwich enzyme immunoassay techn ique and is identical to that
of IL-2 and IL-4 with the exception that the cytokine assayed for is IL-I ra
S8
2.4.4.1 Procedure:
The materials were provided by R&D Systems and were included in the kit. The
n..·Ira standard curve was generated by preparing doubling dilutions of n.·1 ra from 3000
pglml to 46.9 pglml in the 'cal ibrator diluent RD6G' (serum sampl e diluent) pro vided. The
first dilution was prepar ed by reconstituting 6ng of recombinant human [L· I ra with 2 ml
of 'cal ibrator diluent RD6G' to give a concentration of 3000 pglmJ . This stock solution
was left to stand for IS minutes before the dilutions were made.
After the dilutions for the standard curve were made , SOil}oC'assay diluent ROlE'
were added to each of the wells prior to adding the serum samples and standards. When
assaying the culture supernatants this step was not necessary. 200~1 of standard or sample
(serum or culture supernatant) were added to the wells in dup licate, mixed, covered and
incubated at room temperature for 2 hours .
Each well was then washed with the wash buffer pro vided by alternately filling
and aspiratin g the wells 4 times . After the final wash the plat e was inverted and blotted
on paper towel to remo ve any remain ing liquid.
200J.l1of 1L·lra 'conj ugate' (HRP labelled anti·n..-Ira) were then added to all the
wells with a multi-p ipette . The plate was covered and incubated at room temperature for
2 hours .
After washin g the plate 4 times, 200lJ.llwell of 'substrate' were added to the plat e
and incubat ed for 20 minutes. The reaction was stopped by adding SOJ.lUwcll of the 'stop
solution' provided The optical densiti es (00) were read at 4SOnm on a Bio-Rad
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Microplate Reader.
Standard curves were generated with Log OD's planed against Log standard IL-Ira
concentrations. n..-I ra concentrations in the serum samples were determined with the
Microplate Manager software fBio-Rad, Mississauga, ON) . The minimum detectable dose
of the assay was 22 .0 pglmL
This assay was used for both the serum and culture supernatants. In the serum
analysis. the procedure was as stated. In the analysis of the culture supernatants, a dilution
of the sample was needed. For the unstimulated supernatants a dilution of 1: I0 was used
and for the stimulated supernatants a dilution of I:20 was used. In addition, the standard
curve ranged from 2000 pglml to 15.6 pglml when assaying the culture supernatants.
Samples that were above or below the sensitivity of the plate were noted in the tables of
data in Appendix 8 and were omitted from the subsequent calculations. When
considering the raw data. that is, the values obtained from the ELISA, for n..·lra., the
dilution allowed for the highest value measured to be 40,000 pglml , although ,
extrapoLation of the standard curve gave values in the 60,000 pg/ml range. Values that
are seen in the tables as greater than signs (» indicate that these samples exceeded the
3.0 optical density of the plate reader .
2.4.5 General Principle of the IL-la UltraSensitive ImmuDous.,-
The plates were purchased from Biosource International, Camarillo, CA. The
principle of this assay is the same as that of the Biosource IL-4 ELISA with the exception
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that the cytokine assayed for was rr..·IIl. This assay was used. to measure 1L.113in serum
samples .
%.4.5.1 Procedure:
The materials were provided by Biosource International and were included in the
kit. The rr..-Ill standard curve was generated by preparing doubling dilutions of [L-Ij3
from 10 pg/ml to 0.08 pglmI in the 'standard diluent buffer' provided . The first dilution
was prepared by reconstituting 5.9 ng of recombinant human [L.IIl with 2.36 mi of
'standard diluent buffer' to give a concentration of 2500 pglml. This stock solution was
left to stand for IS minutes before the dilutions were made. Then 25,.11 of this stock
solution was diluted in 6.23m1 to give a concentration of 10 pg/ml [L·lj3 .
150J,t1 oftbe 'standard diluent' were added to the blank wells and IOO~1 was added
to the zero wells (0 pglml). 100~1 of the standards and samples (serum) were added in
duplicate followed by SOil) of'biotinylated anti·Q.·11l'(biotin conjugate) solution into each
well except the blank wells. The contents of the wells were mixed by tapping the plate
gently. The plate was covered and incubated for 2 hours at room temperature.
The plate was washed 4 times with the buffer provided, inverted and blotted on
paper towel after the final wash . 100ili of 'streptavidin.HRP working conjugate' were
added to all the wells except the blank wells , the plate was covered and incubated at
room temperature for 30 minutes.
After the plate was washed 4 times , 100jJllwell of 'stabilized chromogen' were
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added and incubated in the dark for 2S minutes. The reaction was terminated with
100llUweUof the 'stop solution' provided. The optical densities (00) were read at 450nm
on a Bio-Rad Microplate Reader . The blank wells contained only chromogen and stop
solution and were used to blank the plate reader .
Standard curves were generated with OD's plotted against standard lL- 1P
concentrations. lL-I P concentrations in the serum samples were determined with the
Microplate Manager software (B io-Rad, Mississauga, ON). The minimum detectable dose
of the assay was 0.083 pglml . Samples that were above or below the sensitivity of the
plate were noted in the tables of data in Appendix B and were omitted from the
subsequent calculations.
2.4.6 General principles of the D-tp lmmuDosssay
The plates were purchased from Biosource International , Camarillo. CA. The
principl e of this assay is the same as that of the Biosource lL-4 EliSA with the exception
that the cytokine assayed for was [L·I p. This assay was used to measure IL·I Pin culture
supernatants.
2.4.6.1 Procedure
The materials were provided by Biosource International and were included in the
kit. The IL-IP standard curve was generated by preparing doubling dilutions of 1L·lp
from 2000 pglml to 3.9 pglml in the 'standard diluent ~er' provided. The first dilution
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was prepared by reconstituting the recombinant human IL-I~ with 'standard diluent buffer'
to give a concentration of 2500 pglmJ . This stock solution was left to stand for 15
minutes before the dilutions were made.
100".11 of the 'standard diluent' were added to the blank. wells and 50).1.1 were added
to the zero wells (0 pglml) . 50IJI of the standards and samples (culture supernatants,
nonstimulated supernatants were assayed neat and stimulated supernatants were diluted
I:10) were added in duplicate followed by 50IJI of 'biotinylated anti-ll..-I tl' (biotin
conjuga te) solution into each well except the blank wells. The contents of the wells were
mixed by tapping the plate gently. The plate was covered and incubated for I hour at
room temperature.
The plate was washed with the buffer provided 4 times, inverted and blotted on
paper towel after the final wash. 100,..1 of 'streptavidin-HRP working conjugate' were
added to all the wells except the blank wells , the plate was covered and incubated at room
temperature for 30 minutes.
After the plate was washed 4 times, 100~well of 'stabilized chromogen' were
added and incubated in the dark for 25 minutes. The reaction was terminated with
l OOJ.lllwell of the 'stop solution' provided. The optical densities (00) were read at 450nm.
on a Bio-Rad Microplate Reader. The blank wells contained only chromogen and stop
solution and were used to blank the plate reader .
Standard curves were generated with OD's plotted against standard IL·lp
concentrations. nAp concentrations in the culture samples were determined with the
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Microplate Manager softwar e (Bio-Rad, Mississauga. ON). The minimum detectable dose
or the assay was 1.0 pglml. Note: the samples that were abov e or below the sensitivi ty
or the plate were Doted in the tables of data in Appendix 8 and were om itted from the
subsequent calculations.
1.4.7 Gmeral Principle of the IFN~y ImmuDoassay
The plates were purchased from R&D Systems, Minneapolis. MN. This assay
employ s the quantitative sandwich enzyme immunoassay technique and is identical to that
of [L. 2 With the exception that the c:ytokine assayed for is IFN -y.
1.4.7.1 Proc<d....
The mat erials were provided by R&D Systems and accompan ied the lOt The IFN ·
y standard curve was generated by preparin g doubling dilutions from 1000 pglmllO 15.6
pglml in the 'calibrator diluent RD6R' provided. The first dilution was prepared by
reconstituting 5.0 ng of recombinant human IFN -y with 5 ml of 'calibr ator diluent RD6R'
to give a concentratio n of 1000 pglml. This stock sol ution was left to stand for 15
minutes before the dilutions were made.
After the samples needed to generate the standard curve were made, SOJ.l.1of 'Assay
Diluent RDIZ ' were added to the wells prior to adding the samples (the supernatants
resulting from the PHA stimulation) and standards. 200J.l.1 of standard or sample were
added to the wells in duplicate, mixed. covered and incubated at room temperature for 2.5
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hours .
Each well was then washed with the wash buffer provided by alterna tely fillin g
and aspirating the wells 4 times . After the final wash the plate was inverted and blotted
on paper towel to remove any remai ning liquid
200~1 of IFN-y 'conjugate', Horse Radish Peroxidase (HRP) labelled anti-IFN-y,
were then added to all the wells with a multi-pipette . The plate was covered and
incubat ed at room temperature for 2 hours .
After washing the plate 4 times, 200J,l1 of 'substrate' (chromogen and hydro gen
peroxide) were added per well and incubated for 20 minutes. The reaction was stopped
by adding SOIlI of the 'stop solution' provided . The optical densities (0 0) were read at
4SOnm on a Bio-Rad Microp late Read er.
Standard curv es were gen erated with Log OD's plotted against Log standard IFN-y
concentrati ons. IFN·y concentrations in the culture sampl es were determined with the
Microplate Manager software (Bio -Rad. Mississauga. ON) . The minimum detectabl e dose
of the assay was 3.0 pglml .
2,4.8 ~Dera1 Principle or the fi....6 UltrtSeD,itive Immunoassay
The plates were purch ased from Biosource Intern ational , Camarillo , CA. The
princi ple of this assay is the same as that of the Biosource IL-4 ELISA with the exceptio n
that the cytokine assay ed for was ll..-6 .
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2.4.8.1 Procedure
The materials were provided by Biosonrce International and were inc:ludedin the
kit. The IL-6 standard curve was generated by preparing doubling dilutions of lL-6 from
10 pglml to 0.156 pglml in the 'standard diluent buffer' provided . The first dilution was
prepared by reconstituting the recombinant human rr..~ with 'standard diluent buffer' to
give a concentration of 310 pg/mi. This stock solution was left to stand for 15 minutes
before the dilutions were made.
150J.11 of the 'standard diluent' were added to the blank wells and 100JlIwas added
to the zero wells (0 pglml). IOOJlI of the standards and serum samples were added in
duplicate. The plate was covered and incubated for 3 hours in a 3T'C chamber.
The plate was washed with the buffer provided 4 times, inverted and blotted on
paper towel after the final wash. 100"al of 'biotinylated anti·IL·6' (biotin conjugate)
solution into each well except the blank wells. The plate was covered and incubated for
45 minutes at room temperature.
The plate was washed with the buffer provided 6 times, inverted and blotted on
paper toweJ after the final wash . 100lJI of 'streptavidin·HRP working conjugate' were
added to all the wells except the blank wells . the plate was covered and incubated at
room temperature for 4S minutes.
After the plate was washed 4 times , lOOJlUwell of 'stabilized chromogen' were
added and incubated in the dark for 25 minutes. The reaction was terminated with
IOOlJUwell of the 'stop solution' provided . The optical densities (OD) were read at 4S0nm
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on a Bio-Rad Microplate Reader . The blank wells contained only chromogen and stop
solution and were usedto blank the plate reader.
Standard curves were generated with OD's ploned against standard llA i
concentrations. IL-6 concentrations in the serum samples were determined with the
Microplate Manager softwar e (Bio-Rad. Mississauga, ON). The minimwn detectab le dose
of the assay was 0.104 pg/ml.
2.43 General PriDciple of the TNF.-a. lRtraseo!itive Immuooauay
The plates were purchased from Biosource International, Camarillo, CA. The
principle of this assay is the same as that of the Biosource ll..-4 EliSA with the exception
that the cytokin e assayed for was TNF-a..
2.4.9.1 Procedu~
The materials were provided by Biosource International and were included in the
kit. The TNF-a standard curve was generated by preparing doubting dilutions of TNF-a
from 32 pglml to O.S pglml in the 'standard diluent buffer' provided. The first dilution was
prepared by reconstituting the recombinant human TNF-a with 'standard diluent buffer'
to give a concentration of 2000 pglmJ. This stock solution was left to stand for 15
minutes before the dilutions were made.
l OOpl of the 'standard diluent' were added to the blank wells and to the zero
weIls(O pglml). 100,,11 of the standards and serum sampl es were added in duplicate . The
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plate was covered and incubated for 3 hours in a 31'C chamber .
The plate was washed with the buffer provided 4 times, inverted and blotted on
paper towel after the final wash. IOOll1 of 'biotinylated anti-TNF-a' (biotin conjugate)
solution into each well except the blank wells. The plate was covered and incubated for
I hour at 3~C.
The plate was washed with the buffer provided 6 times, inverted and blotted on
paper towel after the final wash. 100~1 of 'streptavidin-HRP working conjugate' were
added to all the wells except the blank wells , the plate was covered and incubated at
room temperature for 45 minutes
After the plate was washed 4 times, IOOIJllwetl of 'stabilized chromogen ' were
added and incubated in the dark for 10 minutes. The reaction was terminated with
1OO~l/weli of the 'stop solution' provided The optical densities (OD) were read at 450nm
on a Bio-Rad Microplate Reader. The blank wells contained only chromogen and stop
solution and were used to blank the plate reader .
Standard curves were generated with OD's plotted against standard TNF-a
concentrations. TNF-a concentrations in the serum samples were determined with the
Microplate Manager software (Bio-Rad. Mississauga, ON). The minimum detectable dose
of the assay was <0.112 pg/ml .
2.5 Hormone Radioimmunoassays (RIA)
The hormones in this study were measured by commercial RIA assay. Table 2.2
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Table2.2. Summary of the hormones measured for each of the vohmteerswith reference
to source of the RIA. sample and sample size. and sensitivity of the assay .
Ronnone Commercial Sample Sample Size Sensitivity
SolUce
17ll-Estradi ol ICN Serum 50~1 5 pglmJ
Biomedicals
Progesterone ICN Serum 100~1 0 1 nglm l
BiomedicaJs
Luteinizing lmmunocorp Serum 100~1 0.46 UIL
Hormone
Testosterone leN Serum 50~1 0.05oglmJ
BiomedicaJs
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swnmarius the sour ce of the RIA. the sample assayed. the sample volume used, and the
sensitivity of the assay . All samples were nul in parallel and all the samples collected for
one volunteer during the menstrual cycle were run on the same kit. Specific detail s abo ut
the procedures can be foun d in the following sections.
2..5.1 Gmeral P rin ciple of th e 17p..Estradiol RIA
Tbe RIA kit was purchased from ICN Biomedicals, California The Estradiol(E1)
RIA kit detects the unconjugated form of the stero id. Radioimmunoassays depend on the
ability of an antibody to bind its antigen . To quantitate the antigen. the radioactive and
nonradioacti ve form of the antigen compete for binding sites on a specific antibody . As
more nonradioactive antigen is added. less radi oactive antigen remains bound until
equili brium between free and antibody bound antigen occurs .
In the assay a limited amount of spec ific antibody is reacted with l2"I labelled
estradiol. Upon addition of an increas ing amount of estradiol . a correspondingly
decreased amount of labell ed estradiol is bound to the antibody due to the competitive
binding principle. After separating the antibody boun d lUoy estradio l from the unbo und.
the amount of radioactivity in the anribody-bormone com plex is measured and used to
construct the standard curve from which the unknown sample concentrations are measured.
2..5.1.1 RIA Protocol :
The materials were provided by leN Biomedicals and accompanied the kit The
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appropriate number of disposable glass 2ml tubes were labelled and placed in a test tube
rack. All the reagents and samples were allowed to come to room temperature before use.
The standard curve was constructed using the commerc ial standards provided and
consisted of concentrations 0, 10, 30, 100, 300, 1000, and 3000 pglmL To the Non
Specific Binding (NSB) tubes 500111 of 'diluent buffer ' were added and 50111 of the 0
pg/ml standard . The remaining tubes received 50J.lI each of standards or samples (serum)
in duplicate .
To each tube 500J.lI of Estradiol m I were added followed by 500p 1 of 'anti-
estradiol' to all the tubes except the NSB ones The tubes were vcrtexed and incubated
at 3rc for 90 minutes.
After the incubation 500J.lI of 'precipitant solution ' were added to all the tubes.
The tubes were spun at 1000 x g for 15 minutes and supernatants aspirated . The tubes
were counted in a gamma counter calibrated for mI for 2 minutes and the CPM (counts
per minute) recorded .
Standard curves for 'percent bound (%8)' versus 'log concentration ' were generated
with the InPlot (GraphPad , San Diego) software . Estradiol concentrations in the serum
samples were determined by the software used The minimum detectable dose of the
assay was 5 pglml, as determined by the manufacturer . The fonnula for %8 is:
%8 =
CPM(sample) • CPM(NSB)
CPM(O pg/ml) - CPM(NSB)
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X 100
2.5.2 Genera l Principle of the Progesterone RIA
The assay was purchased from ICN Bicmedicals. California . This assay employs
the same quantitative technique as the 17fl--estradiol RIA and is identical to that of E2
with the exception that the hormone assayed for is progesterone.
2.5.2.1 RIA Protocol:
The materials were provided by ICN Biomedicals and accompanied the kit The
appropriate number of disposable glass 2ml tubes were labelled and placed in a test tube
rack. All the reagents and samples were allowed to come to room temperature before use.
The standard curve was constructed using the commercial standards provided and
consisted of concentrations 0, 0.2, 0.5, 2.0, 5.0, 10.0, 25.0, and 50.0 ng/m!. To the Non
Specific Binding (NSB) tubes 500J.l1 of 'diluent buffer' were added and 100J.l1 of the 0
nglml standard. The remaining tubes received 1O01l1 each of standards or samples
(serum)in duplicate .
To each tube 500lli of 'anti-Progesterone' were added to all the tubes except the
NSB ones, followed by 200pl of progesterone mi. The tubes were vortexed and
incubated at 3'rC for 60 minutes
After the incubation 5001l) of 'precipitant solution' were added to all the tubes
The tubes were spun at 1000 x g for 15 minutes and supernatants aspirated. The tubes
were counted in a gamma counter calibrated for lUI for 2 minutes and the CPM recorded .
Standard curves for 'percent bound' (%B)' versus 'log concentration' were generated
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with the InPlot (GraphPad. San Diego) software. Prog esterone serum val ues were
determined by the softwar e used.. Calculation of %8 is the same as for Estradiol. The
minimum detectab le dose of the assay was 0.1 nglml . half the lowest standard.
2.5.3 General Principle of tbe Testosterone RIA
The assay was purchased fro m ICN Bic medicals, CA . This assay employs the same
technique as the estradio l and progesterone ones . The protocol is very similar .
2.5.3.1 RIA Protocol:
The materials were provided by ICN BiomedicaJs and accompanied the kit . The
appropriate number of disposable glass 2mJ tubes were labelled and placed in a test tube
rack. All the reagents and samples were allowed to come to room temperature before use.
The standard curve was constructed using the commercial standards provi ded and
consiste d of concentrations 0, 0.1, 0.25, 0.5. 1.0,2.5, S.O, and 10.0 nglml. To the Non
Specific Binding (NSB) tubes SOOIlI of 'di luent buffer' were added and SOIlI of the 0
ng/ml standard. The remaini ng tubes received SOIlI each of standards or samples (serum )
in duplicate.
To each tube 100jJi of'SBGI solution' (sex binding glob ulin inhibito r) were added,
followed by SOOjJl of Testosterone 1251. Following the addition of Testosterone, SOOf.11 of
'anti-Testosterone' were added to each of the tubes except the NSB ones. The tubes were
vonexed and incubated at 3,o C for 120 minutes .
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After the incubation 100J.lI of 'second antibody' were added. the tubes were then
vortexed and incubated at 3T'C for 60 minutes . The tubes were then spun at 2300 rpm
for 15 minutes and supernatants aspirated . The tubes were counted in a gamma counter
calibrated for l~ for 2 minutes and the CPM recorded
Standard curves for 'percent bound ' (%8) versus 'log concentration' were generated
with the InPlot (GraphPad. San Diego) software. Testosterone serum values were
determined by the software used. Calculation of %8 is the same as E2. The minimum
detectable dose of the assay was 0.05 ng/ml , half the lowest standard .
205.4 General Principle of the Luteinizing Hormone RIA
The assay was purchased from Immunocorp, Montreal . The Immunocorp coated
tube assay is a two site immunoradiometric assay that utilizes a solid phase coupled
antibody and a second antibody labelled with m L
2.5.4.1 RIA Protocol:
The material s were provided by Immunocorp and accompanied the kit . The coated
tubes provided were labelled and placed in a test tube rack. All the reagents and samples
were allowed to come to room temperature before use. The standard curve was
constructed using the commercial standards provided and consisted of concentrations 0,
2, 5, 20, 50, and 100 UIL. In addition , there were 2 non-coated tubes in the assay that
were used to determine total radioactivity .
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To each tube IOOlJ.1 of standard. contro l, or sampl e (se rum ) were added in dup licat e
, followed by IOOJ.11 ofa mixture consisting of equal volumes of 'Anti-hLH 1:51 and mo use
IgG' . The tubes were vc rtexed and incubated at 3t'C for 60 min utes.
After the incubation the tubes were washed twic e by altern ately filling wi th 4ml
wash buffer and aspirating . After the final wash the tubes were inverted for S mi nutes,
then counted in a gamma counter calibrat ed for I~I for 2 minutes and the CPM recorded.
Standard curves 'CPM' versus 'concentration (UIL) ' were generated with the InPlot
(GrapbPad, San Diego) softwar e. tH serum values were determined by the software used .
The sensiti vity of the assay was 0.46 UIL.
1.6 C'RSO ...d CJ
One assay tested the percen t of C'HSOin the serum of the volunteers . Th e an alysis
was perform ed by student, Trina Fourni er, as part of a anoth er project. The method of
Mayer was used (Kab at and Mayer , 197 1). The coefficient of variation for the intra-
assay control was 2.1%, the mean for inter- assay variation was 7.0%.
The concentratio n of serum C3 was measured by nephel ometry in a Beckman
automated Specific Protein Anal yze r (Beckman OH-3427 Array 360, Model 4480) using
Beckman C3 kits by Meredith Steev es. The mea -essay coefficient of variati on valu es
were less than S% and inter-assay values less than 8%. Normal values ace given as 0.88·
2.0 1 mglml .
Both of these assays were done with the sampl e set I had created . The results for
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these factors are given in Tables 8 .1·8.15 in Appendix B. There will be a brief
discussion in the last chapter of this document .
1.7 Coefficient of Variation (ev)
The CV was determined by including the same sample 0 0 all the ELISA plates and
hormone assays carried out . This sample had been prepared identical to the volunteer
samples, aliquoted, and stored at ·70oC. The concentration of the sample read from the
standard curve was used to calc ulate the CV. As a control, this sample could be used to
examine inter-assay variatio n day to day and techn ique on a particular day .
1.8 Statistical Meth ods
1.8..1 CoemcicDt of variarioD
The coefficients of variation for the ELISA and Hormone assays were determined
by the formula :
Standard Deviation
___ ______ X 100
Mean
The standard deviation and mean were calc ulated using the statistical softw are
inStal (GraphPad. San Diego).
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2.8.2 F T..t
The F fest was used to assess variati on over time comparing the males to females.
testin g equal ity of variances between the two groups. Th is test is done manually and the
resulting F value is then referenced in stati sti cal tables to determine if it is significant at
a :::=O.05. If the F value is large then one group bas significantly larger vari ation than the
other. If the F value is not found to be signi ficant then we have no evidence against the
hypothesis that they are the same. All data gathered on the volunteers was used to
calculate this value . The following formula was used :
~(n,.l)(s,')/~(n,.l)
-F
~(n,. l)(s,')I ~ (n,. l )
The numerator of the above equati on represents the variation of the cycling females .
The denominator of the above equati on represents the male variation .
L the sum of
n, the number of data values for each volunteer
5,: the variance for each volunteer squared
2.8.3 t Te st
The t test (two- tailed) was used to co mpare the means of the cycling females to
the male contro ls for each cytokine measured. This statistical test is used when the rwo
samples are independent and wben they hav e been drawn from a normall y distributed
population. Due to the larg e number of samples we obtained from the volunt eers we were
able to assume normal distri bution within the sampl e set All the data obtained from the
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males and the raw data for one full cycle in the females was used to compare the means.
The statistical signi ficance level was set at: S% (a=O.OS) which is the probability of not
rejecting the hypothes is thai:the two means are the same when in fact they are different.
The t test was calculat ed with the statistical software SPSS, Version 6.1.3 and the
computer software automatically corrected calcul ations when the variances were found to
be unequal .
The objective of the paired t test is to eliminate as many sources of extraneous
variation as possible by making the pairs similar with respect to as many variables as
possible (Daniel, 1995 ). The use of the paired t test was necessary for comparison of the
phases of the menstrual cycle. From nine cyclin g women we obtained 9- 14 samples over
the course of one full mensuuaJ cycle, thus the samples were not independent of one
another within the cycle . As a result of the multiple consecutive samples the paired t test
was wed to contro l for the exttaneous variabl es helping to determin e if the means of
various phases of the cycle were different . The data gathered 0 0 the females. converted
to portion of phase. for one full cycle was used to calculate the p values, data obtained
from the second cycle was not used. The statistical software package InStat (GraphPad.
San Diego) was used. No correction factor for multiple comparisons within the cycle was
used.
2.8.4 Multiple Rez ress ioa
Multiple regression used to analyze the results was done by using the statistical
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software SPSS (Version 6.1.3, 1990-1 99 5). The purpose of multiple regression is to
predict the response variable when the other independent variables. which infl uence the
response variable. are known . The softwar e first calculates the multiple correlation
coefficient and tests whethe r or not it is signi fican tly different from ZCfO. If a significant
differen ce is found then there is a relationship between the response variable and the
independent variables and this corre lation is then used to predict the response variable.
If the correJation coefficient is between -0 .5 • +O.S the relationship is weak and the
resultant prediction is Dot reliable . In additi on to giving the correlati on coefficient the
computer also generates the coeffi cient of determination, the square of the corre lation
coefficient, and this indicates the amount of variation in the response variable that is due
to the influence of the independent variables . This test was done using the original data
gathered on the female volunteers in one full cycle.
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CHAPTERm
RESULTS
In this chapter I will present the data [ have gathered on the volunteers . I will
discuss the cycling volunteers Phase I data and the hormone results from Phase U. In
addition, the comparison done on the male controls will also be presented. Data from the
cytokines that were studied will be presented along with the statistical analysis . AIl
original data can be found in Appendix B. The organization of the results will follow the
aims presented in the introduction portion of this document.
3.1 Establisbment or StimulatioD Conditions
The culture conditions for the various cytokines were determined using PHA
stimulation . We wanted optimal conditions for proliferation based on amount of PHA,
amount and type of serum added and optimal time for harvest To do this we examined
the differences in proliferation (measured as counts per minute) at different times to
determine the optimum time for harvesting cells when quantitating IL-2, ll.-4, and INF-y.
We also wanted to see if there wasa difference in the response when different media were
used.
In an initial experiment to address this question we stimulated PBMe in RPM!,
containing various amounts of FCS or autologous serum.. Varying amounts of a PHA
solution, at a final concentration of 0.1 mg/ml , were added. This solution was obtained
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from the Clinical Diagnostic Immunology Laboratory in St. John 's, and was used for the
initial experiment. Radioactive thymidine was added IS hours before the cultures were
harvested . The counts per minute results of these experiments are seen in Tables 3.1a-d
Analysis of the cpm generated at different concentrations of PHA and different
lengths of cultures with various media indicated that 39 and 72-hour stimulations were
inappropriate because the cells were dividing . Conversely , 15 hours was rejected due to
the fact that the cells had not yet begun to divide (were not incorporating the thymidine).
The times chosen for potential future work were that of 18 and 24 hours. It was
determined that there was little difference in the counts when using either autologous or
FCS in the media across all concentrations of PHA tested. Consequently autologous
serum was discarded as a possible media supplement. We felt that due to the large
amount of blood needed to get PBMCs for the many cultures and serum for cytokine and
hormone measurements. it was not possible to obtain the amount of serwn needed from
each individual to include it in the media. Finally , since it was our intention to try and
control for extraneous variables and keep all volunteer cultures as similar as possible. it
was thought that the addition of autologous serum would circumvent this aim.
In response to the data obtained from the first set of experiments we purchased
new PHA and conducted further experiments using the new supply and various
concentrations of FCS. The new PHA (20 mg) (Boehringer Mannheim) was reconstituted
in 4 ml of sterile water to give a stock solution of 5 mglml. The results of this
experiment demonstrated that the new PHA did induce lymphocyte stimulation .
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Table 3.1a. Time study measuringincorporation of )H-thymidine. Cells cultured in RPM!
with varying concentrationsof serum. No PHA added Values are seen in cpm.
Time Hrs 10% FCS 1% FCS ross o.s- 1%0.5.
15 95 83 147 83
18 86 61 95 85
24 258 /139' 135 215/132 91/196
39 92 93 103 88
72 168 108/275 131 98/404
• These values indicate the inability to average due to the marked difference in parallels.
• Autologous serum
Table 3.tb . Time study measuring incorporation of )H-Ihymidine at 25 IJglml PHA .
Values are seen in cpm.
Time Hrs
15
18
24
39
72
10% FC5
131
282
4913
13972
1% FCS
95
136/275'
1394
7806
10% 0 .5.-
128
164/409
9126
14133
I%O.S.
184
7736
19802
• These values indicate the inability to average due to the marked difference in parallels.
• Autologous serum
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Table 3.1c:. Time study measuring incorporation of lH. thymidine at 50 lJ.glml PHA.
Values are seen in c:pm.
Time Hrs 10% FCS 1% FCS 10% O.S.- I%O.S.
15 107 103 109 83
18 137 111 126 94
24 1701324" 128 215 1051203
39 6319 1135 IIn6J73 62 7021
n 10845/80 10 9 156 16789 18008
"Th ese values indicate the Inability to average due to the marked difference in parallels .
• Autologous serum
Table 3.1d. Time study measuring incorporation of lH-thymidine with 75 lJ.g/ml PHA.
Values areseen in cpm.
TimeHrs 10% FCS 1% FCS 10% O.S.- 1% 0 .5.
15
18 126 98 131 97
24 196 117 1781279" 162
39 1838 72 1 9028 6207
72 14620 9808 18560 17993
• These values indicate the inability to average due to the marked difference in parallels.
· Autologo us serum
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It was decided that future cultures would be stimulated for 24 boun.
We thea focused on the amounts of cytokine produced in culture when stimulated
for 24 hours with various amounts of PHA and FCS in the medi a. In the first experiment
we incubated PBMe with two con centrations of PHA ( 10 and SO IJ.glml) In media
containing 1 and 10% FCS for 24 hours. n. -2. lL.-4 and IFNy were then assayed using
the harvested culture supernatants. These results are presented in Tabl e 3.2 In shan.
IFN y was not found to be present in any of the supernatants. while n.-2 and ll..-4 were
found in vary ing concentrations. It is apparent that stimulation with 10 ug/ml ofPHA at
either concentration of FCS results in very low amounts of lL- 2 and no UA. When
considering cytokin e values for the SO ug/ml PHA stimulation. 1% FCS gives greater
values for IL-2 and lL-4 SO%of the time. whereas 10"/0 FCS gives higher values 3S% of
the tim e.
A followup experiment was conducted to confirm this and the results are given in
Table 3.3. In this experiment we wanted to explore stimulating at higher concentrations
of PHA. 7S and 100 ug/ml . It was decided that the cytckine con centration that resulted
after such stimulations were too high .
From all these results we concluded that for n.-2 and lL-4 we would use 1%FCS
in the media and stimulat e at SO ug/ml for 24 hours .
The last expe riment that was carried out concentrated on IFN y. We bad observed
in publications that stimulating for 48 or 72 hours resulted in measurabl e amounts of
lFNy. Based on this information we then proceeded to test this for our study.
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Table 3.2. Cytokine concentrations in culture supernatants using various stimulation
conditions for 24 hours.
Subject Cytekine 1% FCS 10% FCS
pglml 10· 50· 10 50
lL-2 I.S 208.0 10.3 29.0
lL-4 18.4
lL-2 33.9 2.7 45 .0
lL-4 20.6
lL-2 9.7 345 15.7 105.1
lL-4 184.5 95.8
1L-2 17.8 132.5 16.7 196.1
IL-4 23.9 59.1
• fJglml PHA concentration.
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In this experiment we stimulatedPBMC for 48 and 72 hours with the two concentrations
of PHA 10. and SOIJ.glml i.n media supplemented with 1'% FCS . The results, in Table
3.4, show thatoptimal conditions for IFNy producttoo were cultureswith SO IJglmI of
PHA for 48 hours . Thus we decided tb~ in order to obtain lFNr we would stimulate
with SO~glml PHA for 48 bours in 1% FCS in Ibis study .
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Table 3.3. Cytokines in culture supernatants after stimulation of PBMC with three
diffe rent concentrations of PHA for 24 hours in media supplemented with 1% FCS .
Cytoki ne pglml
IL ·2
IL-4
50 ug/ml PHA
97.5
45 .0
75 ug/ml PHA
114.4
53.1
100 ug/ml PHA
178.3
57.9
Table 3.4. IFNy concentrations in culture supernatants when PBMC are stimulated for 48
and 72 hours with two different concentrations of PHA in media supplemented with 1%
FCS .
48 hours 72 hours
10 Ilglml PHA
60.3 pg/ml
50 ug/ ml PHA
196.8 pglml
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10 Ilg/ml PHA
60.3pglml
50 ug/ml PHA
150.6 pglml
3.2 CrutioD or. Sample Set (rom Female Voluateen
Volunteers were chosen based on the conditions described in 2.J I. Time of
ovulati on and length of cycle were recorded for each of the 21 females .
Table 3.5 shows that only g femal es were eligible for Phase U based on the
conditio ns set in the beginnin g of the study . Some of the volunteers did not ovulate
whereas others wer e not suitable due to the length of the cycle or inconsistent ovulation
days.
The volunteers that participated in Phase Il of the study were chosen based on the
results in Table 3.5. The data indicat es that volunteers 21.04 .70, 01.04.75, 22.09.75,
15.12.73,06.09.72,29 08.71,22.11.75 , and 30.04.65 had relative ly stable menstrual cycles
and ovulat ed around the same time of the cycle with respect to their individual cycles.
Volunteer 09.10.64 does not bave any data available as she was recruit ed after Phase D
was started
This group of volunteers were fairl y uniform in that they were all healthy females
who adhered to the stringent set of cri teria established at the beginnin g of the study.
They were between the ages of 19-29 , they were not taking birth contro ls pills, they had
no major medical problem s, they were of normal height and weight . they were not taking
any medications and they had regular menstrual cycles.
nus group was very cooperative in providing the samp les needed for the study.
The only case where we encoun tered some problems with obtaining samples was when
30.04.65 went on vacation with her husband and two children. preventin g us from
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Table 3.5. Ovulation data and length of cycle of female volunteers participating in
Phase I.
Cycle 1 Cycle 2 Cycle 3
Vol Length' Ovul " Length 0vuJ Length Ovul
21.04.70' 28 16 28 14 27 14
13.08.69 33 32 21 32
01.04.75' 28 17 27 14 32 15
22.09.75' 32 27 15 31 19
15.11.73 26 28 18
22.01.75
06.11.75 27 28 13 15
15.12.73' 29 15 26 13 32 16
03.01.72 31
06.09 .72' 26 14 29 17 25 15
29.08.7 1' 27 15 26 14 27 14
06.03.68 29 15 26 14 14
22.11.75' 31 19 30 19 29 18
04.10.75 34
04.10.75
30.08.71 35 14
30.04.65' 30 17 28 17 29 17
25.01.67 15
18.02.75 29 16 17
, Total length of menstrual cycle
"Day of ovulation
C Volunteerin PhaseD
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obtaining samples for a week. It was unfortunate that this volunt eer was absent for the
study at this time as we lost data on her cycle at the time surrounding ovulation.
In Phase Il of the study. the magnitud e of symptom sev erity was measured and
daily symptoms were monitored with the aid of the Menstrual Cycle Diary (Appendix A).
The symptom severity, calculated from the data the volunteers gave 00 their diary's. was
divided into 2 mean ratings, one for the Intermensuual phase and one for the Luteal
phase. As shown by the results obtained from the calender completed by the volunteers
there is 00 sign ificant difference (p = 0.4375) between the Intermenstrual mean and Luteal
mean for symptoms using the Wilcoxan signed rank test (Table 3.6) . This indicates that
the volunteers as a group were not expe riencing premenstrual syndr ome. This method is
similar to comparisons others have used to determine if the volunteers were experiencing
PMS (Tbys-Jaco bs and Alvir, 1995) .
The length of menstrual cycle for the volunteers in Phase Il ranged from 26-31
days and the time of ovulation ranged from day 13 to 19. The mean cycle length was
28.7 with a standard deviation of 1.66 and the mean day for ovulation was day 15.8 ±
1.99 (Table 3.6).
3.1.1 SampliD& Days:
Each of the nine wom en who participated in the study was bled between 9~I S
times during the course of their cycle. Specific sampling days are seen in Figure 3.1. In
this figure the cyc le is presented in proportion of phase whereby each phase, the follicular
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Table 3.6. Cycle dataduring Phase n for 9 females.
Volunteer Cycle Day of Mean Symptom
Length Ovulation Severity
Inter- Luteal"
Menstrual-
2 1.04.70 29 17 0.857
0 1.04.70 27 16
22.09.75 26 14 J .85 6.43
15.12.73 29 14 2.14 2.14
06.09.72 28 16
29.08.71 29 15 1.86 1.29
22.11.75 31 19 2.14 3.14
30.04.65 31 18 1.29
09 .10.64 28 13 0.857 0.57 1
Mean 28.7 15.8 1.56" 2.12"
S.D 1.66 1.99 1.36 2.16
• Intermenstrual phase mean is defined as the meansymptom score during the 7 daysafter
menstruation had begun.
b Luteal phase mean is defined as the mean symptom score of the 7 days before
menstruation.
• Wilcoxan signed Rank test p=O.43 7S.
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and luteal, is designated a value of 1, and further subdivided according to the proportion
of one. A more in depth explanation of how this was done is seen later in the text
(p.117). It is apparent from the figure that the number of samples obtained from the
volunteers varies ; more samples were collected in the luteal phase of the cycle. The
points seen after the luteal phase constitute those samples obtained at the beginning of the
second follicular phase and were calculated assuming ovulation occurred. In addition, the
red line indicates time of ovulation with three individuals bled at this time.
3.3 Creation of. Sample Set from Male CODtrois
A control group was established that met the same criteria as the females with the
exception of the cycle criteria This group consisted of four males between the ages of
20~25 who were healthy . Males were chosen as controls since they are not known to
cycle with respect to the gonadal hormones examined in this study. These males were
sampled between 9 and 12 times over the course of 4-5 weeks, the same weeks that the
females were sampled .
In addition to providing serum and cells, the volunteers were asked to complete
a self-assessment questionnaire each time they were bled. this questionnaire is similar
to the one that the cycling women had to complete and can be found in Appendix A.
Based on these questionnaires it was apparent that the group was healthy throughout the
study. It is important to Dotehowever that one of the males, 17.02.75, contracted a cold
during the study and as a result of this we refrained from sampling him during this time.
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JOJW.6S
09.10.6-4
22. 11.75
!S. 12.73
29.08.7 1
06.09 .72
0 1.04.75
22.09.75
21.04.75
0 .2 0 .4 0 .6 0. 8 1.0 0.2 0 .4 0 .6 0 .8 1.0 0.2 0 .4 0 .6
I
Follicular Phase Lule al Pbase
Figure 3.1. Day of sampling for each of the nine volunteers expressed as proportion of
phase. Menses commenced on proportionate day 0.1 of the follicular phase; ovulation
occurred at proportionate day 1.0 of the follicular phase. For definitions of propo rtionate
day, see text, p.116.
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J.4 BormoD~ Profiles
Serum progesterone. luteinizing hormone and estro gen were measured on the
cycling volunteers throughout Phase n of the study. The hormone testosterone was
measured on each of the samples obtained from the males.
These horm ones were then graphed and can be seen in Figur es 3.2·3 .10 . It is
apparent from the data that the women were aUnonnal cycl ing females with characteristic
high estrogen in the follicular and luteal phases. LH surge just prior to ovulation and a
progesterone peak in the luteal phase . The aetuaJ values can be seen in Appendix B.
Based on these val ues and patterns one may co nclude that the femal es participating
in the study were a sample o f the normal population.
Volunteen 21.04.70 and 0 1.04.75 each have a visible LH peak that occurred on
day 16 and day 15 respec tively. Estrogen is seen to peak in the folli cular phases and then
again in the luteal phase of each woman . Progesterone charact eristicall y peaks in the
luteal phase.
Volunteer 22.11 .75 is missin g the LH peale mo st likely due to the fact that she was
sampled on day 17 and day 19, day 19 being the day of ovul ation, thus the LH peale.was
missed. Other hormones exhib it the textbook patt ern .
Volunteer 15.12 .73 and 29 .08.71 have the characteristic textboo k hormone pattern.
Volunteers 22.09.7 5, 06.09.72 and 09.10.64 are al l missing the LH peak due to the
sched ule of bleeding days. Aside from that the hormone patterns look normal .
Volunteer 30.04.65 went away for holiday s in the middle of the study and thus
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Figure 3.2. Hormone Profile of volunteer 21.04 .70.
The chan ges in serum concentrati on of estrogen . progesterone and luteinizing hormone
were measured using the radioimmunoassay procedure described in the materials and
methods , section 2.5. All measuremen ts were made in serum which bad been isolated from
a clot tube and then stored frozen at ·70 °C.
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Figure 3.3. Hormone profile of volunteer 01.04.75.
The changes in serum concentration of estrogen, progesterone and luteinizing honnone
were measured using the radioimmunoassay procedure described in the materials and
methods section 2.S. AU measurements were made in serum which bad been isolated
from a clot rube and then stored frozen at a ?Ooe .
~"2- L H- ..
Figure 3.4. Honnone profile of volunteer 22.11.7S.
The changes io serum concentration of estrogen, progesterone and luteinizing honnone
were measured using the radioimmunoassay procedure described in the materials and
methods, section 2.S. All measurements were made in serum which had been isolated
from a clot tube and then stored frozen at -7<re.
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Figure 3.5. Hormone profile of volunteer 15.12.73.
The changes in serum concentr ation of estrogen. progesterone and luteinizing hormone
were measwed using the radio immunoassay procedure described in the materials and
methods, section 2.S. All measurements were made in serum which bad been isolated
from a clot tube and then stored frozen at .7O"C.
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Figure 3.6 . Hormone profile of volunteer 29.08.71.
The changes in serwn concentration of estrogen, progesterone and luteinizing hormones
were measured using the radioimmunoassay procedure described in the materials and
methods, section 2.5. All measurements were made in serum which had been isolated
from a clot tube and then stored frozen at ·70°C .
99
~E2-LH~p
Figure 3.1. Hormone profile of volunteer 22.09.75.
The changes in serum concentration of estrogen, progesterone and luteinizing hormone
were measured using the radioimmunoassay procedure described. in the materials and
methods. section 2.5. All measurements were made in serum which had been isolated
from a clot tube and then stored frozen at _70°C.
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Figure 3.8. Hormone profile of volunteer 06 .09.72.
The changes in serum concentration of estrogen, progesterone and lutein izing hcrmcne
were measured using the radioimmunoassay procedure described in the materials and
methods. section 2.5. All measurements were made in serum which had been isolated
from a clot tube and then stored frozen at _10oe.
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Figure 3.9. Hormone profile of volunteer 09.10.64.
The changes in serum concentration of estrogen. progesterone and luteinizing hormone
were measured using the radioimm unoassay procedure described in the materials and
methods. section 2.S. All measurements were made in serum which bad been isolated
from a clot rube and then stored frozen at .7ooe.
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Figure 3.10. Honnone profile cf vclunt eer 30.04.6S.
The changes in serum concentration of estrogen, progesterone and luteinizing hormone
were measured using the radioimmunoassay procedure described in the materials and
methods. section 2.S. All measurements were made in serum which had been isolated
from a clot tube and then stored frozen at . 700<: .
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several days in her cycle were missed (she W1lS samp led on day 13 and then on day 20).
The pattern that is displayed in Figure 3.6 is lacking several key data points .
It is important to Dote that. as shown in Table 3.2. all the volunteers that
parti cipated in the study did ovulate even though, as the following hormone profiles show,
the LH peak was missed in analysis of the LH serum values using the RIA assay . We
do know that this peale did occur since all volunteers showed the urine LH peale when
using the OvuQuick kits.
3.4.1 Group Means
The group means and ranges for the hormones measured can be seen in Table 3.7
with the expected values and ranges that are provided with each RIA assay. In
examining the dataon the hormone levels and the expected values it is possible to say that
the female vo lunteers in thi s study were all normal with respect to gonadal hormone
levels. In the table it is apparent that DOt all the women fall exactly within the expected
ranges, though this is to be expected when deal ing with any human population. The
expected values are estimates only and our subjects can be consid ered normal though they
do show some deviation from the textbook estimates. This was also found to be true in
the previous section when the length of the menstrual cycles were analyzed .
The male testosterone data gathered on each of the contr ol subjects is also included
in this table and it is eviden t that this group is normal with respect to their tes tosteron e
measurements .
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Tabl e 3.7. Expected and actual ranges. and group means for each of the gonadal
hormones measured in this study .
Honnone Expected Range Aetual
Range Mean + S. D.
171l-Esnadiol
pglml
Follicular 46 40-500 52·302 124 :t 73
Luteal 50 120-350 57-270 143 1052
Progesterone
nglml
Follicular 43 0.2·0.9 0.0.3-1.4 0.29 100.28
Luteal 50 3.0-35 0.1-21.0 7.7 105.9
Luteinizing
HormoneUIL
Follicular 46 0 .5-100 1-60 9.0 1010.8
Luteal 50 not given 1-20 4.6 103.6
Testosterone 3- 10 3-13 7.6 103.1
nglml
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3.4.2 Coefficieat of Variation
The standard curves and values used for the calculation of the coefficient of
variation for the hormone assays are in Appendix C. Table 3.8 shows the coefficients of
variation for each of the RIA assays.
This coefficient of variation is obtained by running the same serum sample on eacb
assay (see section 2.9) . The C.V. value for the progesterone assay is quite high due to
the fact that 3 of the 4 samples gave a value of 0.3 ng/ml while the fourth was 0.6 nglrnl,
50 % higher (see Table C.2 in Appendix C). The lack of a C.V. value for the LO assay
is due to the fact that two of the values obtained from the serum samples were below
detection of the assay and the other was 0,8 UIL, which is coosidered not different from
zero, according to the manual .
3.4.3 Summary
The conclusions obtained from the hormone analysis are that (i) the cycling
volunteers had normal stable menstrual cycles that displayed all the general characteristics
known and (ii) there were problems associated with the use of these volunteers and the
ability to sample them at the appropriate days.
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Table 3.8. Coefficients of Variation for the RIAs.
HOnDone Coefficient of Variation
1711 Estradiol 10.9%
Progesterone 40.0%
Luteinizing hormone(LH) na"
Testosterone 8.0%
- not available . All the values for the serum sample run on each assay were below
detection of the RlA.
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3.5 Variability be tw eee Cydiae Females an d Males
3.5.1 Coefficieat or Variarioa
Before presenting the resul ts of the analysis of males and femal es it is important
10 examine the coefficient of variation values for each of me EliSA assays used in
measuring the cytokines .
The C.V. values ealculared fo r eac h of the assays are presented in Table 3.9. All
the onginal values used 10 calculate this inter-assay variation and the standard curves from
each assay can be found in Appendix C.
II is apparent fro m the table that the inter -assay variation is dramatically high for
some of the assays we performed. The C .V. values for 1L·2,1L.-4 and lFNy are very low
but those of IL-I homserum and culture. were high er. Thes e differenc es may be due 10
the fact that the ELISA's used for measuring JL. 2, 1L-4.and IFNy were from & different
commercial sour ce than the IL-Ill ELISA. R&D Systems supplied the ELIS A kits for IL-
2, n..-4, IFNy. and IL- Ira, whereas Bioso urce was the source for n.·11l and some oflbe
n..-4 kits . In addition, on the IL-4 Biosource EUSA assays, the sample that was used for
calculation of the CV value was off the scal e of the plate , contrib uting to the inability to
calculate a CV val ue . Finally, the fact that many of the samples used to measure IL-I had
to be diluted contributed to the high variability reflected in the CV values.
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Table 3.9. Coe ffici ents of variation for the EUSA assays.
CytOkine Coeffi cient of VariatioD
0.-2' 3.8%
/L-4" 7.6%
lL-4- Da'
1FNy' 4.6%
0. - 111' 35.6%
[Loll!' na
1L·lrat 28.8%
[L..l ra~ 27.9%
• 0. -4 R&D Systems ELISA.
"1L-4 Biosourc:e ElJS A..
C Value for culture supernatants.
.. Value for serum .
• not available.
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3.5.2 Precision of CEil Counts
An experiment was done to detennine the accuracy of cell counting . A suspension
of PBMe s was counted 10 times and the results indicate a precision of 98 .3%.
J.5.J The F test
Having determined that the women had normal menstrual cycles il was possible
to test whether there was more variation in success ive samples taken from the women than
from the men for the cytokines .
The statistical F test was used to determine this with «=0 .05. A full exp lanation
of the F Test is given in section 2.10.2. AU the individual parameter meas urements are
given in Appendix B.
Table 3.10 shows the results of the analysis with the degrees of freedom and the
p value for each individual cytokine. The data in the table show that the cytokines that
had significantly more variation over time in the cycling females as compared to the males
were IFN-y and 1L4 induced by stimulating cells in cultures, and IT..-Ira and lL-1~
detected in serum . The others were not significantly diffe rent. That is to say. that if the
F value is not large enough to be found sign ificant. then we have no evidence against the
hypothesis that the two groups have equal variances.
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Table 3.10 . F test dataon each of the cytokines examined in the study.
Parameter Ratio FiM Degrees of
Freedom
1L_2K 1.38 106/47
D..-4M 1.72 105/47
Ils-I ra" ns" 0.97 82/28
n..lra~ Sd 0.89 80/24
D..·lp'ns' 1.25 74/23
D..-1P's' 0 .316 58/24
IT.-Irab 5.07 103/31
D..-IP' 1.79 92/27
IFN.y"' 11.68 104/34
• values obtained from culture supernatant.
b values obtained from serum aliquot .
C nonstimulated culture supernatant.
d stimulated culture supernatant.
C not significant
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p value
ns"
<0.05
ns
ns
ns
ns
<0.0 1
<0.05
« 0.01
3.5.4 Comparisea or MeaDs between Cydillz:; Females and Males
For each cytoki ne examined the means and ranges for the men and women, and
the p values. are given in Table 3.11 and 3.12. It is apparent from this analysis that
sever al of the mean cytokine values are different for males and females suggesting that
the sexes VaJY ID the amount of eytokine they produ ce, both in culture stimulation
experiments and circulating levels in serum . Thi s is most striking for IF'Ny in stimulated
cultures and the a- I ratio in serum; in both cases the men produce greater amount of
cytokine . This analysis was done using the t test and the data obtained from the females
for one full cycle . The samp les taken in the second cycle were not used as we did not
have an entire sample set and inclusion of the valu es from the follicular phase would only
di stort the mean as luteal phase samples are absen t from the second cycle.
3.6 Crtokine Levell Du rial the Meastrual Cycle
One of the aims of the study was to monitor serum cytokin e levels and cytokine
production by unstimulated and stimulated cells over the course of the menstrual cycle.
This was successful ly completed and the data can be found in Tables 8 .I -B.30 in
Appendix B at the back of this document. In these tables the day in the cycle the sample
was obtained and the corresponding cytokine valu e is presented.
The cytckine IL- I was measured both in serum and in culture supernatants. The
rationale was that the serum values would reflect the in vivo situation and the circulating
levels of c:ytokine at the time the sample was taken . Cell cultures were also used 10yield
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Table 3.11. The means , standard error, ranges and p values for males and females for
eytokines assayedfromculturesupernatants. Thet test for independent samplesof groups
was used, a =O.05.
Cytokine Sex .. SE Ran ge p value
1L·2b F 9S 477.S 34 .S 44 .8-I S94.0 0.945
M 39 474.4 2U 171.2-847 .8
1L-4' F 93 71.6 9.7 2.1-S06.4 0.398
M 39 S8.2 7.S 0.0-195 .2
IFN-y' F 93 276 .8 22.4 11.3- 1262.0 O.OSS
M 38 421.9 70.3 16.9-1669.0
[L.1ral F 80 7.54 0.74 0.47-29.S0 0.022
M 31 4.73 0.94 1.05-23 .53
IL- lra~ F 78 44 .6 1 1.44 19.9 1-76.S3 0.146
M 29 48 .69 2.43 21.70-71.86
IL- I ~' F 71 108.7 17.09 0.5D-60S.30 0.283
M 27 75 .0 23.24 0.20-44 2.2
IL- I ~' F 62 9724 513 3S01 -184OO 0.982
M 26 9702 8S1 3724 -17720
IL-I F 71 1.81 0.4 0.01-25.8 0.162
Ratio' M 27 1.04 0.3 0 .01-S .8
IL- I F 62 23 .4 1.3 8.6-S4 .9 0.212
Ratio" M 24 20 .1 1.6 8.5-34 .S
number of samples used in the calculation.
• measuredin nonstimulated culture supernatant
It measuredin stimulated culturesupernatant
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Table 3.12. The means. standard error, ranges and p vaJues for each group for the
eytokine IL·I assayed in serum from males and females . The t test for independent
samp les of groups was used. CFO.05.
Cytok ine Sex o· Mean SE Range p value
D.-Ira F 93 265.19 25 .94 13.8-1036 .0 0.338
M 40 208.78 66.24 18.5-2578.0
D.-IP F 6 1 3.80 0.62 0.09-14.80 0.577
M 30 4.19 0.33 1.06-8.67
IL-I ratio F 60 2.27 0.39 0.01-13.92 0.000
M 30 7.29 1.14 0.04-33 .74
• number of samples used in the calculation.
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information on IL· I levels. in particular it was felt that the supernatan ts from cell cultures
would indicate what the particular supopularions of cells are capable of produ cing when
stimulated. In addition to measuring cytokine levels in supernatants from stimulated cells
we were also interested in levels of cyte kines produced by unstimulated cells as these
cells, in a sense. reflect the in VIVO situation . One of the questions we wanted to
investigate was whether or not the levels of IL-I in circulation were related to levels
spontaneously secreted in unstimulated cell cultur es. If this were true then it was
postulated that the curves generated from both conditions would look similar . Though this
would assume that the cells that produce IL-I in circulation are the same cells that
produce 1L·1 in culture conditions.
It is important to note here that there were som e problems W1tb. obtain ing values
for some of the a ·I measured. In particular there were several values that were either
above or belo w the sensitivity of the assays . These values are indicated in the tables of
raw data in Appendix 8. In these cases the sampl es that were above or below the
sensitivity of the ELISA were not included in the following statistical calculations. It was
not appropriate to estimate the values and thus they were excluded. An alternate method
of dealing with this would have been to designate a numerical value to each of those
samples. This is dealt ¥11th again in the discussion of IT.·I in Chapter IV.
3.7 Cyclical Variation in Females
Our next aim was to determine if there were cyclical variations of cytokine levels
li S
in serum or cytokines produced by cultured cells . In order to determ ine this we bad to
devise a method of standardizing the data obtained from the cycle SO that each woman
was comparable to the next . Even though we chose individuals with normal meo.strua1
cycles and ovulatioo times each women is diffe rent. they do not all ovulate 00 the same
day in their cycle and have the same length of cycle .
3.7.1 Proportions of the Menstnlal Cyde:
It is appar ent in the hormone graphs that although the cycle lengths were fairly
similar , they were not identical . In order to compare the results of one women with those
of the others we convened all sampling days to "proportion of phase ". Thus a sample
taken on day 6 when the women bad a cycle length of 28 days with ovuJation on day 14
would be 6:14 - 0.4 of lbe follicular phase; a samp le taken on day 21 would be (21- 14)
: (28-14) = 0.5 of the luteal phase. If an individual had more than one value at a
proportionate day then those values were averaged and the resultant mean value was used
as the value of that proporti onate day. By doing this we could graph the results from the
nine cycling women so that they had the same time of ovulation and menses.
To further simplify the comparisons we divided the cycle into eight stages. This
was done so that the majority of women would contribute a value to each stage because
when we converted to proportionate day of the cycle we were still left with an incomplete
data set simply due to the sampling day schedule. The eight stages are as follows :
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1. Early follicular (EF) = proportionate days 0.2 and 0.3 of the follicular phase
2. Midfoll icuIar (MF) = proportionate days 0.4. 0.5 and 0.6 of the follicular phase .
3. Late follicular (LF) == proportionate days 0.7 and 0.8 of the follicular phase.
4. Ovulation (0) = proportionate days 0.9 and 1.0 of the follicular phase and 0.1 of the
luteal phase.
5. Early luteal (EL) ~ proportionate days 0.2 and 0.3 of luteal phase.
6. Midluteal (ML) = proportionate days 0.4, 0.5 and 0.6 of the luteal phase.
7. Late Luteal (LL ) "" proportionate days 0.7 and 0.8 of the luteal phase.
8. Menses (M) = proportionate days 0.9 and 1.0 of the luteal phase and 0.1 of second
follicular phase.
Initially we attempted to create spline graphs with the use of the program S plus .
These spline graphs used all the original data and attempted to smooth the curves to create
a clear curve absent of any noise. This was difficult to do as the values used to spline
are arbitrary and diffe rent for each curve. In addition, th is method did not indicate the
peaks in the data over the course of the cycle. This was most dramatic in the creation of
the LH graph where the point just prior to ovulation is the most important point and the
computer factored it out. Thus we decided against using such a system.
An alternate method that could have been used to standardize the data was
proposed by Daly . 1979. This procedure converts the cycle into 11 phases; 2 menses
phases, 3 follicular phases , one ovulation phases , and 5 luteal phases. Dory. 1979 treats
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ovulation in much the same way we do in that be uses the 0 (LH peak day) and +1 (the
day after LH peak) to stabilize the data and increase the likelihood of encompassing the
actual ovulation event. In contrast to this we used only one menses phase, 3 phases for
each of the follicular and luteal phase of the cycle and one for ovulation. Our method
designates the ovulation phase as encompassing days ·1 , 0 and +1, which Doty suggests
can be done . In addition , the common method of LH~enuingof the data and using onJy
2 phases . that of the folJicu1ar and luteal , was not used because it does not allow for the
possible differences within these two phases .
3.7.2 Composite Ho rm one Proftle
Figure 3.11 displays the composite hormone graph as proportion of the phase of
the mensttuaI cycle. This figure shows the hormo nal changes that occur in the cycling
females that p&rticipated in Phase Il of the study .
As in the individual figures. there is an LH peak at ovulation. an estrogen peak in
the follicular and luteal phases and a progesteron e peak in the luteal phase .
3 .7.3 Cytoki nc Analysis
Each of the eytokines that were measured by EUSA were graphe d (Fig . 3.12·3 .20)
as propo rtion of phase following the procedure describ ed in section 3.7.1 and analyzed
with the paired t test to determine if there were any diffe rences between the lows and
highs indicated by the data. Note that the number of paired comparisons in each of the
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Figure 3.11. Composite hormone profile as seen when the cycle is convened into
proportion of phase .
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following analyses is designated "n". The individual results (raw data) for the IS
volunteers are presented in Appendix 8 , Tables 8 .1-8. 30.
In addition , Appendix B. Table 8 .31 gives the actual converted values as
proportion of phase used in the graphs and the standard deviation of each of the points
in the graphs. This table can be referred to for standard deviations. It was not practical
to include the standard deviations in the graph s which follow due to the fact that these are
very large and in some cases extend outside the graphs. This large stan dard deviation is
due to the very large inter-individual variation that is found among the sample population.
As the cycling volunt eers were bled for appro ximately S weeks the results include the
second early follicular phase. It is apparent in the following graphs that for some
cytolcines there is a discrepancy between the two EF phases of the cycl es. There are
several possible explanations for this. It is not an uncommon phenomenon in that other
investigators have found the same thing when looking at the phases of the cycle in inbred
strains of mice (Gall ichan and Rosenthal, 1996 ). Even in genetically similar animals there
still is intra-individual variation suggesting that this is not a surpri sing finding in
genetically diverse humans. In addition, due to the way that the samplin g days were
organ ized some of the time. the discrepancy could be due 10 the fact that not the same
women contribut e to the first and second EF phases in the graphs. Another important
point to make is that while we obtained sampl es from the second EF phases. we did not
follow these women during this cycle and thus do not know the total length of their cycle
or if the cycle was normal , i.e. if the volunteer ovulated. As a result of not knowing the
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total cycle length the points taken in the beginning of the second cycle were classified as
EF based on the previous cycle length. Thus we don't know for certain that these points
are in the EF phases of the cycle . finally, it was noted that the levels of certain cells in
circulation were significantly different at the end of the study. In other words. there were
differences betweenthe first bleed levels of cenain cells and the final sample levels (Table
A.I. Appendix A). This change in cell populations could very possibly have contributed
to the varying levels between the two EF phases we see in this study,
Each of the individual cytok ine results will be considered in the following sections .
3.7.3.1 laterteukiD 2
ll.- 2 was measured by EUSA in culture supernatant obtained as described in
section 2.3.2.1. IL·2 is expressed in pgfml and the changes that occur over the menstrual
cycle can be seen in Figure 3.12.
The trend of the graph shows a low at ovulation and a high in the midluteal and
late luteal phase when estrogen and progesterone are high . Statistical analysis of the
graph using the paired t test at cx=O.OSconfinns the lows and highs seen. The point at
ovulatioo vs late luteal (0""7) gives a p value of 0.0147. Ovulation vs midluteal (0=8)
gives a p value of 0.0088.
3.7.3.2 loterteulda 4:
ll.-4 was measured by ELISA in culture supernatants obtained as described in
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Figure 3.12. The lL-2 cytokine profile in relation to phases af the menstrual cycle . Each
point represents the mean value for the volunteers tested at that time of their cycle, see
Figure 3.1. ll..-2 was measured in supe rnatants ofPHA stimulated mononuclear cells and
is shown in pglmJ .
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section 2.3.2.1. (L-4 is measured in pglml and the changes that occur over the menstrual
cycle can be seen in Figur e 3.13. Note: results from volunteer 09.10.64 are not included
In the calculation of the grapb as ber values are twice as high as those of the other
volunteers.
The trend of the grapb shows a low at ovulation and a bigh at menses. Statistical
analysis of the graph using the paired t test at a~.05 (one tailed) does not statistically
confirm this trend . The po int at ovulation vs menses (0=7) gives a p value of 0.1350
J .7oJ.J InterferoD y
lFNy was measwed by EUSA in cultur e supernatants obtained as described in
section 2.3.2.3. IFNy is measured in pglml and the changes that occur over the menstrual
cycle can be seen in Figure 3.14.
The trend of the grapb shows peaks at midfollicular and late luteal, a low at
ovul ation and at early luteal . Statistical analysis of the grapb using the paired t test at
a -:O.05 (one tailed) confirm s the low at ovulation and the high in the late luteal phase.
p=O.OI (n=7). Midfoll icular versus ovulation gave a p value of 0.151 (0=7) ; midfollicular
versus earty luteal a p value of 0.224 (n=7); ovulation vs menses (0=7) gives a p value
of 0.143.
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Figure 3.13. The ll.4 cytokine profile in relation to phases of tile menstrual cycle. Each
point represents the mean value for the volunteers tested at that time of their cycle, see
Figure 3,1. IT.-4 was measured in supernatants of PHA stimulated mononuclear cells and
is shown in pg/ml.
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Figure 3.14. The lFNy cytokine profile in relation to phases of the menstrual cycle. Each
point represents the mean value for the volunteers tested. at that time of their cycle, see
Figure 3.1. lFNy was measure d in supernatants a f PHA stimulated mononuclear cells and
is shown in pglml.
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3.7..3.4 IntuSeukiD lra iD Donsb m ula ted cultures:
IL-Ira was measured by EUSA in culture supern atan ts obtained as described in
section 2.3.2.2. n.- lra is measured in nglmJ and the changes that occur over the menstrual
cycle can be seen in Figure 3.1S.
The trend of the graph shows a higb at MF. ML and M. a low at 0 and EL.
Statistical analysis of the graph using the paired t test at «.=0.05 (one tailed) does not
confirm the low at ovulation and the high in midfollicular p value 0..3063 (n=7); ovulation
versus midlut eal gives a p val ue of 0.1230 (n=6) ; ovulation vs menses (0:z::7) gives a p
value of 0.0594.
3.7.3.5 Intemukia Ira iD sti m ulat ed caltuns:
n.- Ira was measured by EllSA in culture supernatants obtaioed as described in
sectio n 2.3.2.2. a -I ra is measured in nglmJ and the changes that occur over the menstrual
cycle can be seen in Figure 3.1S.
The trend of the graph shows a high at 0 and ML and a low at EF. EL. and M.
Statistical analysis of the graph using the paired t test at «=O.OS(one tailed) does not
confirm the lows and highs seen . Early foll icular versus ovulation gave a p value of 0.100
(0=4); ovulation versus early luteal a p value of 0.300 (0=7) ; ovu lation vs menses (n=7)
gives a p value of 0.273.
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Figure 3.15. The a-Ira culture cytokine profile in relation to phases of the menstrual
cycle. Each point represents the mean value for the volunteers tested at that time in their
cycle, see Figure 3.1. Ils-Ira was measured in supernatants of LPS non stimulated (0)
(N5) and stimulated (+) (5) mononuclear cells.
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3.1.3.6 loterieukiD 113 in nODmmulated cultures:
lL-113 was measured by EUSA in culture supernatants obtained as described in
section 2.3.2.2. IL-113is measured in pglml and the changes that occur over the menstrual
cycle can be seen in Figure 3.16.
The trend of the graph shows a high at late follicular and menses and lows at
ovulation, early luteal , and late luteal. Statistical analysis of the graph using the paired
t test at a=O.05 (one tailed) does confirm the low at ovulation and the high at LF.
p=O.0471 (n=8) . Ovulation versus late luteal gave a p value of 0.1633 (n=6) and
ovulation vs menses (n=7) gives a p value of 0.0170.
3.7.3 .7 loterleakia 113 i.a stimulated culturet:
n.-113 was measured by EUSA in culture supernatants obtained as described in
section 2.3.2.2. n.-113 is measured in pglml and the changes that occur over the menstrual
cycle can be seen in Figure 3.16. Note : data from volunteer 22.09.75 was excluded
because there are only two values in the cycle and both are in the luteal phase .
The trend of the graph shows a high at ovulation and menses and a low at
midfoJlicuiar and midluteal . Statistical analys is of the graph using the paired t test at
a=O.05 (one tailed) does not confirm the lows and highs seen. Midfollicular versus
ovulation gave a p value of 0.1274 (n=6) and ovulation versus midluteal a p value of
0.2221 (.=5).
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Figure 3.16. The IL-ItJ culture cytokine profile in relation to phases of the menstrual
cycle. Each point represents the mean value for the volunteers tested at that time in their
cycle. see Figure 3.1. IL-IJ} was measured in supernatants ofLPS non stimulated (0) (NS)
and stimulated (+) (S) mononuclear cells.
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3.7.3 .8 IDterieukiD 1:
a -I is expressed as 100x the ratio of ll..· l Pto n..1ra and the changes that occur
both in the nonstimulaJ:ed and stimulated cultures over the menstrual cycle can be seen in
Figure 3.17. The [L·1 Ratio graph for supernatants of stimulated cells excludes the data
from voluntee r 22.09.7S as there are only two val ues for her and both are in the luteal
phase of the cycle .
As a result of the problems in detennining the correct dilution facto r for som e
of the samples we had a loss of some data thus there were some cases where the n..
IlJlIL-lra was oot available .
The trend of the graph for stimulated cultures shows a high at ovulation and at
menses with a lows at the late follicular and midluteal phase . Statistic:al analysis of the
graph using the paired t test at a=O.05 confirms the lows and highs seen. The point at
midluteal vs menses in the stimulated graph gives a p value of 0.0057 with 0:4. and 0
vs MI. 1""0.1549 (0-5). The trend in the oonstimulated graph shows a high at LF and M.
with a low at time of O. Differences between means were not significant.
3.1.3.9 Problem s with IL- l Data
It is impo rtant to note here that there was some difficulty in assaying the culture
supe rnatants for ll..-lPand a -I ra. A dilution bad to be used in order to determine the
concentrations of each of the cytokines. When assaying lL·1P . eoastimulated culture
supernatants were assayed undiluted, whereas it was necessary to dilute stimulated
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Figure 3.17. The a-I ratio cytokine profile in relation to phases of the menstrual cycle .
Each point represents the mean value for the volunteers tested at that time of their cycle,
see Figure 3.1. IJ...} was measured in supernatants of LPS non stimulated (.)(NS) and
stimulated (+) (5) mononuclear cells and is shown as a ratio of ll.-II3fIL-lra x 100.
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supernatants 1:10 or I :20 (See Appendix B data tables for specific infonnation). For the
ll.-l ra assay, nonstimulated culture supernatants were assayed at a dilution of I: 10 and
stimulated supernatants at 1:20. Even with the dilutions some of the samples still had
values above 0 .0. 3.0. Out of 96 samples there are 21 missing il.-113 values . The loss
of 22% of the data makes the trends we are seeing less reliable and we may be missing
other Important trends .
3.7.3.10 Serum Ioterleukin Ira:
IL- l ra was measured by EUSA in serum obtained as described in section 2.3 .3.2.
IL·l ra was measured in pg/ml and the changes that occur over the menstrual cycle can
be seen in Figure 3.18 .
The trend of the graph shows an increase in IL-Ira from MF to M. Statistical
analysis of the graph using the paired t test at « =O.OS looking at the point at early
follicular vs ovulation in the graph gives a p value of 0.0208 with n=5, and ovulation vs
midfollicular gives a p value of 0.0075 with n=7 .
3.7.3.11 Serum Interleukin 113:
1L·113was measured by EUSA in serum obtained as described in section 2.3.3.2.
IL·113 was measured in pglmJ and the changes that occur over the menstrual cycle can be
seen in Figure 3.19 .
The trend of the graph show highs at EF and ML with lows at LF, 0 and
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Figure 3.18. Serum Il.c lra cytokine profil e in relation to phases of the menstrual cycle .
Each point represents the mean value for the volunteers tested at that time in their cycle .
see Figure 3.1.
133
..
~'=F'-:::M::F:-"-L-=F:--O=-----:E:::L--:M"-L:--LL:-:--"-M:--E=F
Ph__ of the Cyel.
Figure 3.19. The serum IL-I ~ cytokiae profile In relation to phases of the menstrual cycle.
Each point represents the mean value for the volunteers tested at that time of thei r cycle,
see Figure 3.1.
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menses. Statistical analysis of the graph using the paired t test at a::O.OSlooking at the
point at EF vs 0 in the graph gives a p value of 0.2872 with n::3 ~ 0 vs ML gives a p
value of 0.1327 with 0==4,and EF vs M. p::0 .282S with n=3.
3.7.3.12 Sorum IL-I Ratio :
IL·I is expressed as 100x the ratio of n..-I JJ to n..·l ra and the changes that occur
over the menstrual cycle can be seen in Figure 3.20. Note: volunteers 30.04.65 and
01.04.75 were excluded from the graph as they only had one value each during the cycle.
The trend of the graph shows a decline to time of ovulation and a rise to peak in
the luteal phase. Statistical analysis of the graph using the paired t test at a::O.OSlooking
at the point at early follicular vs ovulation in the graph gives a p value of 0.1450 with
n::3, and ovulation vs late luteal gives a p value of 0.1709 with 0==4.
3.7.3.JJ IL-O and TNFa
There were problems obtaining data for IL-6 and TNFa. There were
approximately 75 samples assayed and all were below detection of the ELISA. Thus we
have no data for these cytokines .
3.7.4 Summary
A summary of the cyclical changes that occur during the course of the menstrual
cycle can be viewed in Table 3.13. A feature common to most of the cytokines is a low
IlS
Figure 3.20. Th e ll..·1 ratio cytokine profi le in relation to phases of the menstrual cycle.
Each point rep resents the mean value for the volunteers tested at that time of their cycle.
see Figure 3.1. ll.· l was measured in serum and is shown as a ratio of ll..· IP/IL- l ra x
100.
136
Table 3.13. A summaryof the changesin relative levels of cytokines that were found to
occur duringthe course of the menstrual cycle.
Cytokine Phase
Follicular 0vuJ Luteal Mens es
E M L E M L
IT._2b Low' High High
1l.-4' Low High
IFNY' Low' High
IT.-Ira' High Low High High
IT._lrab Low High Low
!L·W High Lew' High
IL-W Low High Low High
IT.-Ira" Low Low High '
IL-W High Low High
IL-IR' High Low High
IL_IRb High Low High'
IL·IR ' High Low High
• measured in nonstimulated culturesupernatant.
b measured in stimulatedculturesupernatant.
" measured in serum.
I significantp<O.OS
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at ovulation . Il> I (TI..~ IP/D..-Ira) in the stimulated cultures is the exception .
3.8 Regrusions and Cornlati ons
Once we had established that there were cyclical variations in cytokine expression
the next step was to determine if the variation was linked to cyclical changes in the
hormones estrogen. progesterone and luteinizing hormone . This was accomplished by
using multiple regression . The following results indicate what independen t variables
influence the cytolcines. Each cytokine is examined separate ly. AIl the comparisons made
in this section were generated with the original law data obtaine d fOI one full cycle .
3.8.1 1L-2
Multiple stepwise regression of rr..~2 with age of the volunteer . day in the cycle
the sample was taken. day of ovulation. length of the cycle , estrogen. LH. and
progesterone values gives a correlation coefficient of 0.59801 and a coeffic ient of
determination of 0.35761. These values indicate a relationship between day of ovulation.
length of cycle. age and ll.-2. The variab les and the confidence interv als for the equation
are given in Table 3.14.
This correlation indicates that if the day in the cycle that ovulation occurs is closer
to day 1 then ll. -2 will be increased by 30.20 pg/ml per day, that the longer the total
length of cycle the greater the amo unt of n..2 produced by 173.31 pg/ml per day and that
the older the individual is the lower the production ofll.-2 by stimulated cells by 158.14
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Table3.14. Variables in the predictorequationfor IT..-2 with the 95%confidence intervals
and the p values.
Variable B 95% Confidence IntervalB p vaJue
Day of -30 .20 -47.35 -13 .06 0.0007
ovulation
Length of 173.31 112.36 234 .26 0.0000
cycle
Age - 158.14 -203.13 -113.16 0.0000
Constant - 133 1.10 -2497 .32 - 164.89 0.0258
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pg/ml per year . These approximate amounts by which 1L-2 will change are on the
condition that everything else that has an effect on IL·2 be held constant. In addition. the
coefficient of determination indicates that 35% of the variation in 1L-2 is due to the
influence of these independent variables .
3.8.2 IL-4
Multiple stepwise regression of fi.-4 with age of the volunteer, day in the cycle
the sample was taken, day of ovulation, length of the cycle. estrogen, LH, and
progesterone gives a correlation coefficient of 0.63416 and a coeffic ient of detennination
of 0.40215. These values indicate a very good relationship between age, day of ovulation
and IT.-4. The variables and the confidence intervals for the equation are given in Table
3.15.
This correlation indicates that if me day in the cycle that ovulation occurs is closer
to day I then IL-4 will be increased by 13.44 pglml per day, and that the older the
individual is the greater the amount of 1L-4 that will be produced by stimulated PBMC.
IT.-4 will increase by 13.33 pglml for every 1 year increase in age. These approximate
amounts by which ll.-4 will change are on the condition that everything else that has an
effect on fi.,-4 be held constant. In addition. the coefficient of determination indicates that
40% of the variation in IT.-4 is due to the influence of these independent variables.
140
Table 3.15. Variables in thepredietor equation for 0...-4with the 95% confidence mtervals
and the p values .
Variable B 95% Confidence Interval 8 p value
Age 13.33 9.13 17.54 0.0000
Day of -13 .44 -21.29 -5.60 0.0010
Owlation
Constant .20.64 -187.82 146.54 0.8067
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3.8.3 lFNy
Multiple stepwise regression of lFN y with age of the volunteer , day in the cycle
the sample was taken. day of ovulation . length of the cycle, estrogen. LH, and
progesterone gives a correlation coefficient of 0.21940 and a coeffic ient of determination
of 0.04814. These values indicate a weak relationship between age and IFNy . The
variables and the confidence intervals for the equation are given in Table 3.16.
This analysis is not reliable in that the correlation coefficient is only .2 1 and the
amount of variation in IFN y due to the infl uence of thes e variabl es is only 5%. Thus it
is not possible to say that if age increases by I year then lFNy will increases by 12.73
pglml . This prediction is not reliable do to the low correlation.
3.8.4 Culture IL-lra
Multiple stepwise regression cf Ils-Ira with age of the volunteer, day in the cycle
the sample was taken , day of ovulation, length of the cycle, estrogen, LH. and
progesterone tested gives a correlation coefficient of 0.43696 and a coefficient of
determination of0.19093 for unstimulated cultures and a correlation coeffic ient of 0.36596
and a coeffic ient of determination of 0.13392 for stimulated cultures . These values
indicate a relationship between day in the cycle that the sample was taken. age, and ll..·l ra
in nonstimulated cultures and day in the cycle the sample was taken and [L·lra in
stimulated cultures. The vari ables and the confidence intervals for the equation are given
in Table 3.17 and 3.18.
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Table 3.16. Variables in the predictor equation for lFNy with the 95% confidence
intervalsand the p values.
Variable B 95% Confidence Interval 8 p value
Age
Constant
12.73
- 12.86
0.73
-289 .62
143
24.72
263.90
0.0377
0.9266
Table 3.17. Variablesin the predictorequation for IL-Ira in nonstimulated cultures with
the 95% confidence intervals and the p values.
Variable B 95% Confidence IntervalsB p value
Day·
Age
Constant
0.1971
0.7463
-12.56
0.0055
0.3569
-22.26
0.3887
1.136
-2.863
0.0439
0.0003
0.0118
1>ay in the cycle thatthe sample was taken.
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Table3.18. Variables in the predictorequation for Ils-Ira in stimulatedcultures with the
95% confidence intervals and the p values.
Variable B 95% Confidence Intervals B p value
Day"
Constant
0.6376
34.23
0.2620
27.48
\.013
40 .99
0.0011
0.0000
-Dayin the cycle that the sample was taken.
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This regression indicates that for both nonstimulated and stimulated cultures ll.·1 ra
production will increases by 0.1971 and 0.6376 ng/ml, respectively , the later in the cycle
the sample is taken. Thus ll.-Ira increases in the luteal pbases of the cycle which
corresponds to the cycle data results . In addition, n. ·1 ra production by nonstimulated
cells will increase by 0.7463 nglml for every year older a person is.
The coefficient of determination suggests that between 13 and 19% of the variation
occurring in Ils-Ira production in culture is due to these independent variables and that
prediction of Ila-Ira is between 37 and 44% accurate. This is not extremely high but it
does suggest that the variables indicated do playa role in determining how much IT.-Ira
will be produced in culture.
3.8.5 Culture IL-I~
Multiple stepwise regression of rr.-113 with age of the volunteer , day in the cycle
the sample was taken, day of ovulation, length of the cycle. estrogen, LH, and
progesterone tested gives a correlation coefficient of 0.34083 and 0.4277, and a coefficient
of determination of 0.11616 and 0.17874, for nonstimulated and stimulated cultures
respectively . These values indicate a relationship between cycle length and n.·1f,l in
nonstimulated cultures and day of ovulation in stimulated cultures . The variables and the
confidence intervals for the equation are given in Table 3.19 and 3.20.
These correlations indicate that rr.·113production in nonstimulated cultures will be
greater the longer the total cycle length is; it will increases by 32 .84 pglmI for every
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Table 3.19 . Variables in the predictor equation for IL~lP in noostimulated cultures with
the 95% confidence intervals and the p values.
Variable B 95% Confidence Intervals B p value
Length of
cycle
Constant
32.84
-830 .6
10.92
-1458 .68
147
54.76
-202.47
0.0039
00103
Table 3.20. Variablesin the predictor equation for ll.-lP in stimulatedcultures with the
95% confidence intervals and the p values.
Variable B 95% Confidence Intervals B p value
Day of
Ovulation
Constant
972.38
-5733 .25
424.53
·14533 .57
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1520.23
3067.07
0.0008
0.1974
I day longer. In addition. the analysis indicates that ll.- IP production in stimulated
cultures will be larger . by 972.38 pglml per day, the further in the cycle ovulation occurs.
Finally, the suggestion is that between 12 and 180/0 of the variation for IL·I P is due to
influence of the independent variables. The low dependency implies that only a small
portion of IT.-lPvariation can be explained using our independent variables and that other
more significant variables are responsible for the cbanges in ll..-I p.
33.6 Serum IL-I
Multiple stepwise regression ofIL-lra with age of the volunteer. day in the cycle
the sample was taken, day of ovulation, length of the cycle, estrogen . LH, and
progesterone gives a correlation coefficient of 0.58700 and a coefficient of determination
of 0.34456 . These values indicate a good relationship between length of cycle, age. the
bormone estrogen and Il.-Ira in serum.. The variables and the confidence intervals for the
equation are given in Table 3.21.
Multiple stepwise regression of IL-I P with the same variables used for a ·l ra
gives a correlation coefficient of 0.75567 and a coeffic ient of determination of 0.57103 .
These values indicate a very good relationship between length of cycle, age, day of
ovulation and IL·I Pin serum. The variables and the confidence intervals for the equation
are given in Table 3.22.
The statistical analyses is indicating that for n..1ra, if every other influence on a -
I ra is held constant. then. the older the individual is the lower the
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Table 3.21. Variables in the predictor equation for Ils-Ira in serum sample with the 95%
confidence intervals and the p values .
Variable B 95% Confidence Intervals B p value
Length of -58.58 -88 .18 -28.98 0.0002
cycle
Age - 16.34 -28.37 -4.32 0.0083
Estrogen 1.22 0.52 1.9 1 0.0008
Constant 215340 1309 .79 29997 .06 0.0000
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Table 3.22. Variables in the predictor equation for n.-113in serumsample with the 95%
confidenceintervals and the p values.
Variable B 95%Confidence Interval B p value
Age -0 .79 -.98 -0.60 0.0000
Length of 3.27 2.44 4.10 0.0000
cycle
Day of -2 .36 -2.93 -l.80 0.0000
Ovulation
Constant -36 .43 -52.84 -20.03 0.0000
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level oflL·lra will be in circulation, that it will decrease by 16.34 pglmJ for every 1 year
and that the longer the length oftbe cycle,IL·lra levels will decrease by 58.58 pglml for
every I day. Also . we know that: 34% of the variation in 0.,...1 ra is due to these
independent variabl es.
IL-I~ also bas a very good ccrrelanon with, O.76,leog1b of cycle , age and day of
ovulation. Specifically. the older the individual is the lower the amount of ll.·1 P in
circulation; that: it will decrease by 0.79 pglml for every I year and the further away day
of ovulation is from day I, the lower the level of lL-l~ by 2.36 pglml per day . In
contrast. if the length of the cycle is increased more Ils-I P will be present when
individuals are the same age and have the same day of ovulation. These two variables
are connected in that in most cases, as stated in the Introduction . it is the follicular phas e
that is more variable in length than the luteal phase and day of ovulation is considered a
part of the follicular phase, thus if the day of ovulation is further away from day 1 then
the follicular phases will be longer resulting in the probability that the total cycle length
will be longer.
It can also be said that 58% of the variation in circulating levels of IL.lp is due
to the independent variables mentioned above.
3.8.7 Serum Leveh and NODmmuJated ProductioD of [L.l
As discussed in section 3.6 of this chapter we measured both circulating levels of
ll..·l and IL·I production by cultured cells because they give information on different
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phenomenon, both in vivo and in vitro . In addition we wanted to determine if the
circulating levels in serum were comparable to the level of ll.-I produced in
nonstimulated cells. The results suggest that the two measures are not similar at all. The
proportion of phase graphs presented in the subsections of 3.7 indicate that there is no
relationship. Regression analysis comparing the two shows no relationship at all. The
correlation coefficient is 0.07234 and coefficient of determination 0.00523, for IL·Ira
n.~IP is similar to Ils- Jra in that the correlation coefficient is very low. 0.07383 and the
coefficient of detennination is 0.00614. In this study we can find no relationship between
the circulating levels of ll.·1 and fi....l production by nonstimulated cells in culture . This
phenomenon could be due to several factors, first , that there is truly no relationship
between the levels of IL·I in circulation and the levels spontaneously secreted in culture
in the absence of any intentional stimulation. Second, hormones affect the levels and
production of IL·I and the fact that FCS is known to contain low levels of the hormone
estrogen could have altered the secretion of n..·1 from the cultures . Third, circulating
hormones could alter the catabolism thus altering the circulating half time but not
affecting production or secretion. Finally. although we did not intentionally stimulate the
cultures it is possible that low levels of endotoxin present in the equipment used to set up
the cultures and in the media could have resulted in stimulation . This unintentional
stimulation would have been low since that our results show signi ficant differences
between the amount of IL-I produced in stimulated cultures as compared to nonstimulated
cultures.
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3.8.8 Summary
A summ ary of the relevant variables associated with the cyto kine measurements
during the course of the menstrual cycle is presented in Table 3.23.
3.9 JustificatioD of Statistical M~thods
A description of the various statistical tests used to analyze the data were presented
in the Materials and Methods chapter of this text in section 2.10. In this section I will
briefly explain the reasons for doing these tests as they are fwtdamental to the tests
themselves and are already mentioned in the previous section . In addition , I will propose
altemare tests and why they were not used .
The F lest was used to determine if there was more variation in the males than in
the females . This test gives an idea of which group has more amplitudes, or peaks and
troughs than the other . This test was chosen because it would distinguish between a
sample set thai varied more or less than another. in this ease the sample sets were males
and females . There is no other test that can be done in place of this.
The I test was used 10 compare the means of samples taken from one full cycle in
females 10 the means over a similar length of time in males . This test was used 10
distinguish differences in levels for the cytolcines and gave us some indication if females
produced more or less of one cytckine than males . This test was used because the two
samples are independent of each other and we must assume normal distribution of the
sample sets due to the central limit theorem . This theorem states that if the number of
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Table 3.23. Variables, detennined by multiple regression , that significantly influence,
positively (+) or negatively f-) , the cytokines measured in females.
Cytokine E2 Day' Day: Length Age
ers oro or Cycle
1L_2b
!L-4' +
lFNr' +w"
IT._Iraa + +
IT._Irab +
!L-W +
!L-l~'
IL-lra~ +
!L-W +
I Day in the Cycle the sample was taken .
: Day of Ovulation .
a measured in nonstimuJated culture supernatant.
b measured in stimulated culture supernatant.
C meas ured in serum.
a weak .
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samples is greate r than 30. normal distri buti on can be assumed As we combined all the
cycle data for all the nine volunteers the result was greater than 90 points. similarly the
males had greater Iban 30 points. Nonparametric tests coul d be used in place of this test,
but the nonparam etric tests are less stringent than parametric tests . Also. because
nonparametric tests do not use the original values. but convert them to ranks. the
comparisons are more prone to erro r.
The paired t test was used. to com pare within the cycle as the samples are not
independent from each other. Within the cycle. the samples are dependent on each other.
or are successive. We wanted to determine if the highs and lows that the data indicated.
when it was converted to proportion of phase. were statistically the sam e or different. In
ord er to do this we bad to use a pai red test that attempts to control for extraneous
variables . Again nonparametric tests were not substituted for t tests for the reasons
above.
Finally , ANOVA is often used to analyze data such as those obtained in this study
thou gh it should not always be used. Usually a sample set that contains the same number
of observations is needed to perform such a test. This was no t the case in this project as
we obtained a diffe ren t number of samples from each of th e females. In addition, it
should only be used when the samples are obtained on the same days for every volunteer
througho ut the cycle. A final point, there have been studies tha t use ANOVA to compare
males to females in different phases of the menstrual cycle fo r a particular observatio n.
This is not appro priate as males have not been shown to cycle in the same way women
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have with respect to estrogen. progesterone and luteinizing bonnone . Males do not have
a menstrual cycle thus the two are incompatible.
3.10 Tecb.oical problems
There were several problems that were encountered during the course of the study .
To begin with it was very difficult to obtain females who were of the correct age and not
taking oral contraceptives. The university population is a difficult place to tty and obtain
young women who are not taking oral contraceptives . Several hundred students were
presented with an outline of the study and very few conformed to all the criteria needed
to gain entrance to the study. In addition. some of the women who were eligible to
participate did not want to donate what they perceived as large amounts of blood over a
S·week period of time. The level of commitment to this project also resulted in
individuals declining to participate.
There was also a problem with the timing of samples in Phase ITof the study . The
women were scheduled to be bled three times a week. Monday, Wednesday, and Friday.
During the course of this phase there were several Monday holidays thus that day was
missed; in that case some of the volunteers were bled Tuesday , Wednesday, and Friday.
This contributed to missed days in the cycle and loss of samples. We also encountered
difficulty in getting the volunteers to notify us immediately when they began menstruating
resulting in loss of samples in the early follicular phase . In addition, as the study was
voluntary we could not prevent the volunteers from going on vacation during the study.
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This OCCWTed with one of the cycling volunteers. 30.04 .6S~as a result we missed several
key days in ber cycle .
The problem of frequent sampling days (3" a week) also contnbuted to the
inability to obtain samples on some days . At times the subject could donate only a small
amowt of blood before the veto "collapsed".
The ELISA method contrib uted to some of me problems encountered, To cut costs
we purchased EUSAs from Biosourc:e, and as can be seen from the C.V. values. the
results were Dot as reliable as those purchased from R&D . It is weIllmown that differen t
commercial ELISA assays give different results with the same sample tested (Ledur et at.,
1995). This is discussed further in chapter IV.
In addition . the assays for the culture supernatants ofa..IPand n..t ra stimulations
bad to be diluted due to the high conc:eotntions of the e:ytokines presen t. This was
unknown when the fim assay was done an d thus there was a loss of materials and results.
The subsequent assays were performed by diluting the samples as described in the
Materials and Metho ds section . This di luti on washigh and added an additional variab le
in the system leadin g to inaccuracies, and. even with the dilution , some of the values were
too high to be measu red. In this case we put a greate r than sign (» in the table and did
not use that sam ple day for calc ulation.
Final ly, we had intended to measure TNFa and IL-6 in serum using a commercial
EUSA but when tested both e:ytokines were below the sensitivity of the assays . Thi s was
disappointing as we bad inten ded to collect information oa all three inflammatory
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cytokines (IL-l , TNFa. and n..·6) . The infonnation we obtained from the manufacture r
(Biosource) indicated that we should have found measurable amounts of TNFtt and 1L-6
in approximately 75% of the samples .
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CHAPTER I\'
DISCUSS ION
4.1 C rea tion of Sa mple Set
In the introd uction of this thesis I have outlined the many aims and objectives of
this project. The following sections of the discussion will discuss the creation of the
sample set of serum and cells from healthy normal females at known points in their cycle
and a similar sample set created of controls using normal healthy males . In addition , it
was also our intention to monitor serum gonadal hormone levels in females and males
4.1.1 Female Sam ple Set
Nineteen women participated in Phase I of the study . This phase was designed to
determine if the volunteers had stable menstrual cycles with respect to time of ovulation
and length of cycle . Eight women were chosen to proceed to Phase II where the immune
parameters were measured.
There were 9 women, ages 19-29, who participated in Phase II, one of whom was
not studied duri ng Phase I but was demonstrated to have a normal menstrual cycle . These
women were required to complete a daily assessment of any symptoms experienced over
the course of their menstrual cycle in the form of a Menstrual Cycle Diary . The results
indicated that the re were no significant differe nces between the symptoms during the
course of the cycle suggesting that they were not experiencing premenstrual syndrome
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CHAPTER IV
DISCUSSION
4.1 CreatioD or Sample Set
In the introduction of this thesis [ have outlined the many aims and objectives of
this project. The following sections of the discussion will discuss the creation of the
sample set of serum and cells from healthy normal females at known points in their cycle
and a similar sample set created of controls using normal healthy males . In addition , it
was also our intention to monitor serum gonadal hormone levels in females and males.
4.1.1 Female Sam ple Set
Nineteen women participated in Phase [ of the study . This phase was designed to
determine if the volunteers had stable menstrual cycles with respect to time of ovulation
and length of cycle. Eight women were chosen to proceed to Phase II where the immune
parameters were measured.
There were 9 women, ages 19-29, who participated in Phase U. one of whom was
not studied during Phase I but was demonstrated to have a normal menstrual cycle. These
women were required to complete a daily assessment of any symptoms experienced over
the course of their menstrual cycle in the fonn of a Menstrual Cycle Diary . The results
indicated that there were no significant differences between the symptoms during the
course of the cycle suggesting that they were not experiencing premenstrual syndrome
160
(PMS) . This is important to consider because it is believed that women who have PMS
do not have normal menstrual cycles (Thys-Jaccbs and Alvir , 1995).
In addition to not displaying any symptoms of PMS we were also able to establish
that the volunteers were healthy as any medications and/or sickness they experienced were
recorded . Examination of the diary from all the volunteers indicated that while some of
the volunteers did periodically take analgesics they were generally in good health during
the study. This is confirmed by the self-assessment questionnaires the volunteers
completed each day they were sampled. This questionnaire monitored any medications
consumed, sexual activity within 12 hours of sampling, and exercise since the last day
they were bled. Examination of these questionnaires indicate that the volunteers did not
partake of any excessive exercise that could alter bormone levels . Sexual intercourse bas
also been known to alter hormone levels for up to 12 bours and although it would have
been ideal to have the volunteers abstain from sexual intercourse it was felt, considering
the intense involvement in the study already. that abstinence was not an appropriate
request. Some of the volunteers did engage in sexual intercourse during the study though
there appears to be no effect on the results obtained as no bormone value is 50% different
from the previous or subsequent sample .
To control for any influence of season on the menstrual cycle in our volunteers we
also restricted the study to the summer months, that of May to August. All the volunteers
that participated in the study. including the controls. were sampled during these months
to minimize the variability between the groups and individual volunteers .
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It is apparent from the data collected on length of cycle and day of ovulation that
the female cycling volunteers could be considered to have normal stable menstrual cycles.
It is generally accepted that the average cycle length is 29.5 days with a range of 26-34
days (Asso, 1983) and based on our data the females lbat parti cipated in Phase D of the
study fall within this range.
The time of ovulation was measured using urinary LH kits (OvuQuick). A recent
study evaluated the usefulness of this home urine LH assay in women with regular
ovulatory menstrual cycles without any obvious confounding variabl es. The group found
that urine LH testing using this kit is a reliable method of predicting ovulation within the
next 48 hours (Miller <I 01., 1996).
During the course of Phase D the nine cycling female volunteers were bled
between 9-15 times during the course of their menstrual cycles . The volunteers of the
study were all sampled between 8:3().I O:OO am. on all sampling days to reduce variability
due to diurnal changes in number or function of circulating leukocytes. Variability in
cytokine production and numb ers of immune cells has been demonstrated by Born et al .,
1997, in relation to circadian rhythm . There were some problems with sampling days as
illustrated in Figure 3.1. It is apparent from the figure that the number of sample s
obtained from the vohmt eers vary and that the goal of three samples per week was
reached for most donors in the luteal phase of the cycle. Some early samples were missed
since we were not always immedi ately notified when a volunteer first started her cycle .
In addition, SO mJ of blood was not always obtained from the dono rs every sample day
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leading to missing data.
4.1.2 Mal e Coa trol Sampl~ Set
In addition to the experimental group a control group consisting of four males
between the ages of 2()..2S were chosen . Males were chosen as a control group due to the
fact that they do not cycle with respect to the gonadal hormones examined as females do.
Thus the group wouJd constitute a sample that did not have the influence of regular
monthly hormonal changes contributing to the changes seen in the cytokine levels.
The males were required to meet previously set standards (section 2.12) before
entering into the study . Owing the course of the study these individuals were also
required to com plete a self-assessment questionnaire each time they were sampled that
was similar to the assessment the females completed. Based on these questionnaires it is
apparent that the control group was healthy thro ughout the study; one male contracted a
cold during the study and thus was excl uded until after symptoms bad disappeared The
men did not participate in extreme exercise and all sexual activity was reported as in the
females . Examination of the data indicated that sexual interco urse 12 hours before time
of bleeding did not result in the testosterone levels measured exceeding the given normal
range .
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4.1.3 HormoDe Levels
The levels of some of the gonadal bormones were measured via radioimmunoassay .
17~estradiol, progesterone. and luteinizing bonnone were measured each time the
volunteers were bled. The continuous hormone measurement gave us information on the
actual levels of the hormones throughout the menstrual cycle and was used to determine
if the females had the normal levels of the hormones at different phases of the menstrual
cycle. In addition. the males were bled between 9~12 times over the course of 4 weeks
and testosterone levels were measured on each sample.
The diagnostic RIA kits included the expected physiological ranges. The expected
and actual ranges of these hormones are found in Table 3.1 in the results section of thi s
paper. As is apparent from the levels of these hormones during the course of the study,
the females had normal physiological levels of 11~dioi. progesterone and LH during
the cycle that was studied. The hormone profile figures 3.2-3.10 can be viewed and
demonstrate the normality of the individual volunteers when compared to the textbook
profile seen in Figure 1.1.
Five of the volunteers are missing the LH peak due to the pattern of sampling
days. This peak was not found in the LH hormone assays for the five women but was
known to occur as indicated by the OvuQuick assay kit that the women used. Thus we
do know that even though sampling days resulted in missing the serum LH peak it did
occur indicating normal ovulatory cycles.
Based on all the information gathered on the cycling volunteers it is reasonable to
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say that according to conventional terms the volunteers were healthy normal females with
regular ovulatory cycles .
Thus, considering all the data gathered on the volunteers it is apparent that to the
best of our knowledge both the females and the males were normal healthy subjects that
would have fewer extraneous variables influencing the data gathered than a group less
stringently screened.
4.2 Variability between Cycling females and Males
One of the aims of this study was to compare the variability in cytokine production
in circulation and in supernatants of stimulated and nonstimulated cells in culture. in
males and females . In this section the cytokioes will be grouped and discussed as a
group .
We examined the variability in cytokine production of all the cytokines measured
in both the cycling (9 women) and noncycling (4 males) volunteers with the aid of the F
test. Simplified. this test determines if the females have more variable cytokine
production in success ive samples than the males, ~ if the females have more peaks and
troughs than the males .
In addition, this section will discuss the means comparisons between the males
and the females for all the cytokines measured . This statistical comparison provides
information on whether one group actually produces more of one cytckine than the other .
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4.1.1 IL-l. 1L-4. aDd IFNy
Statistical analysis showed that there was more variation over time in the female s
for IT.-4 and lFNy . thus supporting our hypothesis that the cyclical nature of gonadal
hormones in the female system influences the immune system .
When we looked at the mean values of 0..-2, a-4 and lFNy for the two groups
we found that there was no statistical difference (p=O.94S.0 .398 , and 0.05S , respectively)
between the amount of IL·2, lL4 and IFNy produced between the noncycling and cycling
groups. Though we did note that the ranges for the two groups were quite different for
IL·2 and ll.-4. The difference between the minimum and maximum values for the cycling
voJunteers was 1549 pglmJ whereas for the men it was only 677 pglml for ll.-2. IL-4
showed a difference of S04 pglml and 195 pg/ml, respectively. These differences were
primarily due to a greater difference between ranges for the individual women , i&. we had
"high producers" and "low producers" among the women. This difference in ranges
indicates that females , although they do not as a group produce more IL~2 or 1L-4 they
do appear to have a greater individual differences in the amounts produced.
4.1.1 Culture IL-I
The results indicate that , although there are differences in group means between
the cycling and noncycling volunteers. there was no signi fican t difference in variability
in successive samples for any of the isoforms of [l·1 measured in either the stimulated
or nonstimulated culture supernatants.
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For the groups means , our results indicated the following in nonstimulated cultures:
women had higher leve ls of Ils-Ira than did men. While IL- IIl, and the agonist/antagonist
ratio , n.· II3/IL· lra, showed no differences betw een gender.
In cell cultures stim ulated with LPS. no differences were found in IL· l ll or fi....lr a
production from stimulated cultures between males and females. simi larly, th e 1L·113/IL·
I ra ratio analysis indicates that no gender diff eren ces exist based on the data from this
study. However , 2 of the 29 stimulated samples from the men were lost because they
were above the sens itivity of the plate while 17 of the 81 samples from the women were
lost, thus weakenin g our con clusions.
Lynch et al., 1994 looked at IL-la., 1L·111 and IL·lra production in nonsti mulated
and LPS stimulated cul tures . This group found that cells from women iso lated durin g the
follicul ar phase, secrete mor e ll. - Ira in nonstimulated cultures than cells isol ated from
men. In addition , they found that women secrete mor e ll.·lp than men. in contrast to this
we found no difference. In stimulated cultures Lynch and associates determined that there
were no significant gender related concentration differences in any isoform of lL-1 tested
which is consistent with the results of this study . Furthermore, Lync h and asso ciates
found that the ratio of IL·1a + IL· IJ} to Il. sI ra was higher in the luteal phase for
unstimulat ed cultur es but higher in the follicular phase for stimulat ed cultures. Our results
agree with these obse rvation s if we assume that Lynch et at., sampled their volun teers
during the MF and ML phases of the cycle.
The differences observed in the results from the Lynch study , mor e [L·lra and
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ll.-tll produced by women than men in unstimulated cultures , and this study could be due
to a number of factors. The Lynch paper analyzed cytokine concentration by RIA,
whereas in this study cytokine concentration was measured by EUSA. In addition to this,
Lynch et al., cultured PBMC in the presence of I% autologous serum and stimulated with
I nglml of LPS. In this study, 1% FCS was used to supplement the media and
stimulation was with a much larger concentration of LPS, that of 8 uglml. Our values for
ll...Ira production were much higher, particularly in the stimulated cultures, than those
found in the study by Lynch er al. Our values for ll.-Ill in stimulated cultures were also
much higher than theirs. This difference in the amount of LPS used to stimulate the
cultured cells in the two studies could have contributed greatly to the differences in the
data. It is known that LPS activates monocytes to secrete ll.-I by binding to specific
receptors on the cell surface. The differences in the amounts of ll.- l secreted under
stimulation with different concentrations of LPS may be due to differences in the number
or quality of receptor being bound by LPS, thus possibly influencing the levels of ll. -I
produced by the cells in culture.
Not only are there differences in the methods used but there is a large difference
when considering results using the agoni st/antagonist ratio. Lynch et al.; had IL-lll and
IT.-Ia as agonists , whereas we only measured [L. I ll . Perhaps the most important
differen ce is that Lynch et al . did not determine exactly where in the menstrual cycle their
donors were when they were bled (days after first day of menses was known).
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4.2.3 Serum 1L-1
Changes in IL-I Pand ll.-I ra in circulation over time in both the cycling females
and the noncycling males were examined . Statistical analysis demonstrated that both IL·
tp and lL-ira in serum showed more variation over time. p=<O.ot and <0.05,
respectively. in the females as compared to the males. the females had significantly larger
variances in the successive samples than did the males . This lends suppo rt to the
influence of cyclical hormonal changes on cytokine levels supporting the possib ility that
the variation is influenced by the fluctuation in hormones in females and that this
difference might be partly due to these hormones.
Comparing the mean values for the noncycling and cycling groups we found that
there was DO significant difference for ll.·1 p or IL-I ra between the two groups.
The finding that the females have more variation in the samples obtained than the
males but the lack.of any significant difference between the overall means in serum a.-I
suggest that women do not produce more total Il>1 than men but that they do have many
more lows and highs in n.·l production than do the males .
4.3 Cytokines and The Menstrual Cyele
A significant portion of the objecti ves of this study was to monitor serum cytokme
and cytok ine production by cultured cells over the course of the menstrual cycle and then
determine if there was cyclical variation in cytokine levels in females.
169
4.3.1 IL-Z . lL-4 aa d lFNy
We found that the amounts of 1L·2, IT.-4 and IFNy produced by cultured PBMe
stimulated with PHA variedduring the course of the menstrual cycle . 1L-2 and lFNy
production is low at time of ovulation and high at the late luteal phase whereas IL-4 is
low at ovulation and high at menses.
It is obvious from inspection of Figures 3.)2- 3.1S regarding production of 1L-2.
IL-4 and IFNy that the levels of IFNy from the EF phase of the first menstrual cycle are
Dot comparable with the EF phase of the second menstrual cycle. There are several
possible explanations for this which are discussed in section 3.7.3 and will be briefly
mentione d here . First, in the second cycle the female volunteers did not measure their
time of ovulation. or the length of the cycle, thus the time of a volunteer's second EF
phase is assumed rather than actually determined, It is true that all the volunteers had
normal cycles but that does not mean that they will always ovulate or that all their cycl e
lengths will be the same. It is common for females to periodically have annovulatory
cycles (prior et al., 1990) and, as is obvious from our Phase I results , every individual
varies in the total length of cycle, from cycle to cycle . Second, not all nine volunteers
were bled in both the first and the second EF phase. Third, it has been Doted by other
groups that the intra-individual variation of the response of human lymphocytes to
mitogenic stimulation can be quite great in humans (Herrera et at., 1992) and in
production ofIgA and 180 antibodies in inbred strains of mice (Gallichan and Rosenthal ,
1996). Thus , it is apparent that continuous sampling of a small number of females over
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several cycles is an important experiment that needs to be done .
No detectable levels of IL-2 . ll.-4, and IFNy were observed in supernatants of
unstimulated cultures. This is cons istent with results of a study done by Candore et al .,
1994, using PHA stimulated PBMC and harvest times similar to ours .
It is apparent from the statistical analysis that. for aU three cytokines measured in
cultur e, production is low at ovulation and high in the luteal phase of the cycle . This
suggests a dampening of the ability of the T cells to produce these cytokin es at time of
ovulation when estrogen and LH is very high. Estrogen has been shown at high
physiological levels to inhibit pro liferation of PHA stimulated lymphocyte from femal es
(Herrera e/ aJ., 1992 ).
In addition, in male rats, Atherya et al.• 1993, demonstrated that in vivo
admin istration of E2 and PHA caused a decrease in the percentage of CD4· T cells . Since
IL-2, IL-4 and IFNy are produced by CD4· T cells this could explain the lows we see at
ovul ation and the resultant higher levels in the late luteal phase and menses when estrogen
levels are lower.
Studies done on cyc lical variati ons in white cell populations from femal es and
males (Mathur et al ., 1979) also show that lymphocyte counts are negatively correlated
with E2 (decreased at pre-ovulatory E2 peak in the follicular phase ) and monocyte counts
were positively correlated with P. No cyclical variation in WBC populations were seen
in males.
These data suggest that the varia tion observed by us in cytok ine production is Dot
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necessarily due to a change in amount of cytokine produced per cell but rather due to a
change in relative numbers of mononuclear cell subpopularions present m the circulation
and therefore in culture. Th e suggestion is that our results could reflect in vivo changes
in relative numbers of mononuclear cells, controlled by hormones.
It is important to consider the THIff112 paradigm in the immune system . The THI
and Ta2 patterns of cytckine production are well characterized in mice. THI CD4 " T cells
produce ll.-2 and fFNy, whereas TH2 CD4- T cells produce ll.-4, a-5, ll.-IO and IT..-13
(Mossmann and Coffman, 1989 ; Romagnani , 1991, 1995) . TB 1 cells promote cell-mediated
immune responses and macrophage activation . In contrast TB2 cells promote humoral
immune responses (Finkelman and Holmes., 1990).
The type of effector cell , either THI or T82 , tha t develops from the naive THO
CD4" T cells depend largely on the conditions of antigen exposure. It bas been shown
that the cytokines that T cells are exposed to influence the development of a particular
subset . Activation of naive T cells in the presence of ll.-4 promotes TH2 cells , whereas
lFNy and IL-12 promote Till development (Swain et a/. , 1990; Maggi et 01., 1992; Seder
et 01., 1992; Hsieh et 01., 1992 ; McKnight et al ., 1994) .
It is also known that the cytokine products of TH 1 and TH1 cells are mutually
inhibitory. IFNy selectively inhibits proliferation of TH 1 cells and ll.-4 inh ibits
proliferation of TH. cells (Mosmann and Sad, 1996).
The tenns THI or TH2are often used to refer to responses dominated by IFNy and
ll.-4, respectively (Mosmann and Sad, 1996). In this study we saw that both lL-4 and
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IFNy were low at ovulation but that levels of IL-4 were very high at menses and of lFNy
were high at MF and LL. This suggests a tendency toward a TH I response in the MF and
LL phase of the cycle with a TK2 response during menses. Thus it would be reasonable
to suggest that the cycling of these cytokines could reflect the effect of bonnones on the
relative numbers of circulating Tgi and Tg2 T cells. To confirm this it would be
necessary to analyze the T cell populations present at different times in the menstrual
cycle . Such an analysis is now possible with the advent of a new technique that allows
detection of a cell-surface marker that can distinguish Tal from TH2 CD4+T cells. It has
been fOW1d that IT.·12R is not present on unstimulated T cells but that after stimulation
with antigen there is low level expression of the all chains of the receptor . TH I cells
express both receptor chains but in TH2 cells there is selective loss of 112 chain expression
(Rogge et al.• 1997; Gallagher. 1997) .
In future studies it would be poss ible to tag T cells and determine numbers of THI
and TH2 cells present at different times throughout the cycle thus supplying more
information on what is actually occurring.
Marzi et aJ.• 1996, looked at antigen and mitogen stimulated cytokine production
by PBMC of healthy pregnant and nonpregnant controls (with normal menstrual cycles) .
The data showed that as gestation advanced from the 1st to the 3rd trimester of pregnancy ,
production of lFNy by PBMe stimulated in vitro with PHA decreases and the TH2
cytokines IL-t and IL-IO increase in successful pregnancy with a THI to TH2 shift
characterising the third trimester . The progesterone levels in the second and third
173
trimester are similar to the physiological levels of P present in the luteal phase of the
cycle (Polan et aJ.• 1994) .
In addition to finding that ll..4 is high at menses we also observed a steady
increase in 1L4 production from ovulation to menses . In contrast. lFNy levels in the LL
phase are much lower than IFNy levels in the MF phase, though still higher than those
at ovulation . The data seem to parallel the trend seen in pregnancy with decreased IFNy
production and increased ll.-4 production as progesterone levels rise in the luteal pbase.
4.3.2 Culture lL-1
The results of this study indicate that over the course of the menstrual cycle there
are significant changes in both the production by mononuclear cells and in the circulating
levels of Ik-Lra and [L41p. This section deals with the isoforms of [L·I produced in
culture. The next section will deal with the results seen in the circulating levels of the
cytokines.
We have measured by EUSA the production of Il>!ra and a-Ip by cultured
mononuclear cells unstimulated and stimulated with LPS. From the data graphed (Figures
3.154 3.17) as phase of the cycle, it is apparent that there are fluctuations in the production
of these cytokines. Specifically, in nonstimulated cultures representing the baseline
production . IL-Ira fluctuation is characterised by highs in the MF, ML and at menses with
lows at ovulation and EL. Statistical analysis of these lows and highs does not confirm
the trend observed in the cycling women . Ils-Lra production in LPS stimulated cultures
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indicates a pattern of highs seen during ovulation and ML with lows at EF and M.
opposite to that seen in the nonstimuJated cultures. though these changes are not
confirmed by statistical analysis .
When considering ll.·1 fJ production in the supernatants of nonstimulated cultures
the data suggests a trend of a high in the LF phase and at menses and a low at the time
of ovulation. p=O.0471 and p=O.OI70. In the stimulated culture supernatants there is a
high at ovulation. as seen in n.·lra. and during menses with low levels at MF and ML
though these were not significant It is very difficult to deduce anything from the graph
due to the fact that many of the values for n.-IfJ are above the sensitivity of the plate and
thus are not known. Even though the samples were diluted 1:10 or 1:20 (see Appendix
B) there are stilI many points missing in the data.. Out of 96 values there are 21 missing
data points contributing to the uncertainty in dealing with the data; only 4 points of these
missing points occur in the follicular phase suggesting that nA~ values in the luteal
phase are actually higber than seen in the graph. One way to deal with this would be to
convert all values to percent and estimate the high values as possibly 150%, thus allowing
for their use in the calculations and contribution to the graphs.
As a measure of functional IL-l . the biological activities attributed to IL·l depend
in part on the ratio of agonist (1L~la and IL-l~) to antagonist (IL·lra) (Lynch et aJ.•
1994). We therefore calculated the ratio of IL-II3/IlAra. When considering this
agonist/antagonist ratio in unstimulated cultures we see at high at LF and M with a low
at ovulation, however these differences did not reach significance.
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In cell cultur es stimulated with LPS. the agonist/antagonist ratio shows a high at
ovulation and menses, with a low at ML. ML versus menses. p=O.OOS7. In addition.
comparing with the Lynch et aJ.• paper, if we consider the points of Mf vs ML we find
that our results corre late with those of the Lynch study . Both studi es indicate that the
a-I ratio is higher in the follicular phase than in the luteal phase . Th e problem with
comparing the two studies is that Lynch et 01., does not indicat e the exact days in the
follicular and luteal phase the samples were obtained and as is indicated in this study there
are fluctuations in the produ ction of cyto kines during the stages of the two phases as well
as differences betw een the two phases .
It is apparent from the data gath ered 00 the cycli cal changes in IL- I that the
picture is still hazy but is diffe rent in oonstim ulated versus stimulated culture supernatants .
4.J.J SeMlm n-r
The amounts of n.- I ~ and IL~lra in serum were measured by EUSA.
We found that both IL~1ra and IL~ III levels in circulation chang ed during the
menstrual cycle, (Figures 3.19 and 3.20). Ile-l ra levels were found to increase from the
MF phase to menses . Statistical analys is of the graph confirmed that the EF and MF
phases were low compared to the levels seen at ovulation p=O.02 08 and 0.0075.
respectively. Thi s trend implies that during the course of the menstrual cycle the
concentration of IL~I ra in circulati on increases .
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[L·I jJ on the other band. has a different trend . The data from lL·J jJ leve ls were
graphed and there appears to be a high at the EF phase , a decline to time of ovulation ,
with the levels rising again to peak at the ML phase . Analysis of the graph does not
confirm this trend though it is suggested that perhap s with a larger sample size . as only
34 pairs were available . the change would be confirmed .
We also calculated the agonist/antagon ist ratio as lL·Ip;n.·I ra. This gives a
measure of the ftmetionaJ a-I although, as in the culture, we did not measure lL-ln.
When the Il>t ratio was graphed as phase of the cycle. (Figure 3.t 8). we see that there
is a high at the EF phase and a low II time of ovulation, JPO .1450 . Though this change
is Dot found to be significant. again we suggest that with a larger sample size it could
prove to become significant. The levels in the luteal phase are lower than that of the
follicular phase but highe r than the levels at ow.lation. This apparent high in the
follicular phase is in contrast to the results of a study by Cannon and Dinarello in 19&5
where they found IL- I activity in plasma, as measured by a bioassay (D J0 thymocyte
proliferati on assay) to be greater in the luteal phase compared to the follicular phase .
Differences in the results could be due to the fact that we measured actual IL- ljJ
and IL· lra concentration in serum whereas they measured IL-1 bioactivity which would
include IL·la, IL-l jJ and Ils- Ira in combination. The inclusion of IL- Ia in an analysis
of fi. -1 activity or concentration appears to be impo rtant for the entire fi.·1 pictur e. Th ey
judged their five donors to be in the luteal phase when serum progeste rone was 7.4· 12.9
nglml and in the foll icular phase when serum progesterone was 0.7-0 .9 nglmU. In our
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study only two women had progesterone values between 0.7 and 0.9 nglml in the
follicular phase (the other values were lower). The mean lL~I ratio for the corresponding
two samples was 0.03 . Eight women had luteal progesterone values between 7.4-12 .9
ng/mt. The mean ll.-I ratio for the corresponding samples was 1.49 which is similar to
Cannon and Dinarello's findings of higher lL-I values in the luteal phase .
Future studies would have to include a method of measuring IT.- la; we could not
find an ultrasensitive commercial EliSA assay needed for measuring this isofonn of IL·I
in serum. Perhaps using a bioassay for IL-I would be more appropriate for serum levels
and perhaps more biologically relevant
From the data gathered on serum IT.~1 levels it is evident that there is a change in
circulating a-I during the menstrual cycle . This is consistent with the other cyrokines
examined and implies that hormones do affect the production of cytokines supporting the
hypothesis that hormones affect the immune response in humans.
4.4 CorrelatioDs and RqressiodS
A final aim of this study was to determine if the variation we observed in cytokine
expression is linked or correlated with the gonadal hormones estrogen, progesterone and
lutein izing hormone as well as several other variables we had gathered information on.
The various results of the regression analysis are presented in section 3.8 of this
thesis.
178
4.4.1 IL-l, IL-4 ad IFN y
Multiple regression of the data to determine if any of the variables measured had
an influence on the production of the cytckines indicates that 1L-2 is related to day of
ovulation. length of cycle and age of the volunteer r=O.S9801. p==O.OO07, 0.0000 and
0.0000, respectively . 1L-4 bad a relationship with day of ovulation and age of the
volunteer. r=O.634 16, p=O.OOlO. and 0.0000, respectively . IFNy was found to have a
weak relationship with age, _ .21940, p=O.0377.
Specificall y the regression illustrated that ll..-2 decreased with age, though the
production of IL-4 and possibly IFNy increased with age . Similarly, Engwerda et al .,
1996, demonstrated the same phenomenon in male mice T cells stimulated with
immobilized. anti ·CD3& chain monoclonal Ab and soluble anti-CD28 mAb for 24 hrs . In
addition , both [L-2 and ll.-4 production was found to decrease as the follicular phase
becomes longer, meaning that the further away ovulation day is from the beginning of the
cycle the lower the amount of n.-2 and n..-4 will be produced in culture. Unfortunately
it is impossible to deduce information from the lFNy regression due to the low coefficient
of correlation demonstrating a weak relationship, if one at all.
4,4.1 Culture IL-I
Multiple regression analysis indicated that IT.-Ira levels in nonstimulated cultures
had a correlation of _ .43696 with day in the cycle the sample was taken (p=0.0439) and
age of the volunteer (p=O.0003). n..-lra in stimulated cultures showed a significant
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correlation with day in the cycle the sampl es were taken, r=O.J 6S96. p=O.OOl1.
These resul ts indicate the IT.·1ra production from both nonstimulated and
stimulated cultures are related to the day in the menstrual cycle the sample was taken
further supportlDg the hypothesis that IT.- I ra levels change durin g the cycle. Spec ificall y.
these resul ts indicate that the later in the cycl e the sample is taken the greater the amount
of n.-l ra produced in culture. This corresponds to the cycle data we have that indica tes
that n.-I ra production is higher during the later half of the cycle , the luteal phase . As
with n.-4 and lFNy, n. ·lra production in culture also seems to increase with age of the
volunteer. This finding is not obvious when the raw data are examined; the coefficient
of determination for this regression was between IJ and 19%, suggesting that only a
relatively smal l portion of the variance in n..· 1ra can be attributed to these facto rs.
Regression of IL·I P indicates a corr elation with cycle length in nonstimulated
cultures. r=O.J4083, p=O.OOJ9, and in stimulated cultures with day in the cycle ovulation
occurred, r=O.42277, p=O.OO08, suggesting that changes durin g the menstrual cycle do
influence the producti on of n. · lp. Both cycl e length and day of ovulation are contro lled
by hormonal factors in the body . It is these hormones that detennine when in the cycle
a person will ovulate and how long the total length the cycle will be thus contributing to
the hypoth esis that lL~IP production in cultures are influenced by hormonal variation.
ll..-lP production in nonstimulated cultures was found to be greater the looger the total
cycl e length , and,. in stimulated cultures, the further into the cycl e ovulation occ urs. Both
of these variab les are intimately related in that the furthe r into the cycle ovul ation occ urs
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the looger the cycle will be . Examining the mean values in Tables 8 .16-B.30 in
Appendix B shows that 3 of S volun teers who had longer cycles had much higher amounts
of Ils- Iaproduced in stimulated cultures.
4.4.3 Serum IL-I
Multiple regression was also performed on the data to determin e if any of the
variable s measured had an influence on the levels of the a·1 isoforms in serum . IL-Ir a
was found to have a strong correlatio n r=0.S8700 with the length of the cycle. p=O.002,
age of the volunteer, p=O.0083 , and with the concentration of estrogen during the cycle,
JR).OOO8. 1L-1~ was found to correl ate, r-O.7SS67, with the leogtb of the cycle, the day
of ovulatio n, and age, p=O.OOOO for all variables . Thts correlation further sup ports that
changes during the menstrual cycl e influence the leve l of lL-1pand IL·1 ra in circulation.
To clarify, both isoforms of lL-l are found to have lower levels in circ ulation the
older the individual is. In addi tion, 0..·1 is also related to the total length of the cycle.
The regression indicates that n..- l ra decreases as cycle length increases but 1L·1P
increases as cycle length increases . Examining Tables BI-D IS in Appendix B, indicates
approx imately that the four individuals who were the young est of the group had a mean
[L..l ra level of 435.4 pglml compared to the five older individuals who bad a mean of
159.2 pglml. Examination of IL·lp levels shows that the younger individuals have a
mean of greater than 6.03 pglmJ, whereas the older subjects had a mean of less than 0.66
pglml , consistent with the results of the regression analysis. In addition, the data shows
181
that individuals who bad cycle lengths betw een 29 and 31 days bad a mean Ils-I ra leve l
of 212.3 pglml whereas those with cyc le lengths between 26 and 28 days had a mean of
369 .2 pglml ; IL·l~ levels were approximately 4.4 pglml and 0.5 pglml. respectiv ely.
Finally, it is important to note that these r val ues are very high indicating strong
corr elations with the independent vari ables and that the coeffi cient of determinations for
IL-I are 34 and 57%, respectively, sugges ting that much of the variation we see in the
levels of IL-I in circulation is due to theses variab les.
4.5 C3 aDd C'RSO
These components were measured by two othe r students using the sample set
created in this project. The same analyses were done on the results as on the cytokines
measured in this project. Briefly, it was found that C3 concentr ations and hemolytic
activity, CHSO, changed during the menstrual cycle with peaks in early to midfollicular
and midlut eal phase and lows at time of ovulation . Thus the complement components
exhibit the same general pattern of decreased levels in circulation at time of ovulation as
many of the cytckin es we measured . In addition, C1iSO was found to be more variable
in the femal es than in the males in succes sive samples. Finally , men were found to have
signifi cantly higher C3 concentrations than females. This is similar to the findings of
Agostini et al., 1968.
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4.6 Reteplon
Significant differences between the immune systems of males and females have
been demonstrated in this study. II is known that females have a) greater incidence of
autoimmune diseases than males; b) higher levels of immunoglobulin; c) stronger immune
responses; and d) greater resistance to bacterial and parasitic infections than do males (see
Section 1.2 and 1.4). The implication is that sex: hormones or other products of the
gonads play an important role in these differences.
Both estrogen and progesterone are thought to Influence the immune response.
These effects have been demonstrated in a variety of studies. Estrogen has been shown
to increase production of n.·l in vivo by mouse peritoneal (Flynn, 1986) and in vitro by
rat peritoneal macrophages (Hu et aJ., 1988).
The effects of sex hormones could be indirect. as a combination of factors that
influence the immune response. Alternately, the influence of sex hormones could be due
to a direct effect of these hormones on the various arms of the immune response. A direct
effect could possibly be facilitated by the action of the sex hormones on the immun e cells
via specific receptors. Recent evidence has demonstrated the presence of specific
hormone receptors on various cells of the immune system and supports a possible direct
effect.
GuJsban et al., 1990 , using whole cell assays, investigated the possibility of 17P-
Estradiol receptors on male rat peritoneal macrophages and on a human monocytic
leukaemia cell line, JIll, established from a female patient They found that both cell
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types expressed high affinity binding receptors for estrogen. The results also indicated
that there wer e two different estrogen binding receptors.
Similarl y, Cutolo et al ., 1996, investigated human synovial macropbages obtained
from RA and healthy subjects for the presence of estrogen receptors. Specific monoclonal
Ab revealed immuncstainmg for estrogen receptors in cultures of macrophag es obtained
fro m both groups of subjects . Two types of estrogen receptors were demonstrated on
macrophages, a type I (high affinity. low capacity) and type Il (lower affinity, higher
capacity) recepto r. In addition, they found increased levels of estrogen receptors of both
types on cells from rheumatoid samples. The authors suggests that these results correlate
with a stimulatory effect by phys iological levels of estrogen implicanng estrogen in the
pathophysiology of RA.
Both of these studies provide evidence for the possibili ty of a direct action of the
sex hormon e, estrogen , via specific receptors on imm une cells . IL-l, TNFa, and IL--6, are
principally produced by macrophages. The changes we found in this study, in both
secretion of [L.IIl and 1L·lra from cultured cells and in circul ation could be due in part
to the direct effect of estrogen durin g the cycle on the macropbages that produc e these
cytokines .
Estrogen receptors have also been identified on buman blood mononuclear cells
and thymocyt es. Weusten et 01., 1986, investigated the estrogen binding sites in
mononuclear cells from healthy dono rs, patients with leukaemia or SLE and in
thymocyt es, using the dextran-eoated charcoal assay . The results indicated that estrogen
1&4
receptors were present on MNC isolated from both sexes, and from female patients who
had leukaemia or SLE. and on thymocytes.
Not only have estrogen receptors been identified on thymocytes., Cohen er al .,
1993, demonstrated the presence of estrogen receptors on human peripheral T cells. The
peripheral T cells were obtained from thoracic duct drainage performed before renal
transplantation . The results suggested that estrogen receptors are present on CD8~ T cells
but not on CD4· T cells . Thus the authors suggest that the immunoregulatory effects of
estrogen could be modulated by CD8~ cells but not by CD4" cells . Sim ilarly, Stimson,
1988, found the same results for human T lymphocytes.
Thus it is apparent that many studies have shown the presence of estrogen
receptors on various cells of the immune system lending support to the theory that sex
hormones directly influence the immune response.
In addition to the evidence of estrogen receptors on immune cell s, a study done
by Fox et al ., 1991, indicates that estrogen regulates IFNy cytokine gene expression . In
this study male mice spleen ceUsobtained by macerating the spleen s were stimulated with
Con A in the presence or absence of estrogen. Exposure to physiological concentrations
of estrogen increased lFNy expression in mitogen stimulated spleen cells. In addition ,
they demonstrated that estrogen has a direct stimulatory effect on IFNy promoter activity .
Thus the authors suggest that the lFNy gene is subject to direct hormonal control.
lFNy is produced by bothC04' and CDS' T cells as are IL,2 and IL-4. Based
on the published evidence of specific estrogen receptors on CD8+ T cells , and the finding
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that lFNy gene expression is regulat ed by estrogen, we sugg est. that the cyrokine chang es
we see durin g the menstrual cycle in humans, may in part be due to direct bormonal
regulation of these cyteki nes via specifi c recep tors .
In addi tion , Vik et al., 1991, described structural features of the buman C3 gene
and found a number of regions that shar e bomology with known regulatory seq uences
including IFNy, 1L~6 and NF-ICB responsiv e elemen ts and also the estrogen response
element suggesting that C3 production may be influenced by estrogen. However, there
is clearly no simple relationship between estro gen and serum C3 level, since estrogen in
our cycling women peaked at pre-ovulation and agci.nat midlut eal, with the lowest values
at early follicular . One would bave to postulate an inh ibitory effect of bigh concentrations
of estrogen and possib ly a stimulatory effect o f progesterone in order to explain cbanges
in serum C3 concen tration as a direct result of changes in bormone levels.
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4.7 CondusioD'
This study of changes in immune parameters during the menstrual cycle has
indicated that there are cyclical fluctuations in the level of eytckines as well as C3 and
CHSO. over the course of the menstrual cycle in females . The intriguing finding in this
study was that the majority of the parameters examined were low at time of ovulation.
Why this is so is not known. though we know that estrogen is very high just prior to
ovulation and perhaps this has an inhibitory effect on the immune system. The presence
of estrogen receptors on various cells makes possibl e a direct effect of estrogen on the
immun e system. Whether or Dot progesteron e or lutein.izing hormone also has an effect
is unknown . The literature has very little evidence of the effect of these hormones and
fwther investigations into this are needed.
This study suggests a TR I to TH2 shift over the course of the menstrual cycle. from
the follicular to the luteal phase. which is consistent with the finding in pregnancy. This
observation is interesting and could have relevance to selecting the optimal time of
vaccination in women .
The changes in the inflammatory cytokine Ile-I over the menstrual cycle indicates
that there are times during the cycle when women are more likely to prod uce a larger
amoun t of IT.·I in response to antigenic exposure .
We demonstrated that cycling females . as compar ed to males. are more variable
over time for IlA and IFNy. produced by cultured cells. and D..-Ira and IL-tll in
circulation. In addition. nonstimulated cultured cells from females had significandy higher
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mean values for [L-Ira than males though females showed lower mean [L-I ratio levels
in serum than males
Taken together, these results indicate that there are cyclical changes in the
concentration of the cytc kiaes suggesting that regulation of cytokine production are
fundamentally different in women than men and that. in females, the immune response is
influenced by chang es in hormone status .
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4.8 Future Studies
This project had several aims and based on the results obtained it is apparent that
those aims have beenmet. Although we have found that cyclical changes do occur in the
immune parameters measured in serum and in culture, there are still a number of questions
left unanswered .
Future projects investigating the influence of honnones on the immune response
should involve culturing of PBMe with various concentrations of estradiol and
progesterone as have been done in some other studies but also with various concentrations
of luteinizing hormone since the majority of the cytokines appear to be low at ovulation
when LH is very high.
Any future study would also have to involve a larger sample size to allow for
better statistical outcomes. Timing of samples would have to be more rigorous as we
failed to obtain blood during the EF phase from many of the volunteers and missed the
time around ovulation . As ovulation appears to be a time of "immunosuppression" it
would be impe rative to have more samples around this time .
Our data suggests a THI to TH2shift in cytokine production from the follicular to
the luteal phase of the menstrual cycle, based on cytokine production patterns . A new
technique published this year allows separation of the THI and T82 phenotypes by surface
markers thus it would be possible to confirm this trend during the cycle by quantifying
T cells.
The present investigation focused on healthy cycling female responses during the
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menstrual cycle in order to establish a baseline against which results of women with
certain diseases could be compared. An investi gation of women with autoimmune
diseases like SLE or RA would be interesting. Do such females follow a similar or
differ-ent pattern of expression than the normal female population?
A potential future project would be to examin e healthy females taking oral
contraceptives as they do not have the same hormonal changes as women who are not
using them . How do the cytokme levels vary in this group? Do they vary at all, if as we
suspect. hormonal changes are influen cing immune response? Are their immune systems
depressed or enhanced by the oral contraceptive and do they return to "normal " after they
cease using the oral contraceptives? Prior et 01., 1995, has shown that females taking
medroxyprogesterone acetate experience increased basal body temperature, which suggest
changes in cytokines.
There are a large number of questions to be asked about regul ation of cytckine
production and it appears that as more work is done more questions arise . Research in
imm une-endocrine interaction may provide information about basic biology and also be
relevant to such areas as autoimmunity, oncology. and vaccines .
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CYTOKINE EXPRESSION AT DIFFERENT PIIASES OF
TIlE MENSTRUAL CYCLE
INITIAL
QUESTIONNAIRE
CODE _
AGE
HEIGHT
WEIGHT
ADDRESS _
PHONE (HOME), _
(WORK), _
APPROXIMATELY HOW LONG IS YOUR MENSTRUAL CYCLE ?
WOULD YOU DESCRIBE YOUR CYCLE AS REGULAR?
IF NO. EXPLAIN.
YES NO
CAN YOU GIVE A MENSTRUAL CYCLE DIARY OF THE PAST COUPLE
OF CYCLES ?
(i.e. beginnings of your periods)
COULD YOU PLEASE DESCRIBE ANY SYMPTOMS YOU EXPERIENCE
IN ASSOCIATION WITH YOUR PERIOD .
203
(i.e. severity of cramps and pain)
DO YOU TAKE MEDICATION FOR THESE SYMPTOMS ?
PLEASE INDICATE SPECIFICALLY .
WHEN WAS THE LAST TIME YOU TOOK B.C.P.?
YES NO
YES NO
N /A
ARE YOU SEEING A DOCTOR FOR ANY MEDICAL PROBLEMS ?
IF YES, PLEASE EXPLAIN. YES NO
WHAT, IF ANY, MEDICATION ARE YOU CURRENTLY TAKING ?
(include over the counter medication)
DO YOU EXERCISE REGULARLY ? PLEASE OUiUNE BRIEFLY
YOUR SCHEDULE.
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NONE
CYTOKJNE EXPRESSION AT DIFFERENT PHASES OF
THE MENSTRUAL CYCLE
INITIAL
QUESTlONNAlRE
CO NTRO LS
CODE
AGE
HElGIIT
WElGIIT
ADDRESS _
PHONE (HOME), _
(WORK) _
ARE YOU SEEING A DOCTOR FOR ANY MEDICAL PROBLEMS ?
IF YES, PLEASE EXPLAIN. YES NO
WHAT , IF ANY, MEDICATION ARE YOU CURRENTI..YTAKING ?
(include over the count er medication)
DO YOU EXERCISE REGULARLY ? PLEASE OUTLINE BRIEFLY
YOUR SCHEDULE.
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Mel1stnJaI Cyde Diary
Instructions to use the diary
1. On the first day of menstruation prepare the diary : Considering the first day of bleeding
as day I ofyour menstrual cycle enter the corresponding calender day for each day in the
space provided below.
2. Each Evening : At about the same time complete the column for that day as described
below
Bleeding : Indicate if you have bad bleeding by shading the box above that days date
;for spotting use an
Symptoms: If you do Dot experience any symptoms leave the corresponding square
blank . If present indicate severity
MILD : 1 (noticeable but not troublesome)
MODERATE: 2 (interferes with normal activity)
SEVERE : 3 (temporarily incapacitating)
MEDICAnON: On the bottom of the sheet indicate the medications you have taken
during your cycle, include any (over the counter medications : cough syrup, aspirin, cold
tablets, etc). Indicate the days you took them and the dose.
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IEDICATIONS:
CYTOKINE EXPRESSION AT DIFFERENT PIIASES OF
TIlE MENSTRUAL CYCLE
ROUTINE
QUESTIONNAIRE
CODE. _ DATE _
HAVE YOU TAKEN ANY MEDICATION IN THE LAST FEW DAYS?
(i.e. aspirin . cold tablets . prescriptions. birth control pills) YES NO
DO YOU BELIEVE THAT YOU COULD BE PREGNANT?
WHEN DID YOU LAST START YOUR PERIOD?
YES NO
HAVE YOU ENGAGED IN SEXUAL INTERCOURSE IN THE LAST 12
HOURS. YES NO
HOW HAVE YOU BEEN FEELING THESE LAST FEW DAYS ?
ANY NIGHTMARES . RESTLESSNESS . TROUBLE SLEEPING ?
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COULD YOU PLEASE OUTLINE YOUR EXERCISE SCHEDULE
FOR THE PAST FEW DAYS INCLUDE ANY WALKING ,
AEROBICS, WEIGHT LImNG , SWIMMING , ETC.
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CYTOKINE EXPRESSION AT DIFFERENT PHASES OF
TIlE MENSTRUAL CYCLE
ROUTINE
QUESTIONNAIRE
CONTROLS
CODE, _ DATE _
HAVE YOU TAKEN ANY MEDICATION IN TIlE LAST FEW DAYS?
[i.e. aspirin. cold tablets I prescriptions)
HAVE YOU ENGAGED IN SEXUAL INTERCOURSE IN TIlE LAST 12
HOURS. YES NO
HOW HAVE YOU BEEN FEELING TIlESE LAST FEW DAYS?
ANY NIGHTMARES . RESTLESSNESS . TROUBLE SLEEPING ?
COULD YOU PLEASE OUTLINE YOUR EXERCISE SCHEDULE
FOR TIlE PAST FEW DAYS. INCLUDE ANY WALKING.
AEROBICS. WEIGHT LIFTING • SWIMMING . ETC. .
210
Table A.I . The volunteers hemog lobin levels (gIL) and various cell population numbers ( I09/L)at
the beginning (B) of the study and at the end (E) . The mean and the p value for the paired
comparison. Minimum levels of 90 gIL was required to gain entrance to the study .
Volunteer Hgb WBC' Monocytes' Lymphocytes! Neutrophils
B E B E B E B E B E
21.04.70 135 126 5.3 3.8 0.5 0.3 1.4 1.1 3.4 2.4
01.04 .75 141 13 1 6.0 4.8 0.6 0.4 1.9 1.7 3.4 2.6
22.09.75 135 126 5.8 6.5 0.4 0.2 1.6 1.6 3.7 4.3
15.12.73 129 116 5.7 4.3 0.3 0.3 1.6 1.4 3.5 2.4
06 .09.72 145 136 3.7 3.6 0.4 0.4 1.3 1.0 2.0 2.1
29 .08.71 143 na: 5.6 ne 0.5 na 1.6 na 32 na
22 .11.75 137 123 4.5 3.7 0.4 0.2 1.6 1.5 2.3 1.6
09.10.64 152 146 5.7 5.0 0.3 0.3 1.7 1.6 3.5 3.0
30 .04.65 138 123 5.7 4.6 0.4 0.3 2.3 1.9 2.6 2.2
06 .11.7 1 160 na 5.4 na 0.5 na 1.7 na 3.1 na
24.02.71 160 na 5.1 na 0.3 na 1.3 na 3.5 na
17.02 .75 ISS 156 5.7 5.9 0.5 0.5 1.5 1.5 3.6 3.8
16.05.74 157 aa 4.5 na 0.4 1.6 na 2.7 na
19.02.36 136 124 4.4 5.0 0.3 0.3 1.1 1.1 2.8 3.4
17.10.38 138 na 5.6 0.7 na 2.0 na 2.3 na
Mean 140l 131 5.3 4.7 0.4 0.3 1.6J 1.4 3.1 2.8
I cells at 10l
: not available.
) p<0.0 5, two-tailed. non-parametric.
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Table B.l·B.lS. Original sample data. means . and standard deviations. for all the volunteers in
the study . Tables include the parameters measured in serum and day that the sample was taken.
For the female vclunreers -day- is expressed as day in the cycle the sample was taken and for
the males and post-menopausal women "day " is expressed as month and day the sample was
obtained . Serum parameters included in the tables are IL-Ira. IL-IP. C"HSO, C3 and the
hormones . l7~Estradiol. Progesterone and Luteinizing hormone . For the cycling women cycle
length and day of ovulation (0) are given below the volunteer identification code.
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Volunteeer 21.04 .70
Cycle 29 Days (O=Day 17)
DAY CJ lL- 1.. lL- IP c·.... E% LH PRO
_&I_I p&flllli , elml U/ml , &fad all _&lml
0.95 18.3 0.30 282 68 0.4
Dt~ o. ot 70 0.2
0.90 13.8 0.17 262 65 0 .2
IJ 0.77 21.7 0.84 115 0.1
14 0.78 176.7 <' 140 0.2
16 0.88 155.5 et ISO 13 0.8
I' 0.78 185,8 2.21 270 I II 7.7
21 0.79 139 .6 1.26 ISO 13.2
23 0.82 SO.3 027 26' 123 ' .6
26 0 .86 29.3 I.SO 222 17J 12.2
28 0 .91 61.5 2.10 210 102 2.0
0.83 206.7 1.63 226 61 0 .2
0 ." 0.10 2.5 55 0.1
0 .86 70.5 o' 53 0.1
MEAN 0." 94 .3 1.04 255 106 H
SD. 0 .06 73 .1 0.81 31.1 45 4.'
not tested.
: < 0.083 pglml.
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Volunteer 01.04.75
Cycle 27 Days (O=Day 16)
DAY CJ lL- 1.. lL-1 ~ C 'II5O £ 2 Ln PRO
me/ml pglml pglml CUllts pglml
""
aetDlI
1.06 116.1 4.3 196 4' 0.8
0.94 213 .0 »r 111 48 0.2
1.07 180.3 59 0.1
10 n" 141.5 163 19 0.1
12 1.02 380.2 10' 0.1
IS 0.91 230.9 136 '10 25 O.J
11 0.91 337.2 nl 84 1.0
19 0.87 266 .5 144 10' 2.8
zz 0.99 406 .6 11 3 5. 1
24 0.88 399 .8 16 1 ' .8
26 1.05 386.5 IS' IJI 3.8
0.92 507 .0 140 38 0.'
0.92 567.2 114 40 0.2
MEAN 0,97 317 .9 160 98 1.5
S.D. 0.08 139.5 '0 56 1.9
t not tested .
,> 10 pglml.
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Volunteer 06.09.72
Cycle 28 Days (0 =Day 16 )
DAY CJ lL-ln lL-l~ C'HSO E2 LH PRO
lDe/m l plI'ml ,wml unl .. ,gfml uII a&fml
1.16 44.0 1.61 202 68 0.2
0.99 164.0 0.45 . t 63 0.1
II 1.0 3 7 1.3 L03 179 84 0.3
14 0.93 nt 0.50 190 187 10 0 2
16 0.98 (33.3 1.26 196 2SI 22 1.4
18 0 .93 179.2 0.28 nt 10' 30
21 1.06 80.3 0.61 at 161 14.5
23 1.02 66.0 2.02 199 lSI 9.6
2' 1.04 170 .0 0.10 187 14' 12.2
28 1.01 191.7 0.31 206 180 0.0
LI ] 158.6 0.28 ., '7 0.2
1.19 )]2.5 <' ' 2 0.2
MEAN 1.04 144.6 0.77 194 12' 3.6
S.D . o.n 8 1.2 0.63 10 63 ' .3
not tested.
: < 0.083 pg/ml.
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Volunteer 22.09.75
Cycle 26 Days(O=Day 13)
DAY CJ n...'n n....~ C'H5O £1 LH PRO
"'''1111 pc,m' p&l...1 ...... polmJ all . &lml
Q' Ql 112
10 912.2 0.55 ,.3 0.3
12 Ql 1029.0 Q' 302 II 0.2
14 1.21 1025.0 0.086 .. 120 IS 0.7
17 1.23 1007.0 <' ., 140 6.7
"
1.32 1036.0 143 244 17.1
21 1.23 877 .4 5.82 118 244 18.8
24 1.28 972 .9 144 22 1 7.2
26 1.28 851 .9 0.87 163 78 0.'
1.40 929.6 0.14 171 46 0 .3
1.37 116.1 0.086 1S8 73 0.2
MEAN 1.29 inS .' 1.26 ,>3 161 , .2
sn 0.07 274.9 2.26 Il .. 7.3
t not tested .
: < 0.083 pglml.
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Volunteer 29.08.71
Cycle 29 Days (O=Day 15)
DAY CJ lL-1~ lL-1 ~ c...... E2 LH PRO
met·· ,erml , 1'_1 ..." , &1111I1
""
a&'lIl_
1.29 49 .7 0.10 .,' 87 0.1
1.11 S3.8 <' 206 74 0 .1
11 1.111 91.1 0.30 202 87 0 .1
.. 0.91 112.S 0.20 200 169 JJ 0.2
16 0.96 163.4 0.1l 201 112 20 1.2
18 1.12 208 .9 0.4S at 116 46
21 1.21 162.2 W 169 11 6 .0
23 1.14 283 .0 250 137 9.2
2S Ll2 377 .8 0.89 132 14 .0
29 1.12 29 1.4 0.19 239 57 0.5
1.25 267 .2 249 102 0.8
10 1.11 28 1.6 23 2 95 0.2
MEAN 1.l3 195.2 0.32 225 111 3.1
S.D. 0.09 106 .2 0.28 22 3S 4.5
t not tested.
: < 0.083 pglml.
218
Volunteer 15.12.73
Cycle 29 Days (O=Day 14)
DAY CJ lL- 1.. lL-1~ C'H50 E1 LH PRO
Dlg/m ) pgllld ,lIml uait. pli""
""
lI&,ml
0.9 1 107.6 13.82 nl 68 0.2
0.93 96 .9 13.49 205 87 0.1
0.97 181.1 14.39 193 87 0.03
10 0.93 128.8 14 ,80 125 0.0]
13 0.85 236.] 12.49 271 60 0.6
IS 0.93 579.9 13.13 153 116 2.6
17 0.84 344.9 13.63 134 ' 2
20 1.04 754. 1 14.11 2lJ 270 13.2
22 0.98 191.7 11.8 5 193 15.6
24 0.89 201.2 10.04 149 202 10.3
28 0.94 310.4 12.08 186 97 0.6
29 0 .95 408.1 12.43 143 58 0.1
0.96 576.6 11.59 154 56 0.1
0.98 276.1 11.33 196 65 0.1
1.02 ] 16.1 12.20 nl
"
0.1
MEAN 0 .94 3 14.0 12.76 111 I2S 3 2
S.D. 0 .06 192.7 1.30 27 7S 14 53
not tested .
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Volunteer 09.10.64
Cycle 28 Days (O=Day 13)
DAY Cl lL.lra lL-IB C'H50 £2 LH PRO
-&1-. PWml pelml lIaiu pelml uJI Dl:lml
090 73.0 <' ..
"
0.\
0.92 91.1 \81 lIS 0.'
0.94 95.9 .t 123 0.3
\I 0 .86 84 .5 0.93 ,., 2JS 12 0. 1
IJ 1.00 347 .7 0.58 .t 25. 24 0.5
15 0.94 126.3 0.17 92 1.8
\. 0.98 92.1 108 17.0
20 0.95 138.1 . t 14 21.0
22 0.97 too.s \6' 12.8
26 0.90 164 .5 0.25 \ 24 1.'
21 0.93 110.2 0.11 .5 2.8
0.97 108.2 0.19 210 69 0.5
0.83 119.7 ,., 90 0.2
0.96 152. 1 212 \28 0.1
MEAN 0.93 128.9 0.48 19' 126 ' .1
SD. 0.07 68.2 0 .3] \I 58 1.1
not tested .
: < 0.083 pglml.
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Volunteer 22.11.75
Cycle 31 Days (O=Day 18)
DAY C. lL-1.. lL-1 ~ C'R!<I El LH PRO
'"If"" p&,ml pc/_ I ""'.. ..,.., uII allllli
1.20 199.7 2.43 , . 4 61 0.3
1.17 209 .3 2.27 106 ' 2 0.2
1.14 132.1 2.81 nl ' '2 nt
10 1.15 143 .5 1.,59 184 63 0.4
12 1.13 176.9 2.06 . 3 0.4
16 1.09 181.6 4.08 , . 7 170 10 0.3
17 1.04 200.7 3.06 18. 28' .. 0.1
I. 1.07 247.4 3.02 170 12' 13 1.0
23 1.08 141 .3 4.26 16' IH 15.6
24 1.03 154.0 3.n m '70 15.6
26 1.11 193.1 ".OJ nl 111 1S.6
29 Ll7 205.S 4.97 172 211 8.9
1I 1.09 470 .9 ] .76 ' 98 7l 0'>
1.08 286 .6 ] .34 '.7 33 0.3
1.12 200.7 ] .52 m
"
0 4
MEAN 1.11 209.9 3.27 18' 126 4 0
S.D. 0 .05 82.S 0.9 2 13 84 6.'
t not tested.
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Volunteer 30.04.65
Cycle 31 Days (Q=Day 18)
DAY CJ lL-1.. lL-1~ C'oso 11 LO PRO
metDd p2ImJ p2Iml aaiu p2Iml oil o&fml
1.32 262.7 <' .7 .. ..
1.29 249.3 .7 99 0.1
12 1.20 ]68.7 60 0' 0.1
J) ... ]]] .3 0.3' 62 0' 0.2
20 1.21 1I8 .1 11 IS2 1.0
22 LJ6 326.6 11 241 10.8
25 1.4S 261. 7 11 116 60
27 1.36 236.0 14 112 ,.
20 U2 313 .3 70 2.5
1.29 310.4 84 am
MEAN 1.)1 298 .0 6' 123 1.2
S.D. O.OS 43.0
"
1.7
t not tested .
I < 0 .083 pglml.
222
Volunteer 24.02.71
Male Control
DATE C. IL-lra IL-I~ C'H50 TESf
md ml Pllm! petml an i.. aglml
MIS 1.32 2578 1.06
17 1.27 98 1.4 <' ISS
I' nl' n l
23 1.45 ] 05.3 12
2' 1.29 246 .7 164
26 1.29 434 .6 173
2' 1.43 234 .9 I72 13
JI 1.46 276.6 17. 10
J 2 1.36 195.3 a t
1.47 212.9 n l
1.26 223 .9 167
1.29 191.6 16.
MEAN 1.35 534.7 168
SO 0.08 7 14.8
t not tested.
I -c 0.083 pg/ml.
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Volunteer 06.11.71
Male Control
DAT E Cl IL-l~ rr.. lp c'mo E1 TEST
mgl ml pglm) pclm l _ils pg/ad b&fml
M IS 1.29 225.6 4 .91 169 49
17 1.38 302.4 5.28 153 35 10
19 1.33 65.5 5 .41 157 27
23 1.13 133.1 6.49 158 32
24 1.I 1 36.8 4.75 156 44 13
26 1.32 25.8 2.09 171 48
29 1.20 18.5 2.22 1S6 59
31 1.32 46.3 2.06 17 1 64
12 1.26 44.8 1.84 nt' 44
1.21 32.1 2.38 nl 41
1.19 39.4 2.23 168 34
1.24 22.8 3.04 162 55
MEAN US 82.8 3.56 162 44
S.D . 0 .08 91.3 1.67 II
t not tested .
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Volunteer 17.02.75
Male Control
DATE Cl lL-l~ lL-1 ~ C'HS. E% TEST
m"'m1 ,&lml PWml uDlb , 1111I1 al1 m)
"%. i .28 46.3 4.SS .t· 7.
zs 1.21 108.4 4.33 83 ••
J 2 1.16 46.3 4.18 .2 53 13
1.19 42.5 4.05 '2
"
ID
1.24 49.5 7.23 nt
"
12
1.15 45.5 3.97 8. 71 ID
"
1.23 75.9 3.19 ss '8 13I. 1.27 91.9 7.97
"
4'
I' 1.27 25.7 8.67 •• 46
MEAN 1.22 59.l 5.42 .6 .3 I.
S.D. 0.48 26.8 1.95 12
, Dot tested.
225
Volunteer 16.05.74
Male Control
DATE CJ IL-lra IL-I~ C'RSO TEST
mgtml pg/ml pg/m l paits _lIml
114 nt' nt nt
I' 1.06 192.6 3.93 168
21 L09 160.8 ] .59
24 1.00 102.4 .....54 174
26 1.16 81.72 4.06 186
28 1.07 95.55 4.50 188
1I 9 1.61 4.56 178
A I 1.07 90.63 2.90 17' 13
1.02 129.5 5.08
MEAN 1.07 lIB.1 4.15 178
S.D . 0.05 39.7 0.68
t not tested .
226
Volunteer 19.02.36
PM Control
DATE C3 IL-I n IL-I~ c -.... . 2 LH PRO
!befml ,lI ad PW'" pelml PW'" qJJ all'mt
MIS 1.19 137.2 0.57 130 2. 10 0.1
I' 1.43 131.4 0 .55 01' 32 10 0.2
23 1.2 5 135.3 3.19 122 27 10 0'
24 1.25 146.2 US 122 '0 \ 0 0.'
2. 1.27 217.1 0.50 12' 5. 0.2
2. 1.20 86.5 0.37 128 41 0 \
JI2 1.14 115.0 0.75 127 34 0.1
14 1.24 148.2 0.63 138 37 10 OJ
I. 1.22 146 .2 0.86 a t 51 0.'
23 1.36 97.3 0.90 132 ,. 10 0.2
27 1.29 129.4 0.97 125 ,. 0.1
28 1.16 136.3 1.88 122 2' 10 0 .1
30 1.2 1 17 1.5 051 123 44 10 OJ
MEAN 1.25 138.3 1.04 127 ' 0 0.2
S.D . 0.08 32.4 0.92 10 0.1
t not tested.
227
Volunteer 17.10.38
PM Control
DATE C] IL- In IL-I ~ C'h50 .2 LO PRO
m<lm! pllml P<lm! "",.. P<lm! oil Jlgl ml
MIS 1.31 260 .4 »r nt' 2] 2. 0.5
17 1.43 276 .3 28 22 0.3
I' 1.31 234 .7 22' 20 24 0.2
23 1.36 302 .9 a t 13 24 0.1
2' 1.2 1 292. 4 7. 237 13 26 0.]
26 1.24 290. 1 202 JI 2S 0.3
2. 1.25 245.8 at JI 2S 0.2
JI 1.20 368 .6
"
23 0.1
12 1.34 299.4 i .s at 28 2. 0.1
1.23 269.5 at 76 28 0.3
1.21 272 .9 at •• 26 0.3
LIZ 268.3 202 32 2. 0.1
MEAN U7 281.8 216 30 2S 0.2
S.D. 0 .10 34.2 17 17 0.1
t not tested
, >10 pg/ml .
228
Table 8 .16-8 .30. Original sample data. means and standard deviations. for all the volunteers in
the study. Tables include all the cytokines measur ed in culture supernatants and day that the
sample was taken. For the femal e volunteers "day " is expressed as day in the cycl e the sample
was taken and for the males and post-menopausal women "day" is expressed as month and day
the sample was obtained. The cytckines included in the tables are n.~2. ll..-. IFNy, ll..~lra and
ll..·lll For the cycling wom en cycle length and day of ovulation (0) are given directly below
the volunteer identification code.
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Volunteer 21.04 .70
Cycle 29 days (O=Day 17)
DAY lFN 1 1L-2 lL4 IL-l.. D-l~ •
pglml pgfllli pwml agfml pl1ml
••r
.'
.t ' 47.3 8.5 4 .57 38.43 ., 11170
868.9 55.9 8.1 2.93 24.60 9149
1262 67.4 10.5 ] . 16 25.53 140 10
13 293.4 113.7 3.7 2.31 44.88 45 13610
14 510.5 94.6 14.7 2.28 50 .56 8.1 14850I. 257 .2 85 .8 7.7 3.56 36.98 5.2 14480
19 205.8 95 .6 14.3 2.87 49.08 3.9 160 10
2 1 287 .5 44.8 10.1 3.04 34.93 4.3 12300
23 251 .1 103.0 3.2 3.34 74.26 8.2 15970
2. 395.8 94.6 et at at
28 367.1 6 1.9 7.5 7.47 38.92 254.4 9611
676 .8 94 .1 3.0 at
500.7 116.8 10.9 5.87 60 .99 25.7
565.5 126.3 16.9 6.57 27.03 50 ,8 15360
MEAN 500,2 90.1 9.3 4.00 42 .18 40.6 13375
S.D. 300.1 34.9 42 1.73 14.86 81.7 2391
'!" non stimulated.
I stimulated
• Stim ulated culture samples were diluted 1:20.
• Dot tested .
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Volunteer 01.04.75
Cycle 27 Days (lFDay 16)
DAY lFNy IL-l IL-l IL- I... IL-W
pglml ,lIml pwml alfllli pglml
D, T
"
48.6 403 .5 46.6 n" nt
160.6 205.::1 4.0 1.84 49.16 7868
195.1 2 11.9 23.9 ].49 44 .36 >'
10 353.0 5 18.4 20.5 2.76 41.43 8216
11 173.3 17 1.5 1.1 4.82 50.05 173.9 8444
"
66.7 624 .0 23.4 3.34 48.86 71 11
.7 81.0 68.4 38.7 2.87 34.37 2.1 7161
"
344 .4 488.0 21.5 2.55 47.83 8476
22 153.9 386 .5 28.4 3.60 48.03 3.S 6840
l' ]84.2 399 .8 32.6 3.78 37 .48 10.5 7341
26 347.4 368 .5 66.5 3.39 32.32 3.' 8765
202.5 507 .0 49.7 2.36 35.58 I.S 64S.
437.8 567.2 74.4 4.78 40.80 40.3 8153
MEAN 226.8 378 .5 33.7 3.38 42 .46 33.7 7713
SD. 131.1 168.8 21.4 0.79 6.42 63.3 763
Y non stimulated.
,
stimulated
Stimulated culture samples were diluted 1:10.
not tested.
b
< 1 pglml.
> 10,000 pglml.
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Volunteer 06.09.72
Cycle 28 Days (0 =Day 16)
DAY IFNy IL-Z IL-4 IL-tra IL-W
prl ml prl ml prlm l ai:lml prlm l
as' s' s
148.2 245 .9 48 .5 al at
186.2 545.4 67.1 2.62 22.89 2.8 554S
"
39 2.9 6 19.' 27.5 2.69 ]0.62 , .s 6131
"
161.1 332 .8 22 .8 1.39 28.78 05 649.
I. 247.1 3 11.3 33.0 2.37 37.6 1 1.0 8.60
' 8 236 .7 727 .2 219 3.86 51.81 0.7 8294
21 299 .3 693 .2 13.1 57.45 491.1 6234
23 370 .3 328 .9 29.4 3.66 32.26 ,. 7733
"
409 .5 881 .1 24 .4 12.66 63 .54 "8 >'
28 172.1 710 .9 23.3 6.11 45 .93 360.8 ...,
283.6 768.1 30 .3 8.66 48.06 247 .7
211.3 876 .9 ]6 .7 at
MEAN 259 .9 586 .8 33 .2 5.77 4 1.90 123.6 7195
SD . 9 1.9 128.8 13.6 ' .44 13.48 181." 1226
! non stimulated
I stimulated
• Stim ulated culture samples were diluted 1:1O.
t not tested.
, > 10,000 pglml.
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Volunteer 22.09 .75
Cycle 26 Days (O= Day 13)
DAY IFNy 1L-2 IL-4 II-Ira IL-W
petrol p2lml petrol DC/ml p&,ml
D, T
"
D' ,
D' 29.9 at
10 207 .0 166 .3 38.9 3.70 26.92 S5
"
12 119.1 25] .8 20.1 S.46 ' 08
14 51.4 35] .2 S.4 6.26 57A I 30 .1
17 61.6 414 .0 21.0 6.62 46.26 46.1
"
139.2 45 1.4 29.9 5.81 32.47 14.9
21 176.9 173.4 43 .1 7.15 36.12 62 .2 5744
24 199 .8 766 .7 49.0 428 28.88 12.1 5783
2. 276.S 5 10.9 11.2 23.62 39.32 132
44 .0 487.1 38 .6 13.18 59.74 403
SO.3 '66.1 H .S 8.56 57.3] 51.9
MEAN U5 .6 4 14.3 ]1.4 8.47 42.72 86.6
'7"
SD . 78.2 186.3 16.1 5.94 12.91 118.6 27.6
r non stimulated.
l stimulated
Stimulated culture samples were diluted 1:10.
t not tested .
,
> 10,000 pglml.
• > 3.00.0 .
233
Volunteer 29.08.71
Cycle 29 Days (O=Day 15)
DAY IF Ny 1L-2 IL4 I"L- l ra IL- IP"
pg/ml pg/ml pgfml .£lml pg/ml
.,T
"
126 .4 673.4 40.1 15.58 41.16 170.0 159)0
128.3 670 .6 40 .2 6.82 35.62 44 .9 112 10
II 341.1 775.5 10] .6 2 1.73 47 .06 274.6 15460
I. nr .s 778.3 27.5 13.05 56.7 1 149.6 16370
I . 206.8 173.2 39.0 17.34 37.44 177 .7 16710
18 186 .0 747 .3 61.5 16.32 50.23 22 .7 >'
21 113 .5 1102.0 63.0 11.79 51.37 28.7
23 135 .0 460.3 87.7 17.00 76.53 290.8
25 214.6 1021.0 61.1 17.59 6 1.22 22 4. 1 16430
2' 264 .0 880.9 245.8 12.07 59.2 2 128.9 18400
144 .9 999.3 90 .4 18.41 48.75 260. 2 18200
10 104.7 893.1 34.9 14.85 67 .92 61.1
MEAN 179.7 814.6 74.6 1S.2 1 53.27 152.8 16089
sn 68.6 177.1 59.2 3.86 12.28 97 .4 2223
:- non stimulated .
! stimulated
: Stimulated culture samples were diluted 1:20
> 20,000 pglml
234
Volunteer 15.12.73
Cycle 29 Days(O=Day 14)
DAY IFNy IL-l IL-4 IL- I ra lL-W
Pel'" p gfm l Pel'" acfml Pel'"
. sT s' as
206.4 675.3 26.9 a' nt
nf 635 .3 at 10.13 39.6S 51.6 7578
0126.8 584 .0 14.3 0.6 1 27.8 1 28.0 6576
10 1213.0 889 .8 25.2 1.37 6 1.19 212.1 669 9
II S12.8 n os.o 26.4 0.86 >' 12.8 >'
IS 4993 894 .0 47.4 2.2S 60 .08 51.8 5648
IT 509 .2 1109.0 36.1 1.28 19.91 163
20 587 .7 1594.0 66 .8 0.47 45.29 ' .8 HOS7
n 256.9 92 1.3 6 1.8 1.21 13.4
24 508.9 10 35.0 ]11.( I.n 39.82 152.5 8851
28 430.9 1240 .0 85 .7 1.4] ]4 .12 369.0 8133
29 ]38 .7 1348.0 48.1 ot
153 .9 834.3 4 1.8 l.l7 45.60 6l.S
124.1 652.3 35.5 1.68 41 .42 67.9 1679
226.7 109 1.0 47.7
MEAN 428.2 973.9 43.0 2.04 4 1.55 87.4 7403
SD . 272 .0 285.7 18.8 2.60 12.92 108.0 1030
T non stimulate d.
!. stimulated
t not tested.
Stimulated culture samples were diluted 1:20.
.> 20,000 pglml .
> 3.0 O.D.
23S
Volunteer 09.10.64
Cycle 28 Days (O=Day 13)
DAY lFNy JL-' IL-l IL-I~ IL-W
PW'"' pl!m) pgllDl .",... p&lml
• •r
"
..
586. 1 649 .2 506.' 5.51 24.69 19.6 3501
384 .7 942 .6 327 .0 10.08 55 .2 1 16 4886
362.8 280 .7 227 .7 10.03 28.09 33.8 5867
II 307 .7 362.5 246. 2 7.36 46.03 36.0 5547
13 124.5 85.3 123.0 DI ' nt
t S 592.9 407.5 469.1 10.52 59.82 64.' >'
t9 299.4 196 .2 289 .6 29.07 28.53 >' 4221
'0 511 .0 51 8.4 324 .7 nt Dl DI DI
22 247 .7 297.8 53.8 Dt DI e t
26 201 .6 135 .6 183.1 29.50 55. 19 446.7
27 259 .1 ] 75.2 253 .4 DI er
330 .3 424 .6 276.4
"
Dl DI
] 33.3 224 .2 253.1 et
509 .3 380 . 1 449.8 DI nt
MEAN 361.1 377. 1 284 .6 14.58 42.51 102.8 4804
S.D. 142.6 220 .5 127.2 10.20 IS .03 169,3 965
t non stimulated.
t stimulated
t not tested.
.
S timulated culture sampl es wer e dil uted 1:10.
> 20,000 pglmL
,
> 500 pglmJ
23 6
Volunteer 22. 11.75
Cycle 31. Days (O=Day 19)
DAY IFNy lL-' lL-I lL-l n lL- W
Pelm) Pelm) p&lml - &11111 p&fad
D"
"
D'
73.1 116.1 39.5 • .]0 41.27 20.8
"
555.1 2 19.0 112.3 1.88 29.39 21.0 16160
89.9 159.5 10 (.4 42 4 30.14 "0 .6 90.,
'0 59.1 221.1 48 .1 nl' nt ..
12 101.8 282. 1 41.5 48.59 nl
16 11.3 100.2 H .I 12.51 44.71 286 .8 14670
17 76.2 209.9 37.6 7.66 52.86 83.1 16450
I . SI.3 149.6 38.3 nl
23 62.5 152.7 41.3 5.73 43.55 254 .7 12980
' 4 167.7 242.9 62 .9 9.82 55.79 282.7 15910
' 6 51.0 652.6 92.3 DI ..
,. 70.9 432.1 4] .2 9.18 59.56 39 .9 trn o
31 70.1 126.8 20.0 ..
lOl ." lSO.3 60 .8 et
122.8 270.6 49.6 DI
MEAN 111.5 234 .4 54.9 7.16 45.10 128.1 13999
S.D. 127.8 142.6 26.7 U S 10.51 122.8 2630
T non stimulated.
t stimulated
f Dot tested.
• Stimulated culture samples were diluted l:20.
• > 20,000 pglmJ.
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Volunteer 30.04.65
Cycle 31 Days(O=Day 18)
DAY lFNy tL-2 tL-4 tL-ln IL·W
pcJml Pelm) ,glm) lIeflDl , elml
••T
378.8 579.0 42.9 5 .33 50.57 40.3 6226
233.3 468 .6 26.6 27.10 60.57 605.3 7 132
12 187.8 747.6 73.9 7.47 35.06 501.2 6970
lJ 210.7 675.4 56.0 13.49 29.13 397.4 8262
20 148.5 340.8 35.2 4.69 50.26 ' .4 6350
22 241.9 634.3 126.5 7.11 34.98 6] .5 7894
25 496.6 545.9 96.2 10 .6 3 51.6 1 >' >'
27 ]9 .1 244.3 156.5 nl' et et
29 151.5 723 .3 It 9.2 16.43 56.50 146.4 4866
153.9 578.0 85.8 nt ot
MEAN 224.3 553.7 81.9 11.53 46.84 251.8 68 14
S.D. 129.1 162.5 43 .0 7.49 12.05 244 .6 11]6
! non stimulated.
t stimulated
t not tested.
,
Stimulate d culture sampl es were diluted 1:1O.
> 10.000 pglml.
,
> 1000 pg/ml.
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Volunteer 24 .02.71
Male Control
DATE lFNT JL.' 0....0 JL.'" D-W
,111111 ,&11111 PWml _lIml ,&lml
.,'
"
MIS 4S3.0 30] .6 36 .4 .t .t . t
IT 1221.0 262.1 4.5.5 1.67 .,
I' nt : ut . t et . t
' 3 129.5 483.0 32.6 1.91 41.25 0.2
24 1669.0 668.7 44 .4 2.21 32.55 .t 5277
2. 599.5 380.2 61.7 1.05 21.70 3724
2. I ISO.O 559.9 31.0 2.73 l !.7J 672 8
JI 724.2 435.8 60 .4 2.01 11.86 s.s 7294
12 9·'1 .6 531.4 30.8 2.90 49.78 23.9 ., 96
498 .6 512.5 54 .2 53 3 61.18 174 6178
59.4 IU,8 3J..4 2.63 051.80 5.1 7048
1602.0 252. 1 H .2 3.03 58.92 24.5 SOI7
MEAN an .1 414.9 42.5 2.55 .(6.31 39.1 57]]
sn 496.3 153.2 13.1 1.15 16.11 66.8 1276
:' non stim ulated.
t stimulated
t not tested.
Stimulated culture samples were diluted 1:10.
• < I pglml .
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Volunteer 06.11.71
Male Control
DATE tFN, tL-Z n-o tL-l~ tL-W
..I"" PWml PWml nJlml ptl ml
.,'
.' ..
MIS l54 . l 344 .9 48 .7 nl '
17 104.0 212 .8 30.3 nl nt nt
"
199.8 490 .3 56 .2 3.13 41.96 2.7 11770
13 107 .0 321.3 2 1.1 5.32 57.82 3.0 165 10
24 92.5 44 5.1 35.4 3.65 57.50 I., 11220
26 207.9 423.2 21.3 4.99 64.76 3.6 14170
2' 202,] 715 .6 138.9 6 .00 63 .09 3.0 17720
31 311.3 616.8 146.3 23.53 62 .42 384.5 1702 0
1 2 113.3 471.3 54 .8 2.31 45 .66 I.l 157:30
245.7 2 13.8 139.8 4.44 >' 97.4 >'
296 .7 509.2 105.2 4.21 31.99 110.7 660.
471. 7 847 .8 102.9 4 .32 32.37 156.5 8032
MEAN 208 .9 467.7 75.1 6.19 50.84 76.4 13 198
SD . 111 .1 190.4 48.5 6 .18 13.10 122.8 40 23
t Don stimulated.
stimulated
t not tested.
. Stimulated culture samples were diluted 1:20.
b > 20,000 pglm l.
> 3.0 0 .0.
240
Volunteer 17.02.75
Male Contro l
nATE lFN y lL-l lL-I lL-l~ lL-1~'
PWIllI pl1m. pglasl a""" pgflllia,'
"
M2' 68.0 633. 1 Y.8 nt' at n'
I. 16.9 171.2 <" 1.76 >' .. 5173
J I 45.5 41 1.9 17.] 1.12 62 .7 1 1.5 5848
88.1 588.4 18.0 1.04 54.32 .. 10250
63.0 536 .5 13.2 1.60 43.07 3.' 10890
209.1 576 .5 15.1 7.59 442 .2 14500
14 83.7 658 .9 38.1 1.23 34 .54 5.' 11440
I. 94.4 518.9 20.4 2.18 59 .03 ' .3 13980
19 138.6 807 .4 26.9 1.87 61 .02 12.2 9363
MEAN 89.7 544.8 20.9 2.42 52.45 59.9 10181
'D . 56.1 177.0 9.0 2.12 11.26 154.5 3374
1 non stimulated.
! stimulated
t not tested.
• Stimulated culture samples were diluted 1:20.
• > 20.000 pglm L
• < 2 pg/ml
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Volunteer 16.05.74
Male Control
DAT E lFN, lL-2 IL-l IL- I.. lL-W
PW'" p&iml pllm) Il&fml PW'"
D.T
.'
11. Dt' DI nt et at
I. 211.3 397.2 36.3 at a' nt
21 273 .8 376 .2 14.8 9.12 46.11 I.'
"
2' 482 .2 413 .9 95.5 9.05 60.37 145.2
2. ]80 .0 824 .5 195.2 nt
2. 706.7 533.6 146.7 21.S7 38.58 264.7 6167
31 Dt 201.1 58 .6 nl 32.35 at
A I 1016 677 .4 132.3 nt nl
at at nl at at
MEAN 511.7 489.1 105 .6 1] .24 44.35 191.6
S.D. 302.5 208.1 55.5 7 .11 12.06 64.1
T non stimulated.
t stimulated
t not tested .
: Stimulated culture samples were diluted 1:10.
> 10,000 pglml.
242
Volunteer 19.02.36
PM Control
DATE tL-2 1L-4 IL-In IL-IP"
pelml pelml Dc/ml pelml
asT 5'
MIS 275.6 66 .4 nt' at nt
90.8 S."
151.9 20.6
J08 .0 33,9
2 12.9 24.6
210.8 18.4
235.9 36.0
393.6 59.2
346.6 194.9
144.2 77.2
0.11 58.87
2.7S
1.33
0.17 32.48
0.41 59.49
0.70 59.30
7189
"
8587
m.
at
a t
at
at
"
22.3
2.6
).
r.s
...
16.9 9281
at
at
at
30 .6
82.6
26] .3
) 49.1
"2)
2'
26
2'
112
14
16
n
27
2.
]0 147.0 73.9
MEAN 240.7 55.7
3D , 92.5 48.8
0.99 5254
0.86 13.37
' .7
8.2
8208
"6
t Don stim ulated.
! stimulated
t not tested.
• Stimulated culture samples were diluted 1:20.
b > 20,000 pglro!.
> 3.0 0 .0 .1.
• > SOO pglml.
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Volunteer 17.10.38
PM Control
DATE tL-2 tL4 lL- lr a tL-!p"
pg/ml pg/m l ngfml pg/ml
n,T
"
n,
MI S 415 .1 1249 2.32 47 .25 0.7 9879
17 485.1 560 .4 l.l l 1.8
I' 484 .6 59] .3 2.74 52.41 >' 10960
2J 6 17.4 16 17.S s.ts >' 13230
24 523 .8 600.2 1.37 51 .24 08 10530
26 499 .5 6 32.9 1.38 47.48 I.S 7955
2. 1]06 .0 633 .4 3.56 66. 11 2.1 12SLO
1I 762.5 1340.5 2.19 1.8 12440
J 2 S51.7 988 .0 3.29 2.6 12010
.,, 129.S 12.74 2S1 966S
855 .6 1344 .0 9.34 17' 12620
566 .3 4 14 .9 22.52 lS6 >'
MEAN 642.5 842.0 5.87 52 .90 79.2 11180
S.D. 255 .1 453.9 6.27 7.73 132.2 1613
non stim ulated .
stimula ted
not tested.
Stimulated culture samples were diluted 1:20.
.> 20,000 pglm l.
> 3.00.0 .
, > 1000 pglml.
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Table B.31. Means and standard deviations for the phase of the cycle profiles for all the
cytokines measured in culture supernatants.
EF MF LF 0 EL ML LL M EF
lL·2' pglml
7
mean 382 445 434 401 521 528 638 532 476
S.D. 249 213 317 317 338 333 337 367 274
lL-4- psJml
6
38 35 38 28 37 50 55 64 42
S.D. 23 21 33 II 24 34 38 83 23
IFNy' psJmI
7
mean 372.6 376.2 364.2 212.2 230.1 270 .8 309.8 278.1 263.4
S.D. 272.4 373.9 343.2 154.6 146.8 137.1 143.7 1194 198.3
IL·Ira"nglml
mean 4.14 8.36 7.44 6.17 5.65 9.60 9.38 12.05 7.94
SO. 1.27 8.24 6.58 4.76 4.69 8.37 6.37 10.63 4.57
Il> Irac ng/ml
mean 36.87 38.13 43 .00 48.63 43.03 50.62 49.57 44.78 53.84
S.D. 12.65 11.65 11.09 10.53 9.99 14.68 13.83 9.38 11.31
vOhmtcer 09.10.64 exclUded
" Don stimulated culture supernatants.
stimulatedculturesupernatants.
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Table B.31 continued.....
EF MF LF 0 EL ML LL M EF
lL.1P· pg/ml
3
26.9 136.8 161.1 52.6 54.4 107.7 100.5 2 12.2 156.3
S.D. I\.6 232.2 159.1 55.5 89.2 121.2 8\.6 142.9 213.7
lL-1 p" pgiml
5
mean 8571 8752 9850 11289 10205 9664 10044 10485 8153
S.D. 4734 3346 4196 5059 3140 5023 4570 4486
ll..-I Ratiob
mean 0.541 0.874 3.12 1.l0 \.04 1.32 \. 82 3.74 \.45
S.D. 0.202 0.755 4.88 \.25 1.56 1.16 3.02 5.37 \.41
IT._I Ratiocd
mean 26.94 26.56 22.43 2611 23 .01 18.29 1973 24.23 19.98
S.D. 18.62 13.77 8.89 11.59 8.24 5.89 676 4.42
non sbmUlated cUlture supernatants.
stimulated culture supernatants.
d Volunteer22.09.75 excluded
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APPENDIX C
248
eetr.dlol ( p g/m l )
!-Run 1 -Run 2 -Run 3 -Run 4 I
Figure C.I . Standard curves from the Estradiol RIA run at four different times.
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Table C.1. Values for the same serum sam ple nm or different RIA estrogen a:says with
the calculated coefficient of variation .
Assay Number
Mean ± S.D.
C.Y.
Value pglml
24.7
26.7
21.4
2I.l
23.6 ± 2.6
11. 1%
250
120
0'--------"'----'------
0 .2 0.5 2.0 5.0 10.0 25.0 50.0
Prog••terone (ng/ml)
1-Run 1 - Run 2 - Run 3 - Run 41
Figure C.2. Standard curves from the Progesterone RIA om at four different times.
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Table C.2 Values for the same serum sample run on different RIA progesterone assays
with the calculated coefficient of variation.
Assay Number
Mean ± S.D.
C.V.
Value nglml
0.3
0.3
0.3
0.6
0.375 ± 0.15
40.0%
252
100.000
1 .000
200.0205100'-- --- ----- ---2
L ute i n izing Honnone (U /L)
I- RU" 1 -Run 2 Run 3 - Aun 41
Figure c.J . Standard curves from the Luteinizing bormone RIA run at four different
times.
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Table C.J . Values for the same senun sample run on different RIA Luteinizing hormone
assays with the calculated coefficient of variation .
Assay Number
Mean ± S.D.
C.V.
Valu e UIL
0.08
Note: The values seen in the above table are not different from 0 thus the luteinizing
hormone concentration in the sample nm was below the sensitivity of the assay and a
coefficient of variation is Dot available.
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Figure CA . Standard curves from the Testosterone RIA run at three different times .
2SS
Table C.4. Values for the same serum sample om on different testosterone RIA assays
with the calculated coefficient of variation.
Assay Number
Mean± S.D.
C.V.
Value ng/ml
0.19
0.20
0.17
0.187 ± 0.015
8.0%
256
- Plate 1 - Pl ate 2 - P late 3
- Plate 4 - Plate 5 - P late 6
Figure C.S. Standard curves from the IL-2 EUSA run at six different times.
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Table C.S. Values for the same culture supernatant sample run on different lnterleukin 2
ELISA assays with the calculated coefficient of variation
Assay Nwnber
Mean± S.D.
C.Y.
Value pglm l
1326
1322
1378
1245
1393
1359
1377
1342 ± 51
3.8%
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Figure C.6. Standard curves from the R&D Systems ll.-4 ELISA run at three different
times.
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1- Plate 1 - Plate 2 - Plate 3 - Plate 4 - P late 5 I
Figure C.7. Standard curves from the Biosource IT.-4 EliSA run at five different times.
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Table C.6. Val ues for the same culture supernatant sample run on diffe rent lnterleukin 4
EUSA assays with the calculated coefficient of variation.
Assay Num ber
Mean ± S.D.
C.Y.
Value pglml
1200
1187
1043
2998"
1143 :!:. 87
7.6%
"This value was obtained. from the Biosource kits and was not used in the calculation of
the coefficient of variation . The remaining four values were all above 0 .0. 3.0 and not
available .
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Figure C.8. Standard curves from the IFNy ELISA run at eight different times.
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Table C.7. Values for the same culture supernatant sample nm on differen t Interferon
gamma EUSA assays with the calculated coefficient of variation.
Assay Number
Mean ± S. D.
C.v.
Value pglml
556.7
551.4
551.6
498 .6
538.0
546.4
5080
503.4
531.8 ± 24.3
4.6%
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Figure e.9 . Standard curves from the Ils-Lra EUSA nul at ten different times to measure
IL~lra In culture supernatants.
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Table e.8.Values for the same culture supernatant sample runon different Interleukin Ira
EUSA assays with the calculated coefficient of variation.
Assay Number
Mean ± S.D
C.V.
Value nglml
36.70
67 .77
33 .22
38.59
35.83
55.89
42 .06
44 .29 :!: 12.7S
28.79%
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Figure C.IO. Standard curves from the IL-I ra ELISA run at five different times to
measurell..·1 ra in serum .
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Table e.9. Values for the same serum sample run 00 different Interleukin lra ELISA
assays with the calculated coefficient of variation.
Assay Number
Mean ± S.D
C.V.
Value pglml
256.7
121.4
228.3
2160
159.9
196.5 ± 54.8
27.9%
267
'0
a.o\;
::l ~ .., N ~ § ~:5 :!! ;;; :;;:
1L-1B (pg/ml)
-Plate' --Plate 2 -Plate 3 -Plale4
- Pima 5
-- P late 6 ... Plate 7 ..... PlateS
-e-Ptete g -Plate 10
Figure C.ll . Standard curves from the ll. · 113 EUSA CW\ at ten different times to measure
Ila-I P in culture supernatants .
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Table C.IO. Values for the same culture supernatant sample run on diffe rent Interleukin
I PEUSA assays with the calculated coefficient of variation.
Assay Number
Mean± S.D.
C.V.
Val ue pglml
65%
8180
8184
14570
13850
10276 ± 3658.0
35.6%
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1I~1B (pg, ,,II)
I- Plat. 1 - Plat. 2 - Plat. 3 -- P lat. 4 -- Pl a t e 5 I
Figure C.12. Standard curv es from the n.~ltl ELISA run at five different times to
measure n.~1P in serum.
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Table CI I. Values for the same serum sample nut on different Interleukin IJl EUSA
assays with the calculated coefficient of variation.
Assay Number
Mean ±S.D.
C.V.
Value pglml
0.1559
< 0.083
< 0.083
0.1721
< 0.083
< 0.083
Note: Many of the values for IL-la were not measurable in serum as indicated in the
above table. Coeffic ient of variation was not calculated due to this
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